

=> fil hcaplus  
FILE 'HCAPLUS' ENTERED AT 11:43:01 ON 06 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Oct 2005 VOL 143 ISS 15  
FILE LAST UPDATED: 5 Oct 2005 (20051005/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>  
=>

=> d stat que l2  
L2 57 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PARANG K"/AU OR "PARANG  
KAYKAVOOS"/AU OR "PARANG KEYKAVOVS"/AU)

=> d ibib abs l2 1-57

L2 ANSWER 1 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:973071 HCAPLUS  
TITLE: Recent advances in the discovery of Src kinase inhibitors  
AUTHOR(S): Parang, Keykavous; Sun, Gongqin  
CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Expert Opinion on Therapeutic Patents (2005), 15(9), 1183-1207  
CODEN: EOTPEG; ISSN: 1354-3776  
PUBLISHER: Ashley Publications Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Src family kinases are involved in the regulation of a wide variety of normal cellular signal transduction pathways, such as cell growth, differentiation, survival, adhesion and migration. Considerable evidence implicates elevated expression and/or activity of Src kinases in many human cancers, osteoporosis, cardiovascular disorders and immune system dysfunction; thus, this family of protein tyrosine kinases now exists as intriguing targets for both basic research and drug discovery. Herein, a number of examples of currently developed Src family kinase inhibitors in selected patents from 2002 - 2005 will be described. Special attention will be made to the chemical diversity of ATP binding site inhibitors, potency, selectivity and therapeutic application of the compds.

L2 ANSWER 2 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:740638 HCAPLUS  
TITLE: Regioselective solid-phase diphosphorylation and diphosphodithioation of unprotected nucleosides and carbohydrates  
AUTHOR(S): Ahmadibeni, Yousef; **Parang, Keykavous**  
CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), ORGN-589. American Chemical Society: Washington, D. C.  
CODEN: 69HFCL  
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)  
LANGUAGE: English

AB Carbohydrate diphosphates are required for the biosynthesis of complex carbohydrates, glycoproteins, and glycolipids. Nucleosides diphosphates are intracellularly converted to nucleosides triphosphates in the presence of kinases. Organic chemists investigating these fields are required to prepare many kinds of pure nucleosides and carbohydrates monodiphosphates and monodiphosphodithioates in sufficient quantities. Two classes of aminomethyl polystyrene resin-bound linkers of p-acetoxybenzyl alc. were subjected to reactions with bis(2-cyanoethyl diisopropylphosphoramidite) to produce the corresponding polymer-bound phosphitylating reagents. Several unprotected nucleosides (e.g., thymidine, adenosine, AZT) and carbohydrates (e.g., galactose, mannose, melibiose) were reacted with the polymer-bound reagents. Oxidation with tert-Bu hydroperoxide or sulfurization with Beaucage's reagent, followed by removal of cyanoethoxy group with DBU, afforded the corresponding polymer-bound diphosphodiester or diphosphodithioesters. The cleavage of polymer-bound compds. under acidic conditions afforded nucleosides and carbohydrates diphosphates and diphosphodithioates with high regioselectivity in 47-78% overall yield, while the linkers remained trapped on the resins.

L2 ANSWER 3 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:740637 HCAPLUS  
TITLE: Regioselective solid-phase synthesis of dinucleoside and nucleoside-carbohydrate phosphodiester and thiophosphodiester using polymer-bound oxathiaphospholanes  
AUTHOR(S): Ahmadibeni, Yousef; **Parang, Keykavous**  
CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), ORGN-588. American Chemical Society: Washington, D. C.  
CODEN: 69HFCL  
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)  
LANGUAGE: English

AB Nucleosides and carbohydrates phosphodiester are of considerable interest in nucleic acid research and the development of nucleosides with improved antiviral activity and prodrugs containing masked phosphates. Dinucleoside phosphodiester appear to be more stable than nucleoside monophosphates to non-specific phosphohydrolases. Two classes of polymer-bound N,N-diisopropylamino-1,3,2-oxathiaphospholane were synthesized and were reacted with unprotected carbohydrates (e.g., mannose, melibiose) and nucleosides (e.g., adenosine, uridine, thymidine, AZT) in the presence of 1H-tetrazole. Oxidation with tert-Bu hydroperoxide or sulfurization with Beaucage's reagent, followed by the 1,3,2-oxathiaphospholane ring-opening

with the same or different nucleosides or carbohydrates in the presence of DBU, afforded the corresponding sym. or unsym. dinucleoside and nucleoside-carbohydrate phosphodiester and thiophosphodiester derivs. through the elimination of polymer-bound ethylene episulfide in 36-70% overall yield. In total, by using different combinations of nucleosides and carbohydrates, 24 compds. (20 novel compds.) were synthesized. This strategy can be used to create the phosphodiester library of nucleosides and carbohydrates.

L2 ANSWER 4 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:740636 HCAPLUS

TITLE: Regioselective solid-phase synthesis of nucleosides and carbohydrates triphosphates and triphosphotriethioates

AUTHOR(S): Ahmadibeni, Yousef; **Parang, Keykavous**

CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), ORGN-587. American Chemical Society: Washington, D. C.

CODEN: 69HFCL

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)

LANGUAGE: English

AB Nucleosides are activated to triphosphate forms in the presence of kinases. Nucleosides triphosphates are required for the synthesis of nucleotides and nucleic acids and the biol. activity of nucleosides including several antiviral drugs. The regioselective synthesis of unprotected nucleosides and carbohydrate triphosphates is a challenging effort for organic chemists. Two classes of aminomethyl polystyrene resin-bound linkers of p-acetoxybenzyl alc. were subjected to reactions with a triphosphitylating reagent containing bis(1,3-diisopropylphosphoramidite) in the presence of 1H-tetrazole to yield the corresponding polymer-bound triphosphitylating reagents. A number of unprotected carbohydrates (e.g., galactose, mannose, melibiose) and nucleosides (e.g., thymidine, uridine, adenosine, AZT) were reacted with the polymer-bound reagents. Oxidation with tert-Bu hydroperoxide or sulfurization with Beaucage's reagent, followed by removal of cyanoethoxy group with DBU, afforded the polymer-bound triphosphodiester or triphosphotriethiodiesters. The acidic cleavage of polymer-bound compds. with TFA gave nucleosides and carbohydrates triphosphates and triphosphotriethioates with high regioselectivity in 39-74 % overall yield.

L2 ANSWER 5 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:739913 HCAPLUS

TITLE: Converting a weak peptide inhibitor of Src kinase to potent peptide inhibitors by systemic structural modification

AUTHOR(S): Kumar, Anil; Wang, Yuehao; Sun, Gongqin; **Parang, Keykavous**

CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-405. American Chemical Society: Washington, D. C.

CODEN: 69HFCL

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)

LANGUAGE: English

AB The design, synthesis, and evaluation of new compds. against Src tyrosine

kinases are attractive due to the association of Src tyrosine kinases activity with several diseases including cancer and osteoporosis. In contrast to ATP binding site, a few peptides have been identified as substrates for Src tyrosine kinases. Most of these peptide substrates are rather weak inhibitors with  $K_m$  in high micromolar or in millimolar range. The best examples from these studies are peptides, Ac-YIYGSFK and Ac-CIYKYY, which were reported to be inhibitors of Src. Our radioactive kinase assay showed that Ac-YIYGSFK ( $IC_{50} = 570 \mu M$ ) and Ac-CIYKYY ( $IC_{50} = 400 \mu M$ ) were weak inhibitors of polyE4Y phosphorylation by active c-Src. We investigated whether by functional group modifications in the side chains of amino acids in Ac-CIYKYY, the inhibitory activity can be improved. The purpose of this study was to understand the structure-activity relationship of these compds. in order to develop novel Src inhibitors. Peptide Ac-CIYKF(NO<sub>2</sub>)Y, in which the nitrophenylalanine is located at position 5, exhibited a significantly higher inhibitory potency ( $IC_{50} = 0.53 \mu M$ ) by approx. 750-fold vs. Ac-CIYKYY. Addnl., compds. with substituted halogens exhibited significantly high inhibitory potencies in the order of  $I > Cl > F$ . For example, Ac-CIYKF(4-I)Y exhibited ( $IC_{50} = 0.78 \mu M$ ) approx. 510-fold higher inhibitory potency than Ac-CIYKYY. Mol. modeling studies showed that the intramol. hydrogen bonding of the amino group of the K4 with hydroxyl group of Y5 in Ac-CIYKYY is eliminated when the hydroxyl group is substituted with nitro group or halogens. It appears that the free amino group of the lysine is required for the interaction with the kinase domain of Src and generating inhibition. These results suggest that it is possible to convert a weak peptide inhibitor of Sc kinase to potent peptide inhibitors by systemic structural modifications.

L2 ANSWER 6 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:739912 HCAPLUS

TITLE: N-Heteroaromatic-peptide conjugates as Src kinase inhibitors

AUTHOR(S): Kumar, Anil; Wang, Yuehao; Sun, Gonquin; **Parang, Keykavous**

CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-404. American Chemical Society: Washington, D. C.

CODEN: 69HFCL

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)

LANGUAGE: English

AB Src kinase exists as intriguing therapeutic target for drug discovery with respect to cancer and osteoporosis. Although selective inhibitors competitive with ATP have been synthesized for specific protein kinases, the process of inhibitor development is labor intensive due mainly to the presence of a large number of protein kinases that show a conserved ATP binding site. The main objective of this study was to exploit the ATP-binding site mol. recognition motif in combination with other recognition motifs. 3-Phenylpyrazolopyrimidine derivative, substituted with an alkyl carboxylic acid at N1 endocyclic amine, exhibited weak inhibitory potency ( $IC_{50} = 250 \mu M$ ). Addnl., the radioactive kinase assay using polyE4Y as the substrate suggested that peptides YIYGSFK ( $IC_{50} = 570 \mu M$ ) and Ac-CIYKYY ( $IC_{50} = 400 \mu M$ ) were weak inhibitors of polyE4Y phosphorylation by active c-Src. More than fifty N-heteroarom.-peptide conjugates were synthesized using 3-pyrazolopyrimidine derivative as an ATP mimic and CIYKYY and YIYGSFK as peptide substrates. The carboxylic acid of substituted 3-phenylpyrazolopyrimidines was attached to the side chain of different amino acids in the peptide template. Two N-terminal



substituted 3-phenylpyrazolopyrimidine-peptide conjugates, 3-phenylpyrazolopyrimidine-CIYKYY (IC<sub>50</sub> = 0.38  $\mu$ M) and 3-phenylpyrazolopyrimidine-YIYGSFK (IC<sub>50</sub> = 2.7  $\mu$ M), inhibited the polyE4Y phosphorylation by active Src significantly higher than parent compds., N-heteroaroms. and peptides. This study suggests a synergistic inhibition effect of the conjugation of the ATP mimic with the peptide by possibly creating favorable interactions between the conjugate and the kinase domain. Mol. modeling studies of 3-phenylpyrazolopyrimidine-CIYKYY conjugate with Src suggested that the pyrazolopyrimidine ring binds to the ATP binding site and the peptide occupies the exterior space of the N-lobe in the kinase domain creating some new bonding interactions. This study suggests that weak inhibitors of Src kinase can be conjugated to generate potent lead inhibitors that may be used for further optimization.

L2 ANSWER 7 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:739911 HCAPLUS  
 TITLE: Conformationally constrained peptide analogs of CIYKYY as inhibitors of Src tyrosine kinase  
 AUTHOR(S): Ye, Guofeng; Kumar, Anil; Wang, Yuehao; Sun, Gongqin; **Parang, Keykavous**  
 CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
 SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-403. American Chemical Society: Washington, D. C.  
 CODEN: 69HFCL  
 DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)  
 LANGUAGE: English

AB Peptide Ac-CIYKYY was a weak inhibitor (IC<sub>50</sub> = 400  $\mu$ M) of polyE4Y phosphorylation by active Src as shown by the radioactive kinase assay. Peptide Ac-CIYKF(NO<sub>2</sub>)Y, in which the nitrophenylalanine is located at Y5 position, exhibited a significantly higher inhibitory potency (IC<sub>50</sub> = 0.53  $\mu$ M) by approx. 750-fold vs. Ac-CIYKYY. Conformationally constrained derivs. of these compds. were synthesized by solid-phase methods to determine whether the presence of the constrained ring has any effect in inhibitory potency. Due to the presence of three tyrosine residues and one lysine in the C1I2Y3K4Y5Y6, there were several opportunities for linking side chains of amino acids. Four types of conformational constraints were introduced by linking head to tail, C-terminal to side chain, N-terminal to side chain, and side chain to side chain of the amino acids. The structure-activity relationships of these analogs and the comparison of their inhibitory potency with parent linear peptides are discussed.

L2 ANSWER 8 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:739886 HCAPLUS  
 TITLE: Synthesis and evaluation of hydroxamate derivatives as metal-mediated inhibitors of Csk  
 AUTHOR(S): Gu, Xianfeng; Wang, Yuehao; Kumar, Anil; Sun, Gongqin; **Parang, Keykavous**  
 CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
 SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-378. American Chemical Society: Washington, D. C.  
 CODEN: 69HFCL  
 DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)  
 LANGUAGE: English

AB In order to explore the possibility of designing metal-mediated inhibitors

against protein tyrosine kinases, a class of tyrosine and phenylalanine hydroxamate derivs. were synthesized (25 compds.) and evaluated for their ability to inhibit C-terminal Src kinase (Csk), a model tyrosine kinase, in the presence of cobalt. Tyrosine hydroxamate (IC<sub>50</sub> = 9.5  $\mu$ M) and phenylalanine hydroxamate (IC<sub>50</sub> = 15.5  $\mu$ M) inhibited Csk only in the presence of CoCl<sub>2</sub>. The presence of bulky groups (e.g., Cl, Br, I) or pyrazolopyrimidine on the Ph ring enhanced the inhibitory potency (IC<sub>50</sub> = 2.0-6.3  $\mu$ M), possibly due to the presence of interactions between these groups and a hydrophobic pocket in the enzyme. The substitution of amino group of hydroxamate with alkyl or aryl groups or removal of  $\alpha$ -amino group significantly reduced the inhibitory potency. These data suggest that specific functional groups are required for metal-binding affinity and inhibitors with better inhibitory profile can be designed.

L2 ANSWER 9 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:739730 HCAPLUS  
 TITLE: Studying the interactions of toxic metals with protein tyrosine kinases  
 AUTHOR(S): Ahmadibeni, Yousef; **Parang, Keykavous**; White, Millie; Sun, Gongqin  
 CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
 SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-219. American Chemical Society: Washington, D. C.  
 CODEN: 69HFCL  
 DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)  
 LANGUAGE: English

AB A number of tyrosine kinases are activated in the presence of toxic metals. The structural effects of binding of metals, such as arsenite, cadmium, lead, cobalt, and nickel, to tyrosine kinases were examined by CD anal. From all peptide sequences in different domains of c-Src containing one cysteine residue, only CPESLHDLMC in the CT lobe exhibited significant conformational changes. Two cysteine residues with a preserved 10-amino acid insert are also present in the C-terminal of Fyn, C-abl, Lck, Csk, and EGFR. Synthesized peptides containing these two cysteine residues and the whole c-Src and Csk proteins exhibited significant conformational changes in the presence of the metals. <sup>113</sup>Cd NMR and <sup>33</sup>S NMR studies of the peptide CPESLHDLMC confirmed the binding between the free sulfhydryl groups of the cysteine residues and cadmium. These results suggest that the cysteine residues in the C-terminal of tyrosine kinases are part of a common metal-binding domain.

L2 ANSWER 10 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:622866 HCAPLUS  
 DOCUMENT NUMBER: 143:243964  
 TITLE: Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: Molecular yardsticks for analyzing catalytic mechanism and inhibitor design  
 AUTHOR(S): Hines, Aliya C.; **Parang, Keykavous**; Kohanski, Ronald A.; Hubbard, Stevan R.; Cole, Philip A.  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA  
 SOURCE: Bioorganic Chemistry (2005), 33(4), 285-297  
 CODEN: BOCMBM; ISSN: 0045-2068  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bisubstrate analogs have the potential to provide enhanced specificity for protein kinase inhibition and tools to understand catalytic mechanism. Previous efforts led to the design of a peptide-ATP conjugate bisubstrate analog utilizing aminophenylalanine in place of tyrosine and a thioacetyl linker to the  $\gamma$ -phosphate of ATP which was a potent inhibitor of the insulin receptor kinase (IRK). In this study, the authors have examined the contributions of various electrostatic and structural elements in the bisubstrate analog to IRK binding affinity. Three types of changes (seven specific analogs in all) were introduced: a Tyr isostere of the previous aminophenylalanine moiety, modifications of the spacer between the adenine and the peptide, and deletions and substitutions within the peptide moiety. These studies allowed a direct evaluation of the hydrogen bond strength between the anilino nitrogen of the bisubstrate analog and the enzyme catalytic base Asp and showed that it contributes 2.5 kcal/mol of binding energy, in good agreement with previous predictions. Modifications of the linker length resulted in weakened inhibitory affinity, consistent with the geometric requirements of an enzyme-catalyzed dissociative transition state. Alterations in the peptide motif generally led to diminished inhibitory potency, and only some of these effects could be rationalized based on prior kinetic and structural studies. Taken together, these results suggest that a combination of mechanism-based design and empirical synthetic manipulation will be necessary in producing optimized protein kinase bisubstrate analog inhibitors.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:578716 HCAPLUS

DOCUMENT NUMBER: 143:243948

TITLE: Functional Diversity of Csk, Chk, and Src SH2 Domains due to a Single Residue Variation

AUTHOR(S): Ayrapetov, Marina K.; Nam, Nguyen Hai; Ye, Guofeng; Kumar, Anil; **Parang, Keykavous**; Sun, Gongqin

CORPORATE SOURCE: Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Journal of Biological Chemistry (2005), 280(27), 25780-25787

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The C-terminal Src kinase (Csk) family of protein tyrosine kinases contains two members: Csk and Csk homologous kinase (Chk). Both phosphorylate and inactivate Src family kinases. Recent reports suggest that the Src homol. (SH) 2 domains of Csk and Chk may bind to different phosphoproteins, which provides a basis for different cellular functions for Csk and Chk. To verify and characterize such a functional divergence, we compared the binding properties of the Csk, Chk, and Src SH2 domains and investigated the structural basis for the functional divergence. First, the study demonstrated striking functional differences between the Csk and Chk SH2 domains and revealed functional similarities between the Chk and Src SH2 domains. Second, structural anal. and mutagenic studies revealed that the functional differences among the three SH2 domains were largely controlled by one residue, Glu127 in Csk, Ile167 in Chk, and Lys200 in Src. Mutating these residues in the Csk or Chk SH2 domain to the Src counterpart resulted in dramatic gain of function similar to Src SH2 domain, whereas mutating Lys200 in Src SH2 domain to Glu (the Csk

counterpart) resulted in loss of Src SH2 function. Third, a single point mutation of E127K rendered Csk responsive to activation by a Src SH2 domain ligand. Finally, the optimal phosphopeptide sequence for the Chk SH2 domain was determined. These results provide a compelling explanation for the functional differences between two homologous protein tyrosine kinases and reveal a new structure-function relationship for the SH2 domains.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:555141 HCAPLUS

TITLE: Racemic and optically active 2-methoxy-4-oxatetradecanoic acids: novel synthetic fatty acids with selective antifungal properties

AUTHOR(S): Carballeira, Nestor M.; O'Neill, Rosann; **Parang, Keykavous**

CORPORATE SOURCE: Department of Chemistry, University of Puerto Rico, San Juan, 00931-3346, P. R.

SOURCE: Chemistry and Physics of Lipids (2005), 136(1), 47-54  
CODEN: CPLIA4; ISSN: 0009-3084

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The unprecedented ( $\pm$ )-2-methoxy-4-oxatetradecanoic acid and the optically pure (S)-2-methoxy-4-oxatetradecanoic acid were synthesized in 6 steps and in 11-14% overall yields starting with either 1,2-O-isopropylidene-rac-glycerol or 1,2-O-isopropylidene-(S)-glycerol. The key step in the synthesis was the selective monosilylation of a dibutylstannylene intermediate. The title compds. displayed selective fungitoxicity in the range of 0.08-0.22 mM against *Cryptococcus neoformans* ATCC 66031 and *Aspergillus niger* ATCC 16404, but no significant activity against *Candida albicans* ATCC 14053 and ATCC 60193 (>2.6 mM). Albeit being good substrates for N-myristoyltransferases (NMTs), the racemic and the S-enantiomer of the oxygenated 2-methoxylated compds. showed no significant difference in antifungal activity. This finding suggests an alternative mechanism of fungitoxicity other than NMT inhibition.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:310131 HCAPLUS

DOCUMENT NUMBER: 143:7928

TITLE: Polymer-Bound Oxathiaphospholane: A Solid-Phase Reagent for Regioselective Mono-Thiophosphorylation and Mono-Phosphorylation of Unprotected Nucleosides and Carbohydrates

AUTHOR(S): Ahmadibeni, Yousef; **Parang, Keykavous**

CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Organic Letters (2005), 7(10), 1955-1958  
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two polymers bound to N,N-diisopropylamino-1,3,2-oxathiaphospholane were reacted with unprotected carbohydrates and nucleosides in the presence of 1H-tetrazole, followed by oxidation with tert-Bu hydroperoxide or sulfurization with Beaucage's reagent. The 1,3,2-oxathiaphospholane ring-opening with 3-hydroxy-propionitrile, followed by treatment with DBU,

afforded the corresponding monophosphate and mono-thiophosphate derivs., resp., through the elimination of polymer-bound ethylene epi-sulfide. Reactions using this strategy offer the advantages of high regioselectivity, mono-substitution, and facile isolation and recovery of products.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 14 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:76219 HCAPLUS

DOCUMENT NUMBER: 142:177041

TITLE: Preparation of azole monosaccharide as antifungal agents

INVENTOR(S): Parang, Keykavous; Sardari, Soroush; Nam, Nguyen Hai

PATENT ASSIGNEE(S): The Board of Governors for Higher Education State of Rhode Island and Providence Plantations, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005006860	A2	20050127	WO 2004-US23316	20040719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-488319P P 20030718  
US 2004-543972P P 20040212

OTHER SOURCE(S): MARPAT 142:177041

GI



AB The present invention is broadly directed to azole derivs. I, wherein X is COR, P(O)(OR1)(OR2); R is alkyl, aryl, alkene, alkyne, alkyl halide, alkoxy, aryloxy; R1 is H, alkyl, aryl; R2 is alkyl, aryl, alkene, alkyne, alkyl halide, ester substituted six or five member cyclic monosaccharide, that exhibit antifungal activity and methods for making the same. In one aspect, the invention includes carboxylic acid and phosphate ester derivs. of fluconazole that exhibit antifungal activity. In addition, the invention comprises methods for synthesizing the derivs. and pharmaceutical compns. containing the derivs. Thus, monosaccharide II was prepared and tested in vitro as antifungal agent.

L2 ANSWER 15 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:31514 HCAPLUS  
 DOCUMENT NUMBER: 142:298278  
 TITLE: Solid-Phase Reagents for Selective Mono-Phosphorylation of Carbohydrates and Nucleosides  
 AUTHOR(S): Ahmadibeni, Yousef; Parang, Keykavous  
 CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences  
 College of Pharmacy, University of Rhode Island,  
 Kingston, RI, 02881, USA  
 SOURCE: Journal of Organic Chemistry (2005), 70(3), 1100-1103  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Two classes of aminomethyl polystyrene resin-bound linkers of p-acetoxybenzyl alc. were subjected to reactions with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite to produce the corresponding polymer-bound phosphitylating reagents. These were reacted with a number of unprotected nucleosides and carbohydrates in the presence of 1H-tetrazole. Oxidation with tert-Bu hydroperoxide followed by removal of the cyanoethoxy group with 1,8-diazabicyclo[5.4.0]undec-7-ene afforded the corresponding polymer-bound phosphate diesters. Acidic cleavage of the p-acetoxybenzyl alc. linker yielded mono-phosphorylated products with high regioselectivity and trapped linkers on the resins that can be reused.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 16 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:31216 HCAPLUS  
DOCUMENT NUMBER: 142:275949  
TITLE: Probing the Communication between the Regulatory and Catalytic Domains of a Protein Tyrosine Kinase, Csk  
AUTHOR(S): Lin, Xiaofeng; Ayrapetov, Marina K.; Lee, Sungsoo; Parang, Keykavous; Sun, Gongqin  
CORPORATE SOURCE: Department of Cell and Molecular Biology and Department of Biomedical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Biochemistry (2005), 44(5), 1561-1567  
CODEN: BICHAW; ISSN: 0006-2960  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Protein tyrosine kinases (PTKs) are important regulators of mammalian cell function, and their own activities are tightly regulated. Underlying their tight regulation, all PTKs contain multiple regulatory domains in addition to a catalytic domain. C-terminal Src kinase (Csk) contains a catalytic domain and a regulatory region, consisting of an SH3 and an SH2 domain. In this study, we probed the communication between the regulatory and catalytic domains of Csk. First, kinetic characterization of SH3 and SH2 domain deletion mutants demonstrated that the SH3 and SH2 domains were crucial in maintaining the full activity of Csk, but were not directly involved in Csk recognition of its physiolo. substrate, Src. Second, highly conserved Trp188, corresponding to a key residue in domain-domain communication in other PTKs, was found to be important for maintaining the active structure of Csk by the presence of the regulatory region, but not required for Csk activation triggered by a phosphopeptide binding to the SH2 domain. Third, structural alignment indicated that the presence of the regulatory domains modulated the conformation of multiple substructures in the catalytic domain, some directly and others remotely. Mutagenic and kinetic studies supported this assignment. This report extended previous studies of Csk domain-domain communication, and provided a foundation for further detailed investigation of this communication.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 17 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:916843 HCAPLUS  
DOCUMENT NUMBER: 142:32454  
TITLE: Carboxylic acid and phosphate ester derivatives of fluconazole: synthesis and antifungal activities  
AUTHOR(S): Nam, Nguyen-Hai; Sardari, Soroush; Selecky, Meredith; Parang, Keykavous  
CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(23), 6255-6269  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 142:32454

AB Two classes of fluconazole derivs., (a) carboxylic acid esters and (b) fatty alc. and carbohydrate phosphate esters, were synthesized and evaluated in vitro against Cryptococcus neoformans, Candida albicans, and Aspergillus niger. All carboxylic acid ester derivs. of fluconazole, such as O-2-bromooctanoylfluconazole (MIC = 111 µg/mL) and O-11-bromoundecanoylfluconazole (MIC = 198 µg/mL), exhibited higher

antifungal activity than fluconazole (MIC  $\geq$  4444  $\mu\text{g/mL}$ ) against *C. albicans* ATCC 14053 in SDB medium. Several fatty alc. phosphate triester derivs. of fluconazole exhibited enhanced antifungal activities against *C. albicans* and/or *A. niger* compared to fluconazole in SDB medium. For example, 2-cyanoethyl- $\omega$ -undecylenyl fluconazole phosphate with MIC value of 122  $\mu\text{g/mL}$  had at least 36 times greater antifungal activity than fluconazole against *C. albicans* in SDB medium. Methyl-undecanyl fluconazole phosphate with a MIC value of 190  $\mu\text{g/mL}$  was at least 3-fold more potent than fluconazole against *A. niger* ATCC 16404. All compds. had higher estimated lipophilicity and dermal permeability than those for fluconazole. These results demonstrate the potential of these antifungal agents for further development as sustained-release topical antifungal chemotherapeutic agents.

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 18 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:891773 HCAPLUS

DOCUMENT NUMBER: 142:70676

TITLE: ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases

AUTHOR(S): Nam, Nguyen-Hai; Lee, Sungsoo; Ye, Guofeng; Sun, Gongqin; **Parang, Keykavous**

CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(22), 5753-5766

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:70676

AB A number of Src SH2 domain inhibitors enhance the kinase catalytic activity by switching the closed inactive to the open active conformation. ATP-phosphopeptide conjugates were designed and synthesized as Src tyrosine kinase inhibitors based on a tetrapeptide sequence pTyr-Glu-Glu-Ile (pYEEI) and ATP to block the SH2 domain signaling and substrate phosphorylation by ATP, resp. In general, ATP-phosphopeptide conjugates with optimal linkers such as compds. 5 and 7 ( $K_i = 1.7$ - $2.6 \mu\text{M}$ ) showed higher binding affinities to the ATP-binding site relative to the other ATP-phosphopeptide conjugates having short or long linkers, 1-4 and 6, ( $K_i = 10.1$ - $16.1 \mu\text{M}$ ) and ATP ( $K_m = 74 \mu\text{M}$ ). These ATP-phosphopeptide conjugates may serve as novel templates for designing protein tyrosine kinase inhibitors to block SH2 mediated protein-protein interactions and to counter the activation of enzyme that resulted from the SH2 inhibition.

REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 19 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:839015 HCAPLUS

DOCUMENT NUMBER: 142:168609

TITLE: Design strategies for protein kinase inhibitors

AUTHOR(S): **Parang, Keykavous**; Sun, Gongqin

CORPORATE SOURCE: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Current Opinion in Drug Discovery & Development (2004), 7(5), 617-629

CODEN: CODDF; ISSN: 1367-6733



PUBLISHER: Thomson Scientific  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. The deregulation of protein kinases due to mutation or overexpression is a hallmark of several diseases, e.g., cancer, diabetes, inflammation, and cardiovascular disorders. Consequently, there has been a growing interest in the discovery of protein kinase inhibitors as novel drugs. Here, the authors focus on key milestones and advances in protein kinase inhibitor drug discovery over the last year, with an emphasis on novel strategies such as targeting of single and multiple binding sites, inactive conformations of kinases allosteric sites, regulatory domains, and heat shock proteins. The authors highlight recent developments for specific inhibitors in clin. studies for growth factor receptors, non-receptor tyrosine kinases and serine/threonine kinases.

REFERENCE COUNT: 139 THERE ARE 139 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 20 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:581031 HCAPLUS

DOCUMENT NUMBER: 141:309958

TITLE: Copper dipicolinates as peptidomimetic ligands for the Src SH2 domain

AUTHOR(S): Schmidt, Boris; Jiricek, Jan; Titz, Alexander; Ye, Guofeng; **Parang, Keykavous**

CORPORATE SOURCE: Institute for Organic Chemistry and Biochemistry, Darmstadt Technical University, Darmstadt, D-64287, Germany

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4203-4206

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:309958

AB The introduction of copper chelates into peptide mimetics creates the Src SH2 binding ligands and paramagnetic complexes suitable for EPR studies of peptide protein interactions. The dipicolinic acid was attached to SH2 domain targeting fragments by two different linkers.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 21 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:377215 HCAPLUS

DOCUMENT NUMBER: 141:89359

TITLE: Conformationally Constrained Peptide Analogues of pTyr-Glu-Glu-Ile as Inhibitors of the Src SH2 Domain Binding

AUTHOR(S): Nam, Nguyen-Hai; Ye, Guofeng; Sun, Gongqin; **Parang, Keykavous**

CORPORATE SOURCE: Department of Biomedical Sciences and Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(12), 3131-3141

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of conformationally-constrained peptides were designed and

synthesized as the Src SH2 domain ligands based on a tetrapeptide sequence pTyr-Glu-Glu-Ile (pYEEI). In general, the constrained peptides showed higher binding affinities to the Src SH2 domain relative to the corresponding linear peptides as evaluated by a fluorescence polarization assay. Mol. modeling studies revealed that in constrained peptides, the isoleucine side chain penetrates very deeply into the hydrophobic binding pocket (P + 3 site) of the Src SH2 domain. These constrained peptides can serve as novel templates for the design of small and nonpeptidic inhibitors of the Src SH2 domain.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 22 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:298961 HCAPLUS

DOCUMENT NUMBER: 141:277230

TITLE: Total synthesis and in vitro antifungal activity of (+)-2-methoxytetradecanoic acid

AUTHOR(S): Carballeira, Nestor M.; Ortiz, Denisse; **Parang, Keykavous**; Sardari, Soroush

CORPORATE SOURCE: Department of Chemistry, University of Puerto Rico, San Juan, 00931-3346, P. R.

SOURCE: Archiv der Pharmazie (Weinheim, Germany) (2004), 337(3), 152-155

CODEN: ARPMAS; ISSN: 0365-6233

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:277230

AB The marine fatty acid (+)-2-methoxytetradecanoic acid was synthesized in two steps (71% overall yield) starting from com. available Me 2-hydroxytetradecanoate. The total synthesis of title racemic was accomplished by methylating com. available Me 2-hydroxytetradecanoate with Me iodide and hydrolysis with sodium hydride in DMSO which afforded Me 2-methoxytetradecanoic acid. The title compound was antifungal against *Candida albicans* (ATCC 14053) in RPMI medium and *Aspergillus niger* (ATCC 16404) and *Cryptococcus neoformans* (ATCC 66031) in SDB medium at the min. inhibitory concentration (MIC) of 100 mM, which compares to the fungi-toxicity

of

a 2-iodotetradecanoic acid against the same fungi. The title compound was also five to ten times more cytotoxic than capric acid to *C. albicans* and *A. niger* in the tested medium but comparable in cytotoxicity to either capric acid and its 2-methoxylated analog to *C. neoformans*. The antifungal activity of (+)-2-methoxytetradecanoic acid is explained in terms of inhibition of N-myristoyltransferase.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 23 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:192742 HCAPLUS

DOCUMENT NUMBER: 141:306676

TITLE: Inhibitors of Protein Kinase Signaling Pathways

AUTHOR(S): Force, Thomas; Kuida, Keisuke; Namchuk, Mark;

**Parang, Keykavous**; Kyriakis, John M.

CORPORATE SOURCE: Molecular Cardiology Research Institute, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, MA, USA

SOURCE: Circulation (2004), 109(10), 1196-1205

CODEN: CIRCAZ; ISSN: 0009-7322

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Protein kinases are enzymes that covalently modify proteins by attaching phosphate groups (from ATP) to serine, threonine, and/or tyrosine residues. In so doing, the functional properties of the protein kinase's substrates are modified. Protein kinases transduce signals from the cell membrane into the interior of the cell. Such signals include not only those arising from ligand-receptor interactions but also environmental perturbations such as when the membrane undergoes mech. deformation (ie, cell stretch or shear stress). Ultimately, the activation of signaling pathways that use protein kinases often culminates in the reprogramming of gene expression through the direct regulation of transcription factors or through the regulation of mRNA stability or protein translation. Protein kinases regulate most aspects of normal cellular function. The pathophysiol. dysfunction of protein kinase signaling pathways underlies the mol. basis of many cancers and of several manifestations of cardiovascular disease, such as hypertrophy and other types of left ventricular remodeling, ischemia/reperfusion injury, angiogenesis, and atherogenesis. Given their roles in such a wide variety of disease states, protein kinases are rapidly becoming extremely attractive targets for drug discovery, probably second only to heterotrimeric G protein-coupled receptors (eg, angiotensin II). Here, we will review the reasons for this explosion in interest in inhibitors of protein kinases and will describe the process of identifying novel drugs directed against kinases. We will specifically focus on disease states for which drug development has proceeded to the point of clin. or advanced preclin. studies.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 24 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:94576 HCAPLUS

DOCUMENT NUMBER: 140:350021

TITLE: Design of tetrapeptide ligands as inhibitors of the Src SH2 domain

AUTHOR(S): Nam, Nguyen-Hai; Pitts, Rebecca L.; Sun, Gongqin; Sardari, Soroush; Tiemo, Amie; Xie, Mingxing; Yan, Bingfang; **Parang, Keykavous**

CORPORATE SOURCE: College of Pharmacy, Department of Biomedical Sciences, The University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Bioorganic &amp; Medicinal Chemistry (2004), 12(4), 779-787

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Src homol.-2 (SH2) domains are noncatalytic motifs containing approx. 100 amino acid residues that are involved in intracellular signal transduction. The phosphotyrosine-containing tetrapeptide pTyr-Glu-Glu-Ile (pYEEI) binds to Src SH2 domain with high affinity ( $K_d = 100$  nM). The development of five classes of tetrapeptides as inhibitors for the Src SH2 domain is described. Peptides were prepared via solid-phase peptide synthesis and tested for affinity to Src SH2 domain using a fluorescence polarization based assay. All of the N-terminal substituted pYEEI derivs. (class II) presented binding affinity ( $IC_{50}$  = of 2.7-8.6  $\mu$ M) comparable to pYEEI ( $IC_{50}$  = 6.5  $\mu$ M) in this assay. C-Terminal substituted pYEEI derivs. (class III) showed a lower binding affinity with  $IC_{50}$  values of 34-41  $\mu$ M. Amino-substituted phenylalanine derivs. (class IV) showed weak binding affinities ( $IC_{50}$  = 16-153  $\mu$ M). Other substitutions on Ph ring (class I) or the replacement of the Ph ring with other cyclic groups

(class V) dramatically decreased the binding of tetrapeptides to Src SH2 (IC<sub>50</sub> > 100  $\mu$ M). The ability of pYEEI and several of the tetrapeptides to inhibit the growth of cancer cells were assessed in a cell-based proliferation assay in human embryonic kidney (HEK) 293 tumor cells. The binding affinity of several of tested compds. against Src SH2 domain correlates with antiproliferative activity in 293T cells. None of the compds. showed any significant antifungal activity against *Candida albicans* ATCC 14053 at the maximum tested concentration of 10  $\mu$ M. Overall, these

results provided the structure-activity relationships for some FEEI and YEEI derivs. designed as Src SH2 domain inhibitors.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 25 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:992912 HCAPLUS

DOCUMENT NUMBER: 140:177191

TITLE: Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase

AUTHOR(S): Lee, Sungsoo; Lin, Xiaofeng; Nam, Nguyen Hai;

**Parang, Keykavous**; Sun, Gongqin

CORPORATE SOURCE: Departments of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2003), 100(25), 14707-14712  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein tyrosine kinases (PTK) are key enzymes of mammalian signal transduction. For the fidelity of signal transduction, each PTK phosphorylates only one or a few proteins on specific Tyr residues. Substrate specificity is thought to be mediated by PTK-substrate docking interactions and recognition of the phosphorylation site sequence by the kinase active site. However, a substrate-docking site has not been determined on any PTK. C-terminal Src kinase (Csk) is a PTK that specifically phosphorylates Src family kinases on a C-terminal Tyr. In this study, by sequence alignment and site-specific mutagenesis, we located a substrate-docking site on Csk. Mutations in the docking site disabled Csk to phosphorylate, regulate, and complex with Src but only moderately affected its general kinase activity. A peptide mimicking the docking site potently inhibited (IC<sub>50</sub> = 21  $\mu$ M) Csk phosphorylation of Src but only moderately inhibited (IC<sub>50</sub> = 422  $\mu$ M) its general kinase activity. Determination of the substrate-docking site provides the structural basis of substrate specificity in Csk and a model for understanding substrate specificity in other PTKs.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 26 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:924736 HCAPLUS

DOCUMENT NUMBER: 140:209724

TITLE: Protein kinases and their modulation in the central nervous system

AUTHOR(S): Sardari, S.; Pourmorad, F.; Tiemo, A.; Nam, N. H.;

**Parang, K.**

CORPORATE SOURCE: Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Current Medicinal Chemistry: Central Nervous System

Agents (2003), 3(4), 341-364  
 CODEN: CMCCCO; ISSN: 1568-0150  
 PUBLISHER: Bentham Science Publishers Ltd.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. Protein kinases (PKs) mediate neuronal morphol., differentiation, survival, repair, and plasticity in central nervous system (CNS). In this review, the structure and function of PKs involved in CNS function, various neurol. disorders, learning process, and memory are discussed. Certain types of PKs and their ligands have been implicated in memory and learning, axon guidance, the formation of neural projections, axon fasciculation, cell migration, and neurotrophin signaling. Many of these functions are regulated via the action of protein tyrosine kinases (PTKs) and their ligands, such as epidermal growth factor (EGF) receptor, Janus kinase-signal transducer and activator of transcription (JAK/STAT), Fyn-tyrosine kinase, Eph receptors, and neurotrophins (NTs) [e.g., brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF)]. Serine/threonine kinases, such as activins, bone morphogenic proteins (BMPs), mitogen-activated protein (MAP) kinases (e.g., p44/42 MAPK, c-Jun N-terminal kinase, p38 MAPKs), and protein kinases A (PKA) and C (PKC) and their function in the CNS are also discussed. The role of protein kinase inhibitors (PKIs), isolated from microbial, botanical sources or synthesized by conventional approaches, in determining CNS signaling cascades and function, and the treatment of neurol. disorders is reviewed.

REFERENCE COUNT: 407 THERE ARE 407 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 27 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:701491 HCAPLUS  
 DOCUMENT NUMBER: 140:23107  
 TITLE: Anti-HIV Design. [In: Curr. Pharm. Des., 2003; 9(22)]  
 AUTHOR(S): Parang, K.; Editor  
 CORPORATE SOURCE: United Arab Emirates  
 SOURCE: (2003) Publisher: (Bentham Science Publishers Ltd.: Sharjah, United Arab Emirates), 71 pp.  
 DOCUMENT TYPE: Book  
 LANGUAGE: English  
 AB Unavailable

L2 ANSWER 28 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:634960 HCAPLUS  
 TITLE: Modeling of activity for biological samples using artificial neural network  
 AUTHOR(S): Sardari, S.; Parang, K.  
 CORPORATE SOURCE: Department of Biomedical Sciences, University of Rhode Island, Kingston, RI, 02881-0809, USA  
 SOURCE: Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), MEDI-352. American Chemical Society: Washington, D. C.  
 CODEN: 69EKY9  
 DOCUMENT TYPE: Conference; Meeting Abstract  
 LANGUAGE: English

AB Purpose: The applicability of artificial neural network (ANN) modeling to bioactivity determination of a group of natural product samples based on bioinformatic descriptors, laboratory data and database indexing terms is studied. Method: The system of analyzing large amts. of indexing term from CA database, using ANN is presented. The architecture was optimized

to prevent memorization while maximizing the efficiency. The group of selected descriptors applied into the optimized ANN included designated taxonomic position of the sources, DNA-C values, chemical, ecol. and bioactivity notions. The predictability of the model was tested on members of the training and test groups. Results: The average error of 0.049 for a target of 0.05 after 63 cycles was obtained. The relative importance for descriptor data was pooled. The top three were biol. activity, DNA values and chemical notion. Predictability of the model was %95.00. The applicability of database terms in such modeling has been discussed.

L2 ANSWER 29 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:617637 HCAPLUS  
 DOCUMENT NUMBER: 139:276446  
 TITLE: Reactions of Solid-Supported Reagents and Solid Supports with Alcohols and Phenols through Their Hydroxyl Functional Group  
 AUTHOR(S): Nam, Nguyen-Hai; Sardari, Soroush; **Parang, Keykavous**  
 CORPORATE SOURCE: Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA  
 SOURCE: Journal of Combinatorial Chemistry (2003), 5(5), 479-546  
 CODEN: JCCHFF; ISSN: 1520-4766  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review discusses the attachment of alcs. and phenols to resins through reactions with either supported reagents or with the supports themselves. The reactions of alcs. and phenols with solid-supported reagents, the attachment of alcs. and phenols as ethers and esters through Mitsunobu reactions, the synthesis and functionalization of carbohydrates on solid support, the synthesis of oligonucleotides on solid support, and miscellaneous other methods for the attachment of alcs. and phenols to supports are discussed in the review.

REFERENCE COUNT: 434 THERE ARE 434 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L2 ANSWER 30 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:89031 HCAPLUS  
 DOCUMENT NUMBER: 139:46173  
 TITLE: Current targets for anticancer drug discovery  
 AUTHOR(S): Nam, Nguyen-Hai; **Parang, Keykavous**  
 CORPORATE SOURCE: Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA  
 SOURCE: Current Drug Targets (2003), 4(2), 159-179  
 CODEN: CDTUUAU; ISSN: 1389-4501  
 PUBLISHER: Bentham Science Publishers Ltd.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biol. have led to the identification of a number of mols., which are important for the progression of these processes. Of particular interest is a group of growth factors including fibroblast growth factor, platelet-derived growth

factor, and vascular endothelial growth factor. These growth factors and their corresponding receptor tyrosine kinases have become important targets for inhibition of the proliferation of endothelial cells, the main component of blood vessels. The validated targets for inhibition of angiogenesis also include a family of matrix metalloproteinases and cell adhesion mols. In the closely related area, protein kinases have emerged as one of the most important targets for drug discovery. Besides growth factor receptor tyrosine kinases, numerous other protein kinases implicated in malignancies have been identified including non-receptor kinases such as Bcl-Abl and Src kinases. In addition, the cell cycle regulators (cyclin-dependent kinases, p21 gene) and apoptosis modulators (Bcl-2 oncoprotein, p53 tumor suppressor gene, survivin protein, etc) have also attracted renewed interest as potential targets for anticancer drug discovery. Other mol. targets include protein farnesyltransferase (FTase), histone deacetylase (HDAC), and telomerase, which have essential roles in cellular signal transduction pathways (FTase, HDAC) and cell life span (telomerase). This review presents a comprehensive summary and discussion on the most important targets currently attracting a great deal of interest in contemporary anticancer drug design and discovery. Recent advances complementing these targets are also highlighted.

REFERENCE COUNT: 147 THERE ARE 147 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 31 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:617960 HCAPLUS

TITLE: Design and synthesis of peptide analogues as inhibitors of Src tyrosine kinase

AUTHOR(S): Pitts, Rebecca L.; Parang, Keykavous; Sun, Gonquin

CORPORATE SOURCE: Biomedical Sciences, University of Rhode Island, Kingston, RI, 02881, USA

SOURCE: Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (2002), MEDI-107. American Chemical Society: Washington, D. C.

CODEN: 69CZPZ

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB The role of Src tyrosine kinase in disease states including cancer has been well elucidated. The rational design and synthesis of potent Src inhibitors provides an attractive target in the development of anti-cancer agents. Src homol.-2 (SH2) domains are noncatalytic motifs that recognize phosphorylated tyrosine (pTyr) residues on substrate proteins and elicit phosphorylation events downstream in the signaling pathway. Affinity of the SH2 domain to phosphopeptide substrates is highly dependent on the amino acid sequence C-terminal to the pTyr. The affinity of the tetrapeptide pTyr-Glu-Glu-Ile (pYEEI) to Src SH2 domains presents a lead structure in the rational design of Src inhibitors. Several unnatural Y\*EEI and F\*EEI (\* is a substituent(s); e.g. -I, -F, -NO2) tetrapeptides have been synthesized via solid phase peptide synthesis and assayed against Src SH2. Early work using 4-nitrophenylalanine in the pTyr position failed to yield a compound more potent than the endogenous ligand (Kd > 1000 nM). However, reduction of the nitro group allows subsequent substitution of anionic groups to mimic the interactions of pTyr with the SH2 domain. This current investigation focuses on the design and synthesis of a small library of such derivs. whose affinity to Src SH2 domain are evaluated by fluorescence polarization.

L2 ANSWER 32 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:481780 HCAPLUS  
DOCUMENT NUMBER: 137:325588  
TITLE: Polymer-supported reagents for methylphosphorylation and phosphorylation of carbohydrates  
AUTHOR(S): Parang, Keykavous  
CORPORATE SOURCE: Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(14), 1863-1866  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 137:325588

AB Two polymer-supported reagents for methylphosphorylation and phosphorylation of carbohydrates have been developed. P-Hydroxybenzyl alc. and  $\beta$ -mercaptoethanol were immobilized on cross-linked divinylbenzene-polystyrene copolymer and conjugated with Me N,N-diisopropylchlorophosphoramidite. Carbohydrates were reacted with polymer-bound phosphitylating reagents. Further oxidation, with or without the methoxy group deprotection, and cleavage yielded methylphosphorylated or phosphorylated carbohydrates, resp.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 33 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:440277 HCAPLUS  
DOCUMENT NUMBER: 138:100144  
TITLE: Designing bisubstrate analog inhibitors for protein kinases  
AUTHOR(S): Parang, Keykavous; Cole, Philip A.  
CORPORATE SOURCE: College of Pharmacy, Department of Biomedical Sciences, University of Rhode Island, Kingston, RI, 02881, USA  
SOURCE: Pharmacology & Therapeutics (2002), 93(2-3), 145-157  
CODEN: PHTHDT; ISSN: 0163-7258  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Protein kinases play critical roles in signal transduction pathways by transmitting extracellular signals across the cell membrane to distant locations in the cytoplasm and the nucleus. The development of protein kinase inhibitors has been hindered by the broad overlapping substrate specificities exhibited by these enzymes. The design of bisubstrate analog inhibitors could provide for the enhancement of specificity and potency in protein kinase inhibition. Bisubstrate analog inhibitors form a special group of protein kinase inhibitors that mimic two natural substrates/ligands and that simultaneously associate with two regions of given kinases. Most bisubstrate analogs have been designed to mimic the phosphate donor (ATP) and the acceptor components (Ser-, Thr-, or Tyr-containing peptides). Recent studies have emphasized the importance of maintaining a specific distance between these two components to achieve potent inhibition. In this review, we present a discussion of the methods for designing protein kinase inhibitors by mechanism-based approaches. Emphasis is given to bivalent approaches, with an interpretation of what has been learned from more and less successful examples. Future challenges in this area are also highlighted.

REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L2 ANSWER 34 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:417366 HCAPLUS  
 DOCUMENT NUMBER: 137:212726  
 TITLE: Development of photo-crosslinking reagents for protein kinase-substrate interactions  
 AUTHOR(S): Parang, Keykavous; Kohn, Jeffrey A.; Saldanha, S. Adrian; Cole, Philip A.  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA  
 SOURCE: FEBS Letters (2002), 520(1-3), 156-160  
 CODEN: FEBLAL; ISSN: 0014-5793  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 137:212726

AB The identification of relevant protein kinase-protein substrate partners remains a serious challenge on a genome-wide scale. The design and synthesis of a photo-activatable nucleotide reagent to crosslink protein kinases with their substrates is described in which an azido group is appended to the  $\gamma$ -phosphoryl and purine moieties of ATP. In the absence of UV, compds. of this class were shown to act as competitive inhibitors vs. ATP and non-competitive inhibitors vs. peptide substrate for the protein tyrosine kinase Csk, suggesting that they can form a ternary complex with kinase and protein substrate. In vitro expts. with protein kinases indicate the bifunctional reagent can induce covalent protein-protein crosslinking that is dependent on UV irradiation. That significant kinase-substrate crosslinking occurs is suggested by the fact that this crosslinking is competitively inhibited by ATP. The crosslinked adducts can be readily cleaved by phosphodiesterase which supports the model for crosslinking and provides a simple method to deconvolute the linked protein partners.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 35 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:303593 HCAPLUS  
 DOCUMENT NUMBER: 137:150183  
 TITLE: Anti-HIV Design  
 AUTHOR(S): Parang, Keykavous; Editor  
 CORPORATE SOURCE: Neth.  
 SOURCE: (2002) Publisher: (Bentham Science Publishers: Hilversum, Neth.), 107 pp.  
 DOCUMENT TYPE: Book  
 LANGUAGE: English  
 AB Unavailable

L2 ANSWER 36 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:298454 HCAPLUS  
 TITLE: Preface  
 AUTHOR(S): Parang, Keykavous  
 CORPORATE SOURCE: Department of Biomedical Sciences College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA  
 SOURCE: Current Pharmaceutical Design (2002), 8(8), NO pp.given  
 CODEN: CPDEFP; ISSN: 1381-6128  
 PUBLISHER: Bentham Science Publishers  
 DOCUMENT TYPE: Journal; Miscellaneous  
 LANGUAGE: English

AB Unavailable

L2 ANSWER 37 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:713377 HCAPLUS  
 DOCUMENT NUMBER: 135:253738  
 TITLE: Bisubstrate inhibitors of kinases  
 INVENTOR(S): Courtney, Aliya; Cole, Philip A.; **Parang, Keykavous**; Abloogu, Ararat; Kohanski, Ron  
 PATENT ASSIGNEE(S): Johns Hopkins University, USA  
 SOURCE: PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070770	A2	20010927	WO 2001-US8886	20010321
WO 2001070770	A3	20020704		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002031820	A1	20020314	US 2001-811870	20010321

PRIORITY APPLN. INFO.: US 2000-190799P P 20000321

AB Protein kinase inhibitors have applications as anti-cancer therapeutic agents and biol. tools in cell signalling. Potent and selective bisubstrate inhibitors for the insulin receptor tyrosine kinase are based on a phosphoryl transfer mechanism involving a dissociative transition state. One such inhibitor is synthesized by linking ATPyS to a peptide substrate analog via a two-carbon spacer. The compound is a high-affinity competitive inhibitor against both nucleotide and peptide substrate and shows a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirms the key design features inspired by a dissociative transition state, and reveal that the linker takes part in the octahedral coordination of an active site Mg<sup>2+</sup> ion. A Kemptide-ATPyS compound was also prepared This compound was an inhibitor of protein kinase A.

L2 ANSWER 38 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:37882 HCAPLUS  
 DOCUMENT NUMBER: 134:218831  
 TITLE: Mechanism-based design of a protein kinase inhibitor  
 AUTHOR(S): **Parang, Keykavous**; Till, Jeffrey H.; Ablooglu, Ararat J.; Kohanski, Ronald A.; Hubbard, Stevan R.; Cole, Philip A.  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA  
 SOURCE: Nature Structural Biology (2001), 8(1), 37-41  
 CODEN: NSBIEW; ISSN: 1072-8368  
 PUBLISHER: Nature America Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Protein kinase inhibitors have applications as anticancer therapeutic agents and biol. tools in cell signaling. Based on a phosphoryl transfer mechanism involving a dissociative transition state, a potent and selective bisubstrate inhibitor for the insulin receptor tyrosine kinase was synthesized by linking ATPyS to a peptide substrate analog via a two-carbon spacer. The compound was a high affinity competitive inhibitor against both nucleotide and peptide substrates and showed a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirmed the key design features inspired by a dissociative transition state, and revealed that the linker takes part in the octahedral coordination of an active site  $Mg^{2+}$ . These studies suggest a general strategy for the development of selective protein kinase inhibitors.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 39 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:6627 HCAPLUS

DOCUMENT NUMBER: 134:178758

TITLE: A Solid Phase Reagent for the Capture Phosphorylation of Carbohydrates and Nucleosides

AUTHOR(S): Parang, Keykavous; Fournier, Eric J.-L.; Hindsgaul, Ole

CORPORATE SOURCE: Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Can.

SOURCE: Organic Letters (2001), 3(2), 307-309  
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:178758

AB A 1% cross-linked divinylbenzene-polystyrene copolymer, containing cyanoethoxy N,N-diisopropylamine phosphine was prepared as a phosphitylating agent. The polymer-bound phosphitylated precursor was subjected to reaction with alcs. in the presence of 1H-tetrazole to produce the corresponding polymer-bound phosphite triesters. These were then oxidized with tert-Bu hydroperoxide to give the polymer-bound monophosphate triesters. Removal of cyanoethoxy on the resin with DBU followed by basic cleavage of the p-hydroxybenzyl linker products yielded monophosphate derivs.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 40 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:722331 HCAPLUS

DOCUMENT NUMBER: 134:53060

TITLE: Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate

AUTHOR(S): Ablooglu, Ararat J.; Till, Jeffrey H.; Kim, Kyonghee; Parang, Keykavous; Cole, Philip A.; Hubbard, Stevan R.; Kohanski, Ronald A.

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Journal of Biological Chemistry (2000), 275(39), 30394-30398  
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The interaction of a synthetic tetrafluorotyrosyl peptide substrate with the activated tyrosine kinase domain of the insulin receptor was studied by steady-state kinetics and x-ray crystallog. The pH-rate profiles indicate that the neutral phenol, rather than the chemical more reactive phenoxide ion, is required for enzyme-catalyzed phosphorylation. The pKa of the tetrafluorotyrosyl hydroxyl is elevated 2 pH units on the enzyme compared with solution, whereas the phenoxide anion species behaves as a weak competitive inhibitor of the tyrosine kinase. A structure of the binary enzyme-substrate complex shows the tetrafluorotyrosyl OH group at hydrogen bonding distances from the side chains of Asp1132 and Arg1136, consistent with elevation of the pKa. These findings strongly support a reaction mechanism favoring a dissociative transition state.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 41 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 2000:678356 HCAPLUS

DOCUMENT NUMBER: 133:358790

TITLE: Novel approaches for designing 5'-O-ester prodrugs of 3'-Azido-2',3'-dideoxythymidine (AZT)

AUTHOR(S): Parang, Keykavous; Wiebe, Leonard I.; Knaus, Edward E.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205-2185, USA

SOURCE: Current Medicinal Chemistry (2000), 7(10), 995-1039  
CODEN: CMCHE7; ISSN: 0929-8673

PUBLISHER: Bentham Science Publishers

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 272 refs. 3'-Azido-2',3'-dideoxythymidine (AZT, 1, zidovudine, Retrovir) is used to treat patients with human immunodeficiency virus (HIV) infection. AZT, after conversion to AZT-5'-triphosphate (AZT-TP) by cellular enzymes, inhibits HIV-reverse transcriptase (HIV-RT). The major clin. limitations of AZT are due to clin. toxicities that include bone marrow suppression, hepatic abnormalities and myopathy, absolute dependence on host cell kinase-mediated activation which leads to low activity, limited brain uptake, a short half-life of about one hour in plasma that dictates frequent administration to maintain therapeutic drug levels, low potential for metabolic activation and/or high susceptibility to catabolism, and the rapid development of resistance by HIV-1. These limitations have prompted the development of strategies for designing prodrugs of AZT. A variety of 5'-O-substituted prodrugs of AZT constitute the subject of this review. The drug-design rationale on which these approaches are based is that the ester conjugate will be converted by hydrolysis and/or enzymic cleavage to AZT or its 5'-monophosphate (AZT-MP). Most prodrug derivs. of AZT have been prepared by derivatization of AZT at its 5'-O position to provide two prominent classes of compds. that encompass: (A) 5'-O-carboxylic esters derived from (1) cyclic 5'-O-carboxylic acids such as steroidal 17 $\beta$ -carboxylic acids, 1-adamantanecarboxylic acid, bicyclam carboxylic acid derivs., O-acetylsalicylic acid, and carbohydrate derivs., (2) amino acids, (3) 1,4-dihydro-1-methyl-3-pyridinylcarboxylic acid, (4) aliphatic fatty acid analogs such as myristic acid containing a heteroatom, or without a heteroatom such as stearic acid, and (5) long chain polyunsatd. fatty acid analogs such as retinoic acid, and (B) masked phosphates such as (1) phosphodiester that include monoalkyl or monoaryl phosphate, carbohydrate, ether lipid, ester lipid, and foscarnet derivs., (2) a variety of phosphotriesters that include dialkylphosphotriesters,

diarylphosphotriesters, glycolate and lactate phosphotriesters, phosphotriester approaches using simultaneous enzymic and chemical hydrolysis of bis(4-acyloxybenzyl) esters, bis(S-acyl-2-thioethyl) (SATE) esters, cyclosaligenyl prodrugs, glycosyl phosphotriesters, and steroidal phosphotriesters, (3) phosphoramidate derivs., (4) dinucleoside phosphate derivs. that possess a second anti-HIV moiety such as AZT-P-ddA, AZT-P-ddI, AZTP2AZT, AZTP2ACV, and (5) 5'-hydrogen phosphonate and 5'-methylene phosphonate derivs. of AZT. In these prodrugs, the conjugating moiety is linked to AZT via a 5'-O-ester or 5'-O-phosphate group. 5'-O-Substituted AZT prodrugs have been designed with the objectives of improving anti-HIV activity, enhancing blood-brain barrier penetration, modifying pharmacokinetic properties to increase plasma half-life and improving drug delivery with respect to site-specific targeting or drug localization. Bypassing the first phosphorylation step, regulating transport and conferring sustained release of AZT prolong its duration of action, decrease toxicity and improve patient acceptability. The properties of these prodrugs and their anti-HIV activities are now reviewed.

REFERENCE COUNT: 272 THERE ARE 272 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 42 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:454823 HCAPLUS

DOCUMENT NUMBER: 133:219288

TITLE: Tyrosine analogues as alternative substrates for protein tyrosine kinase Csk: Insights into substrate selectivity and catalytic mechanism

AUTHOR(S): Kim, K.; Parang, K.; Lau, O. D.; Cole, P. A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(6), 1263-1268

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein tyrosine kinases are critical enzymes in cell signal transduction but relatively little is known about the mol. recognition of the tyrosine substrate by these enzymes. Details of tyrosine substrate specificity within the context of a short peptide were investigated for protein tyrosine kinase Csk. It was found that aryl ring functional group substitutions the size of Me group or smaller were generally well tolerated by the protein tyrosine kinase Csk whereas larger groups caused a decline in substrate efficiency. Extension of the phenol from the peptide backbone by a single methylene was acceptable for phosphorylation whereas removal of a methylene nearly abolished reactivity. Only the L-tyrosine derivative was processed. A neg. charge ortho to the phenol hydroxyl was incompatible with substrate reactivity, consistent with previous pH rate profiles which indicated the importance of the neutral phenol. Overall, these studies confirmed the interpretation of a previous linear free energy relationship anal. which suggested that the enzyme followed a dissociative transition state mechanism.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 43 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:332295 HCAPLUS

TITLE: Solid-phase strategy in the monophosphorylation of

carbohydrates and nucleosides.

AUTHOR(S): **Parang, Keykavous**; Fournier, Eric J-L.; Hindsgaul, Ole

CORPORATE SOURCE: Dept. of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (2000), ORGN-170. American Chemical Society: Washington, D. C. CODEN: 69CLAC

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB A novel solid-phase assisted strategy for the regio- and stereoselective monophosphorylation of carbohydrates and nucleosides has been developed. Phosphorylation using solid-phase offers the advantages of facile isolation and the recovery of monophosphorylated products. A 1% crosslinked divinylbenzene-polystyrene copolymer, containing cyanoethoxy N,N-diisopropylamine phosphine was prepared as a phosphite donor. To demonstrate the utility and specificity of a solid-phase monophosphorylation system, the polymer-bound phosphorylated precursor was subjected to reactions with 1,2:3,4-di-O-isopropylidene-D-galactopyranose, n-octyl- $\beta$ -D-glucopyranoside, D-galactose pentaacetate and uridine in the presence of 1-H-tetrazole to give the appropriate polymer-bound phosphite triesters. The resulting polymer-bound phosphite triesters were then oxidized with tert-Bu hydroperoxide to give the polymer-bound monophosphate triesters of the corresponding compds. The deprotection of cyanoethoxy with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) followed by basic cleavage cleavage from the resin yielded 1,2:3,4-di-O-isopropylidene-D-galactopyranosyl-6-phosphate, n-octyl- $\beta$ -D-glucopyranosyl-6-phosphate,  $\alpha$ -D-galactopyranosyl 1-phosphate and uridine-5'-monophosphate, resp.

L2 ANSWER 44 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:327119 HCAPLUS

TITLE: Substrate selectivity of unnatural tyrosine derivatives for protein tyrosine kinase csk.

AUTHOR(S): Kim, Kyonghee; **Parang, Keykavous**; Lau, Ontario D.; Cole, Philip A.

CORPORATE SOURCE: Dept. of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (2000), BIOL-078. American Chemical Society: Washington, D. C. CODEN: 69CLAC

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Protein tyrosine kinases are critical enzymes in cell signal transduction. Details of tyrosine substrate specificity were investigated including features of charge, steric bulk, stereochem., aryl displacement from peptide backbone and hydrogen bonding. For example, a neg. charge ortho to phenol hydroxyl was incompatible with substrate reactivity, consistent with previous pH rate profiles which indicated the importance of the neutral phenol. Overall, these studies confirm the interpretation of a previous linear free energy relationship anal. which suggested that the enzyme follows a dissociative transition state mechanism.

L2 ANSWER 45 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:506025 HCAPLUS

DOCUMENT NUMBER: 132:87779

TITLE: In vitro anti-hepatitis B virus activities of 5'-O-myristoyl analogue derivatives of 3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-azido-2',3'-dideoxythymidine (AZT)

AUTHOR(S): Parang, Keykavous; Wiebe, Leonard I.; Knaus, Edward E.

CORPORATE SOURCE: Fac. Pharmacy and Pharmaceutical Sciences, Univ. Alberta, Edmonton, AB, T6G 2N8, Can.

SOURCE: Journal of Pharmacy & Pharmaceutical Sciences [Electronic Publication] (1998), 1(3), 108-114  
CODEN: JPPSFY; ISSN: 1482-1826

PUBLISHER: Canadian Society for Pharmaceutical Sciences

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB The objective of this study was to evaluate a dual action prodrug concept wherein an unnatural myristic acid analog is coupled via an ester moiety to the 5'-position of FLT or AZT. Subsequent intracellular cleavage of the prodrug ester would simultaneously release FLT or AZT that could inhibit reverse transcriptase (RT), and the myristic acid analog that could inhibit myristoyl-CoA:protein N-myristoyltransferase (NMT). Cytotoxicity (2.2.15 cell culture), and anti-hepatitis B activity of 5'-O-myristoyl analog prodrug derivs. of FLT and AZT (2-8) were evaluated in vitro using human liver hepatitis B virus (HBV) producing 2.2.15 cell lines. The 5'-O-(12-methoxydodecanoyl) ester derivs. of AZT (2, EC50 =  $2.7 \pm 0.3 \mu\text{M}$ ; CC50 =  $727 \pm 19 \mu\text{M}$ ) and FLT (4, EC50 =  $2.8 \pm 0.3 \mu\text{M}$ ; CC50 =  $186 \pm 20 \mu\text{M}$ ) were the most effective anti-hepatitis B virus (anti-HBV) compds. of this series in a replication assay. In the series of 5'-O-myristic acid analog ester prodrug derivs. of FLT, the relative anti-HBV potency order was  $\text{MeO}(\text{CH}_2)_{11}\text{CO}_2-$  >  $\text{N}_3(\text{CH}_2)_{11}\text{CO}_2-$  and  $\text{Br}(\text{CH}_2)_{11}\text{CO}_2-$  >  $\text{EtS}(\text{CH}_2)_8\text{CO}_2-$  (n = 10 or 11) >  $\text{Me}(\text{CH}_2)_{12}\text{CO}_2-$  (myristoyl). The in vitro data suggest that the 5'-O-myristoyl analog prodrug concept offers a potential drug design approach to design dual acting antiviral agents, with superior pharmacokinetic, biodistribution, reduced cytotoxicity and/or increased efficacy. In this regard, the 5'-O-(12-methoxydodecanoyl) prodrug ester of 3'-thia-3'-deoxythymidine (3TC) may offer the greatest potential for the treatment of HBV infection.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 46 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:681024 HCAPLUS

DOCUMENT NUMBER: 130:60568

TITLE: Pharmacokinetics and tissue distribution of ( $\pm$ )-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice

AUTHOR(S): Parang, Keykavous; Wiebe, Leonard I.; Knaus, Edward E.

CORPORATE SOURCE: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2N8, Can.

SOURCE: Journal of Pharmacy and Pharmacology (1998), 50(9), 989-996  
CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Royal Pharmaceutical Society of Great Britain

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The in-vivo biodistribution and pharmacokinetics in mice of 3'-azido-2',3'-dideoxythymidine (AZT), 2-bromomyristic acid and their common prodrug, ( $\pm$ )-3'-azido-2',3'-dideoxy-5'-O-(2-

bromomyristoyl)thymidine (I) are reported. The objectives of the work were to enhance the anti-human immunodeficiency virus and anti-fungal effects of AZT and 2-bromomyristic acid by improving their delivery to the brain and liver. The pharmacokinetics of AZT ( $\beta t_{1/2}$  (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) =  $29.1 \pm 2.9 \mu\text{mol g}^{-1} \text{ min}$ ; CL (blood clearance) =  $10.5 \pm 1.1 \text{ mL min}^{-1} \text{ kg}^{-1}$ ) and its ester prodrug (I,  $\beta t_{1/2}$  = 428.5 min; AUC =  $17.3 \pm 4.7 \mu\text{mol g}^{-1} \text{ min}$ ; CL =  $17.6 \pm 4.8 \text{ mL min}^{-1} \text{ kg}^{-1}$ ) were compared after i.v. injection of equimolar doses ( $0.3 \text{ mmol kg}^{-1}$ ) via the tail vein of Balb/c mice (25-30 g). The prodrug was rapidly converted to AZT in-vivo, but plasma levels of AZT (peak concentration  $0.17 \mu\text{mol g}^{-1}$ ) and AUC ( $12.3 \mu\text{mol min g}^{-1}$ ) were lower than observed after AZT administration (peak concentration  $0.36 \mu\text{mol g}^{-1}$ ; AUC  $29.1 \mu\text{mol min g}^{-1}$ ). The prodrug also accumulated rapidly in the liver immediately after injection, resulting in higher concns. of AZT than observed after administration of AZT itself (resp. peak concns. 1.11 and  $0.81 \mu\text{mol g}^{-1}$ ; resp. AUCs 42.5 and  $12.7 \mu\text{mol min g}^{-1}$ ). Compared with doses of AZT itself, I also led to significantly higher brain concentration of AZT ( $25.7$  compared with  $9.8 \text{ nmol g}^{-1}$ ) and AUCs ( $2.8$  compared with  $1.4 \mu\text{mol min g}^{-1}$ ). At the doses used in this study the antifungal agent 2-bromomyristic acid was measurable in plasma and brain within only 2 min of injection. Hepatic concns. of 2-bromomyristic acid were higher for at least 2 h after dosing with 3 than after dosing with the acid itself. In summary, comparative biodistribution studies of AZT and its prodrug showed that the prodrug led to higher concns. of AZT in the brain and liver. Although the prodrug did not result in measurably different concns. of 2-bromomyristic acid in the blood and brain, it did lead to levels in the liver which were higher than those achieved by dosing with the acid itself.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 47 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:529727 HCAPLUS

TITLE: In vitro anti-hepatitis B virus activities of 5'-O-myristoyl analog derivatives of 3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-azido-2',3'-dideoxythymidine (AZT).

AUTHOR(S): Parang, K.; Wiebe, L. I.; Knaus, E. E.; Huang, J.-S.; Tyrrell, D. L.

CORPORATE SOURCE: Department Chemistry, University Alberta, Edmonton, AB, T6G 2G2, Can.

SOURCE: Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-242. American Chemical Society: Washington, D. C. CODEN: 66KYA2

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Cytotoxicity and anti-hepatitis B activity of 5'-O-myristoyl analog prodrug derivs. of FLT and AZT were evaluated in vitro in 2.2.15 cells. The 5'-O-(12-methoxydodecanoyl)ester derivs. of AZT ( $\text{EC}_{50} = 2.7 \pm 0.3 \mu\text{M}$ ;  $\text{CC}_{50} = 727 \pm 19 \mu\text{M}$ ) and FLT ( $\text{EC}_{50} = 2.8 \pm 0.3 \mu\text{M}$ ;  $\text{CC}_{50} = 186 \pm 20 \mu\text{M}$ ) were the most effective anti-hepatitis B virus (anti-HBV) compds. of this series in a replication assay.

L2 ANSWER 48 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:529652 HCAPLUS

TITLE: Novel methodologies for carbohydrate sulfation.

AUTHOR(S): Parang, K.; Hindsgaul, O.

CORPORATE SOURCE: Department Chemistry, University Alberta, Edmonton,



SOURCE: AB, T6G 2G2, Can.  
Book of Abstracts, 216th ACS National Meeting, Boston,  
August 23-27 (1998), MEDI-166. American Chemical  
Society: Washington, D. C.  
CODEN: 66KYA2

DOCUMENT TYPE: Conference; Meeting Abstract  
LANGUAGE: English

AB Crucial biol. roles for sulfated carbohydrate polymers, most notably heparin sulfate, chondroitin sulfate and tetrasaccharide sulfo-sialyl-LeX have long been recognized. The chemical required to synthesize this increasingly important class of mols. has not kept pace with the demands for structurally well defined inhibitors of the adhesion between the target protein receptors and the sulfated sugars. A new method has been developed for sulfation of some carbohydrates using derivs. of 2-hydroxy or 2-aminobenzyl alc. and sulfuryldiimidazole in an inert condition. For example, diacetone glucose was sulfated using 2-( $\alpha$ -hydroxyisopropyl)phenol and sulfuryldiimidazole in DMF to yield diacetone glucose 3-sulfate in 47% yield. This method may be used to develop a solid-phase technique for monosulfation of carbohydrate by immobilizing the sulfating agent on a highly rigid polystyrene matrix.

L2 ANSWER 49 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:513188 HCAPLUS

DOCUMENT NUMBER: 129:239454

TITLE: Synthesis, in vitro anti-human immunodeficiency virus structure-activity relationships and biological stability of 5'-O-myristoyl analog derivatives of 3'-azido-2',3'-dideoxythymidine (AZT) as potential prodrugs

AUTHOR(S): Parang, K.; Wiebe, L. I.; Knaus, E. E.

CORPORATE SOURCE: Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, AB, T6G 2N8, Can.

SOURCE: Antiviral Chemistry & Chemotherapy (1998), 9(4), 311-323

CODEN: ACCHEH; ISSN: 0956-3202

PUBLISHER: International Medical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 5'-O-Myristoyl analog derivs. of 3'-azido-2',3'-dideoxythymidine (AZT), designed as potential double-barrelled prodrugs to AZT and the myristic acid analogs, were synthesized. Their ability to protect CEM cells against human immunodeficiency virus (HIV)-induced cytopathogenicity was determined and structure-activity paradigms were developed. 3'-Azido-2',3'-dideoxy-5'-O-(4-oxatetradecanoyl)thymidine (EC<sub>50</sub>=1.4 nM) and 3'-azido-2',3'-deoxy-5'-O-(12-bromododecanoyl)thymidine (EC<sub>50</sub>=3.2 nM) were the most effective anti-HIV-1 agents, relative to AZT (EC<sub>50</sub>=10 nM). These myristoyl analog derivs. were more lipophilic (calculated log P=4.5-8.1 range) than the parent compound AZT (log P=0.06), and a linear correlation between their log P and HPLC log retention times was observed. The ester cleavage half-lives (t<sub>1/2</sub>) for esters upon in vitro incubation with porcine liver esterase, rat plasma or rat brain homogenate was dependent on the steric bulk, and electroneg. inductive effect of the  $\alpha$ -substituent (H, Br, F), of the 5'-O-myristoyl analog moiety. 3'-Azido-2',3'-dideoxy-5'-O-(11-(4-iodophenoxy) undecanoyl)-thymidine exhibited t<sub>1/2</sub> values of 80.4, 3.7 and 150.0 min upon incubation with porcine liver esterase, rat plasma and rat brain homogenate, resp.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 50 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:329096 HCAPLUS  
DOCUMENT NUMBER: 129:54523  
TITLE: Synthesis, in vitro anti-HIV activity, and biological stability of 5'-O-myristoyl analog derivatives of 3'-fluoro-2',3'-dideoxythymidine (FLT) as potential bifunctional prodrugs of FLT  
AUTHOR(S): **Parang, Keykavous**; Knaus, Edward E.; Wiebe, Leonard I.  
CORPORATE SOURCE: Faculty of Pharmacy, University of Alberta, Edmonton, AB, T6G 2N8, Can.  
SOURCE: Nucleosides & Nucleotides (1998), 17(6), 987-1008  
CODEN: NUNUD5; ISSN: 0732-8311  
PUBLISHER: Marcel Dekker, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A group of 5'-O-myristoyl analog derivs. of FLT were evaluated as potential anti-HIV agents that were designed to serve as prodrugs to FLT. 3'-Fluoro-2',3'-dideoxy-5'-O-(12-methoxydodecanoyl)thymidine (EC50 = 3.8 nM) and 3'-fluoro-2',3'-dideoxy-5'-O-(12-azidododecanoyl)thymidine (EC50 = 2.8 nM) were the most effective anti-HIV-1 agents. There was a linear correlation between Log P and HPLC Log retention time for the 5'-O-FLT esters. The in vitro enzymic hydrolysis half-life (t1/2), among the group of esters in porcine liver esterase, rat plasma and rat brain homogenate was longer for 3'-fluoro-2',3'-dideoxy-5'-O-(myristoyl)thymidine, with t1/2 values of 20.3, 4.6 and 17.5 min, resp.  
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 51 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:217046 HCAPLUS  
DOCUMENT NUMBER: 128:316947  
TITLE: Evaluation of myristic acid analogs and 5'-o-ester prodrugs of thymidine (dthd), 3'-azido-3'-deoxythymidine (azt) and 3'-fluoro-3'-deoxythymidine (flt)  
AUTHOR(S): **Parang, Keykavous**  
CORPORATE SOURCE: Univ. of Alberta, Edmonton, AB, Can.  
SOURCE: (1997) 288 pp. Avail.: UMI, Order No. DANQ23054  
From: Diss. Abstr. Int., B 1998, 58(11), 5905  
DOCUMENT TYPE: Dissertation  
LANGUAGE: English  
AB Unavailable

L2 ANSWER 52 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:595314 HCAPLUS  
DOCUMENT NUMBER: 127:272236  
TITLE: Syntheses and biological evaluation of 5'-O-myristoyl derivatives of thymidine against human immunodeficiency virus  
AUTHOR(S): **Parang, K.**; Wiebe, L. I.; Knaus, E. E.  
CORPORATE SOURCE: Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, AB, Can.  
SOURCE: Antiviral Chemistry & Chemotherapy (1997), 8(5), 417-427  
CODEN: ACCHEH; ISSN: 0956-3202  
PUBLISHER: International Medical Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A series of 5'-O-acyl derivs. of thymidine (dThd) were prepared by direct acylation of thymidine using the Mitsunobu reaction Further reaction of

the bromo analogs with sodium azide gave azido ester analogs. Anti-human immunodeficiency virus type 1 (HIV-1) activities were determined against HIV-infected T4 lymphocytes. 5'-O-(12-Azidododecanoyl)thymidine exhibited moderate activity (EC<sub>50</sub> 4.6  $\mu$ M) against HIV-infected T4 lymphocytes. 5'-O-(2-Bromotetradecanoyl)thymidine was found to be the most stable ester (t<sub>1/2</sub> 15.3 min) to hydrolysis by porcine liver esterase in vitro. Partition coeffs. (P) in n-octanol-phosphate buffer were determined (log<sub>10</sub> P 3.96-6.53) using the PALLAS program. Anti-HIV structure-activity data suggest that the exptl. partition coefficient should be in the log<sub>10</sub> P 4.6-4.8 range for optimum anti-HIV activity. The structures of these thymidine analogs were optimized using mol. mechanics (MM+ force field) and semi-empirical quantum mechanics PM3 calcns. The moderately active compds. adopted a similar C-2' endo sugar conformation and exhibited similar energies for the lowest energy conformer. A quant. structure-activity relationship (QSAR) regression equation was developed, based on the optimized structures and anti-HIV data using the SciQSAR program, which showed that log P was a determinant of anti-HIV activity.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 53 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:395287 HCAPLUS

DOCUMENT NUMBER: 127:90130

TITLE: In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses

AUTHOR(S): Parang, Keykavous; Wiebe, Leonard I.; Knaus, Edward E.; Huang, Jyy-Shiang; Tyrrell, David L.; Csizmadia, Ferenc

CORPORATE SOURCE: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2N8, Can.

SOURCE: Antiviral Research (1997), 34(3), 75-90

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A group of myristic acid analogs, designed as alternative substrates for N-myristoyltransferase (NMT), were evaluated against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and duck hepatitis B virus (DHBV) in vitro. Antiviral potency was increased when S or O was substituted for -CH<sub>2</sub>- in myristic acid and selectivity was affected by the presence and position of the heteroatoms and Ph groups. A correlation was established among anti-HIV activity, Log P and Log D<sub>7.4</sub> and between anti-HIV activity and carbonyl-heteroatom interat. distances in the myristoyl analogs. 12-Thioethyldodecanoic acid was moderately active (EC<sub>50</sub> = 9.37  $\mu$ M) against HIV-infected T4-lymphocytes (CEM-SS cell line), and it exhibited in vitro activity (EC<sub>50</sub> = 17.8  $\mu$ M) against HBV-producing 2.2.15 cell cultures derived from a human hepatoblastoma cell line (Hep G2). 12-Methoxydodecanoic acid exhibited in vitro activity (EC<sub>50</sub> = 20-30  $\mu$ M) against hepatitis B in the HBV DNA-transfected 2.2.15 cell line. At a concentration of 10  $\mu$ g/mL, none of the fatty acids significantly inhibited the replication of DHBV in infected hepatocytes.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 54 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:20501 HCAPLUS

DOCUMENT NUMBER: 126:117733


TITLE: Synthesis and antifungal activities of myristic acid analogs

AUTHOR(S): Parang, Keykavous; Knaus, Edward E.; Wiebe,

Leonard I.; Sardari, Soroush; Daneshtalab, Mohsen;  
Csizmadia, Ferenc  
CORPORATE SOURCE: Faculty Pharmacy Pharmaceutical Sciences, University  
Alberta, Edmonton, AB, T6G 2N8, Can.  
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996),  
329(11), 475-482  
CODEN: ARPMAS; ISSN: 0365-6233  
PUBLISHER: VCH  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 126:117733  
AB Myristic acid analogs were prepared and tested in vitro for activity against  
yeasts and filamentous fungi. Improved synthetic methods were developed  
for the synthesis of 12-fluorododecanoate and 12-chlorododecanoate.  
12-Chloro-4-oxadodecanoate, 12-phenoxydodecanoate, and  
11-(4-iodophenoxy)undecanoate were also prepared and tested. Several  
2-halotetradecanoates including 2-bromotetradecanoate exhibited potent  
activity against *C. albicans* (MIC = 39  $\mu$ M), *C. neoformans* (MIC = 20  
 $\mu$ M), *S. cerevisiae* (MIC = 10  $\mu$ M), and *A. niger* (MIC < 42  $\mu$ M) in  
RPMI 1640 media.

L2 ANSWER 55 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1995:300828 HCAPLUS  
DOCUMENT NUMBER: 122:160547  
TITLE: Syntheses of 1-substituted 1,2,4-triazoles, imidazoles  
and benzimidazoles  
AUTHOR(S): Sharifian, Abdollah; **Parang, Kaykavoos**;  
Zorrieh-Amirian, Hassan; Nazarinia, Mehrdad; Shafiee,  
Abbas  
CORPORATE SOURCE: Dep. Chem., Med. Sci. Univ. Tehran, Tehran, Iran  
SOURCE: Journal of Heterocyclic Chemistry (1994), 31(6),  
1421-3  
CODEN: JHTCAD; ISSN: 0022-152X  
PUBLISHER: HeteroCorporation  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Substituted 2-phenylethyl-1,2,4-triazoles, 1-phenethylimidazoles and  
1-phenethylbenzimidazoles were synthesized by dechlorination of the  
corresponding chloro derivative with tributyltin hydride in good yield. The  
reaction of substituted-2-phenethyl halide with 1H-1,2,4-triazoles,  
imidazoles and benzimidazoles gave a low yield. The yield was increased  
by the use of substituted-2-phenethyl p-toluenesulfonate.

L2 ANSWER 56 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1993:191631 HCAPLUS  
DOCUMENT NUMBER: 118:191631  
TITLE: Nitroimidazoles. X. Syntheses of substituted  
2-(1-methyl-5-nitro-2-imidazolyl)quinolines  
AUTHOR(S): Shafiee, A.; **Parang, K.**; Khazan, M.;  
Ghasemian, F.  
CORPORATE SOURCE: Fac. Pharm., Med. Sci., Univ. Tehran, Tehran, Iran  
SOURCE: Journal of Heterocyclic Chemistry (1992), 29(7),  
1859-61  
CODEN: JHTCAD; ISSN: 0022-152X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB Reduction of 2-aminobenzaldehydes followed by cyclization with 2-acetyl-1-methyl-5-nitroimidazole under basic conditions afforded substituted 2-(1-methyl-5-nitro-2-imidazolyl)quinolines I (R = H, F, Cl, Me, MeO; R1 = H, Cl; R2 = H, MeO). Oxidation of I (R = Cl, F, R1 = R2 = H; R = R2 = H, R1 = Cl) with H<sub>2</sub>O<sub>2</sub> in HOAc afforded the N-oxide which was chlorinated with POCl<sub>3</sub> to give addnl. title compds. II (R = H, Cl, F, R1 = H, Cl).

L2 ANSWER 57 OF 57 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:591759 HCAPLUS

DOCUMENT NUMBER: 117:191759

TITLE: Nitroimidazoles. IX. Synthesis of 2-acetyl-1-methyl-5-nitroimidazole

AUTHOR(S): Shafiee, A.; Pirouzzadeh, B.; Ghasemian, F.; Parang, K.

CORPORATE SOURCE: Coll. Pharm. Med. Sci., Univ. Tehran, Teheran, Iran

SOURCE: Journal of Heterocyclic Chemistry (1992), 29(4), 1021-3

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:191759

AB Manganese dioxide oxidation of 2-hydroxymethyl-1-methyl-5-nitroimidazole (6) gave 1-methyl-5-nitroimidazole-2-carboxaldehyde (7) in high yield. Reaction of diazomethane with 7 afforded the title compound 1 in low yield. Treatment of Et acid malonate with two equivalent of isopropylmagnesium bromide in THF and subsequent addition to 1-methyl-5-nitroimidazole-2-carbonylimidazolidine (12) yielded Et (1-methyl-5-nitroimidazole-2-carbonyl)acetate (10) in 70% yield. Hydrolysis and decarboxylation of compound 10 gave the desired compound 1 in 97% yield.

=> => d stat que 13

L2 57 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PARANG K"/AU OR "PARANG KAYKAVOOS"/AU OR "PARANG KEYKAVOUS"/AU)

L3 8 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ABLOOGLU ARARAT J"/AU OR "ABLOOGLU ARARAT JAN"/AU OR "ABLOOGLU ARARAT"/AU) NOT L2

=>

=>

=> d ibib abs 13 1-8

L3 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:925443 HCAPLUS

DOCUMENT NUMBER: 136:178085  
 TITLE: Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain  
 AUTHOR(S): **Ablooglu, Ararat J.**; Frankel, Mark; Rusinova, Elena; Ross, John B. Alexander; Kohanski, Ronald A.  
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Journal of Biological Chemistry (2001), 276(50), 46933-46940  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Low catalytic efficiency of protein kinases often results from intrasteric inhibition caused by the activation loop blocking the active site. In the insulin receptor's kinase domain, Asp-1161 and Tyr-1162 in the peptide substrate-like sequence of the unphosphorylated activation loop can interact with four invariant residues in the active site: Lys-1085, Asp-1132, Arg-1136, and Gln-1208. Contributions of these six residues to intrasteric inhibition were tested by mutagenesis, and the unphosphorylated kinase domains were characterized. The mutations Q1208S, K1085N, and Y1162F each relieved intrasteric inhibition, increasing catalytic efficiency but without changing the rate-limiting step of the reaction. The mutants R1136Q and D1132N were virtually inactive. Steric accessibility of the active site was ranked by relative changes in iodide quenching of intrinsic fluorescence, and A-loop conformation was ranked by limited tryptic cleavage. Together these ranked the openness of the active site cleft as  $R1136Q \approx D1132N \geq D1161A > Y1162F \approx K1085N > Q1208S \geq$  wild-type. These findings demonstrate the importance of specific invariant residues for intrasteric inhibition and show that diverse activation loop conformations can produce similar steady-state kinetic properties. This suggests a broader range of regulatory properties for the activation loop than expected from a simple off-vs.-on switch for kinase activation.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:852985 HCAPLUS  
 DOCUMENT NUMBER: 137:17065  
 TITLE: Regulation by autoinhibition in the insulin receptor kinase: mechanistic and mutagenic studies  
 AUTHOR(S): **Ablooglu, Ararat Jan**  
 CORPORATE SOURCE: Mount Sinai School of Medicine, New York Univ., New York, NY, USA  
 SOURCE: (2001) 207 pp. Avail.: UMI, Order No. DA9999466  
 From: Diss. Abstr. Int., B 2001, 61(12), 6447  
 DOCUMENT TYPE: Dissertation  
 LANGUAGE: English  
 AB Unavailable

L3 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:447849 HCAPLUS  
 DOCUMENT NUMBER: 135:175627  
 TITLE: Intrasteric inhibition of ATP binding is not required to prevent unregulated autophosphorylation or

signaling by the insulin receptor

AUTHOR(S): Frankel, Mark; **Ablooglu, Ararat J.**; Leone, Joseph W.; Rusinova, Elena; Ross, J. B. Alexander; Heinrikson, Robert L.; Kohanski, Ronald A.

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Molecular and Cellular Biology (2001), 21(13), 4197-4207  
CODEN: MCEBD4; ISSN: 0270-7306

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Receptor tyrosine kinases may use intrasteric inhibition to suppress autophosphorylation prior to growth factor stimulation. To test this hypothesis the authors made an Asp1161Ala mutant in the activation loop that relieved intrasteric inhibition of the unphosphorylated insulin receptor (IR) and its recombinant cytoplasmic kinase domain (IRKD) without affecting the activated state. Solution studies with the unphosphorylated mutant IRKD demonstrated conformational changes and greater catalytic efficiency from a 10-fold increase in kcat and a 15-fold-lower Km ATP although Km peptide was unchanged. Kinetic parameters of the autophosphorylated mutant and wild-type kinase domains were virtually identical. The Asp1161Ala mutation increased the rate of in vitro autophosphorylation of the IRKD or IR at low ATP concns. and in the absence of insulin. However, saturation with ATP (for the IRKD) or the presence of insulin (for the IR) yielded equivalent rates of autophosphorylation for mutant vs. wild-type kinases. Despite a biochem. more active kinase domain, the mutant IR expressed in C2C12 myoblasts was not constitutively autophosphorylated. However, it displayed a 2.5-fold-lower 50% effective concentration for insulin stimulation of autophosphorylation and was dephosphorylated more slowly following withdrawal of insulin than wild-type IR. In tests of the regulation of the unphosphorylated basal state, these results demonstrate that neither intrasteric inhibition against ATP binding nor suppression of kinase activity is required to prevent premature autophosphorylation of the IR. Finally, the lower rate of dephosphorylation suggests invariant residues of the activation loop such as Asp 1161 may function at multiple junctures in cellular regulation of receptor tyrosine kinases.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:267728 HCAPLUS

DOCUMENT NUMBER: 135:30699

TITLE: Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase. Insights into kinase mechanism

AUTHOR(S): Till, Jeffrey H.; **Ablooglu, Ararat J.**; Frankel, Mark; Bishop, Steven M.; Kohanski, Ronald A.; Hubbard, Stevan R.

CORPORATE SOURCE: Skirball Institute of Biomolecular Medicine and Department of Pharmacology, New York University School of Medicine, New York, NY, 10016, USA

SOURCE: Journal of Biological Chemistry (2001), 276(13), 10049-10055  
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The tyrosine kinase domain of the insulin receptor is subject to autoinhibition in the unphosphorylated basal state via steric interactions involving the activation loop. A mutation in the activation loop designed to relieve autoinhibition, Asp-1161 → Ala, substantially increases the ability of the unphosphorylated kinase to bind ATP. The crystal structure of this mutant in complex with an ATP analog has been determined at 2.4-Å resolution. The structure shows that the active site is unobstructed, but the end of the activation loop is disordered and therefore the binding site for peptide substrates is not fully formed. In addition, Phe-1151 of the protein kinase-conserved DFG motif, at the beginning of the activation loop, hinders closure of the catalytic cleft and proper positioning of  $\alpha$ -helix C for catalysis. These results, together with viscometric kinetic measurements, suggest that peptide substrate binding induces a reconfiguration of the unphosphorylated activation loop prior to the catalytic step. The crystallog. and solution studies provide new insights into the mechanism by which the activation loop controls phosphoryl transfer as catalyzed by the insulin receptor.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:887032 HCAPLUS

DOCUMENT NUMBER: 134:174807

TITLE: Activation of the Insulin Receptor's Kinase Domain  
Changes the Rate-Determining Step of Substrate  
Phosphorylation

AUTHOR(S): Ablooglu, Ararat J.; Kohanski, Ronald A.

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, The  
Mount Sinai School of Medicine, New York, NY, 10029,  
USA

SOURCE: Biochemistry (2001), 40(2), 504-513

CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The insulin receptor and many other protein kinases are activated by relief of intrasteric inhibition that is regulated by reversible phosphorylation. The changes accompanying activation of the insulin receptor's kinase domain were analyzed using steady-state kinetics, viscometric anal., and equilibrium binding measurements. Peptide phosphorylation catalyzed by the unphosphorylated basal-state kinase is limited by a slow rate of the chemical step, and the activated enzyme is limited by product release rates. Underlying these changes were a 36-fold increase in the rate constant for the chemical step of the enzyme-catalyzed reaction, a 5-fold increase in the affinity for MgATP, and an 8-fold increase in the affinity for peptide substrate. This results in binding of substrates that is 2.2 kcal/mol more favorable and a free energy barrier for transition state formation that is lowered by 2.1 kcal/mol in the activated enzyme. Therefore, the change in conformational free energy inherent in the protein after autophosphorylation [Bishop, S. M., Ross, J. B. A., and Kohanski, R. A. (1999) Biochem. 38, 3079-3089] is equally distributed between formation of the substrate ternary complex and formation of the transition state complex.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:709640 HCAPLUS

DOCUMENT NUMBER: 132:10355



TITLE: Conformational changes in the activation loop of the insulin receptor's kinase domain  
 AUTHOR(S): Frankel, Mark; Bishop, Steven M.; **Ablooglu**, Ararat J.; Han, Yuan-Ping; Kohanski, Ronald A.  
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Protein Science (1999), 8(10), 2158-2165  
 CODEN: PRCIEI; ISSN: 0961-8368  
 PUBLISHER: Cambridge University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The low catalytic efficiency of basal-state protein kinases often depends on activation loop residues blocking substrate access to the catalytic cleft. Using the recombinant soluble form of the insulin receptor kinase domain (IRKD) in its unphosphorylated state, the activation loop conformation was analyzed by limited proteolysis. The rate of activation loop cleavage by trypsin was slow in the apo-IRKD. Bound MgADP and MgATP increased the cleavage rate with half-maximal effects observed at 0.4-0.9 mM nucleotide concentration. AMP at concns. of  $\leq 10$  mM was not bound appreciably by the IRKD and had virtually no impact on activation loop cleavage. N-terminal and C-terminal core-flanking regions of IRKD had no statistically significant impact on the ligand-dependent or -independent activation loop cleavages. Furthermore, the core-flanking regions did not change the inherent conformational stability of the active site or the global stability of IRKD, as determined by guanidinium chloride-induced denaturation. These measurements indicated that the intrasterically inhibitory conformation encompassed  $\geq 90\%$  of the ligand-free basal state kinase. However, normal intracellular concns. of Mg-adenine nucleotides, which were in the millimolar range, would favor a basal-state conformation of the activation loop that was more accessible.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:475698 HCAPLUS  
 DOCUMENT NUMBER: 129:227372  
 TITLE: Partial Activation of the Insulin Receptor Kinase Domain by Juxtamembrane Autophosphorylation  
 AUTHOR(S): Cann, Aaron Darius; Bishop, Steven M.; **Ablooglu**, Ararat J.; Kohanski, Ronald A.  
 CORPORATE SOURCE: Department of Biochemistry, The Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Biochemistry (1998), 37(32), 11289-11300  
 CODEN: BICHAW; ISSN: 0006-2960  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Increased enzymic activity of receptor tyrosine kinases occurs after trans-phosphorylation of one or two tyrosines in the activation loop, located near the catalytic cleft. Partial activation of the insulin receptor's kinase domain was observed at dilute concns. of kinase, suggesting that cis-autophosphorylation was occurring. Autophosphorylation during partial activation mapped to the juxtamembrane (JM) tyrosines and not to activation loop tyrosines. Furthermore, a double JM Tyr-to-Phe mutant kinase (JMY2F) did not undergo partial activation but catalyzed substrate phosphorylation at a very low rate. Steady-state kinetics of peptide phosphorylation were determined with and without JM autophosphorylation. The JMY2F mutant was used to prevent concurrent cis-autophosphorylation and therefore to approx. the basal state apoenzyme in the kinetic anal.

Partial activation was dominated by a decreased Michaelis constant for peptide substrate, from  $K_m, \text{PEP} \geq 2.5 \text{ mM}$  in the basal state to  $0.2 \text{ mM}$  in the partially activated state; the  $K_m, \text{ATP}$  remained virtually unchanged at  $\approx 1 \text{ mM}$ , and  $k_{\text{cat}}$  increased from 180 to  $600 \text{ min}^{-1}$ . The high  $K_m, \text{PEP}$  suggests weak binding of peptide substrates to the apoenzyme. This was confirmed by  $K_i > 1 \text{ mM}$  for peptide substrates used as inhibitors of JM autophosphorylation. The absence of comparably large changes in  $k_{\text{cat}}$  and  $K_m, \text{ATP}$  suggests that the JM region is primarily a strong barrier to the peptide entry step of trans-phosphorylation reactions. The JM region therefore functions as an intrasteric inhibitor in the basal state of the insulin receptor's kinase domain.

REFERENCE COUNT: 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:257983 HCAPLUS  
DOCUMENT NUMBER: 126:302279  
TITLE: A *Bacillus subtilis* locus encoding several gene products affecting transport of cations  
AUTHOR(S): Sturr, Michael G.; **Ablooglu, Ararat J.**; Krulwich, Terry A.  
CORPORATE SOURCE: Dep. Biochem., Mount Sinai Sch. Med. CUNY, New York, NY, 10029, USA  
SOURCE: Gene (1997), 188(1), 91-94  
CODEN: GENED6; ISSN: 0378-1119  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A 3.6-kb DNA fragment from *Bacillus subtilis* was found to complement the  $\text{K}^+$  uptake-deficient *Escherichia coli* strain TK2420. Transformation with a pKLO61 plasmid harboring this fragment conferred the capacity to grow on a minimal medium containing only  $10 \text{ mM K}^+$ . Insertional mutagenesis and subcloning identified a single gene responsible for the complementation. This gene coded for an apparent homolog of *E. coli* TrkA. Sequence anal. of the cloned region also revealed three addnl. open reading frames. These included: a gene encoding a homolog to the *czcD* gene product of *Alcaligenes eutrophus*, a *lysR*-type regulatory gene which was found to enhance  $\text{Na}^+$  resistance in *E. coli* NM81 ( $\Delta\text{nhxA}$ ) in a sep. complementation test, and an orfD with no significant similarity to sequences deposited in Genbank.

=> => d stat que

L2 57 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PARANG K"/AU OR "PARANG KAYKAVOOS"/AU OR "PARANG KEYKAVOUS"/AU)  
L3 8 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ABLOOGLU ARARAT J"/AU OR "ABLOOGLU ARARAT JAN"/AU OR "ABLOOGU ARARAT"/AU) NOT L2  
L4 45 SEA FILE=HCAPLUS ABB=ON PLU=ON ("KOHANSKI R"/AU OR "KOHANSKI R A"/AU OR "KOHANSKI RON"/AU OR "KOHANSKI RON A"/AU OR "KOHANSKI RONALD"/AU OR "KOHANSKI RONALD A"/AU) NOT (L2 OR L3)

=> d ibib abs l4 1-45

L4 ANSWER 1 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:103697 HCAPLUS  
DOCUMENT NUMBER: 143:188336  
TITLE: Biotinylation of proteins  
AUTHOR(S): **Kohanski, Ronald A.**  
CORPORATE SOURCE: The Johns Hopkins University, Baltimore, MD, USA

SOURCE: Encyclopedia of Biological Chemistry (2004), Volume 1, 179-181. Editor(s): Lennarz, William J.; Lane, M. Daniel. Elsevier Ltd.: Oxford, UK.  
CODEN: 69GLBX; ISBN: 0-12-443710-9

DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

AB A review. The biotinylation of proteins is the covalent coupling of biotin to an amino acid or carbohydrate moiety of the protein. Biotinylation occurs in a specific group of proteins known as carboxylases. These are enzymes that are important in several metabolic pathways, including amino acid metabolism, fatty acid biosynthesis, and gluconeogenesis. Each of these carboxylases is biotinylated on a single Lys residue through the action of a biotin-protein ligase, and are found in all organisms (bacteria, plants, and animals). Biotinylation of proteins is also done by in vitro chemical synthesis, whereby biotin can be covalently coupled to any reactive functional group on the protein, and is not necessarily restricted to a single amino acid residue.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:298522 HCAPLUS

DOCUMENT NUMBER: 139:98157

TITLE: Axons guided by insulin receptor in Drosophila visual system

AUTHOR(S): Song, Jianbo; Wu, Lingling; Chen, Zun; Kohanski, Ronald A.; Pick, Leslie

CORPORATE SOURCE: Brookdale Department for Molecular, Cell and Developmental Biology, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Science (Washington, DC, United States) (2003), 300(5618), 502-505

CODEN: SCIEAS; ISSN: 0036-8075

PUBLISHER: American Association for the Advancement of Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Insulin receptors are abundant in the central nervous system, but their roles remain elusive. Here we show that the insulin receptor functions in axon guidance. The Drosophila insulin receptor (DInR) is required for photoreceptor-cell (R-cell) axons to find their way from the retina to the brain during development of the visual system. DInR functions as a guidance receptor for the adapter protein Dock/Nck. This function is independent of Chico, the Drosophila insulin receptor substrate (IRS) homolog.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:963302 HCAPLUS

DOCUMENT NUMBER: 138:231872

TITLE: Dual mechanism of signal transducer and activator of transcription 5 activation by the insulin receptor

AUTHOR(S): Le, Maithao N.; Kohanski, Ronald A.; Wang, Lu-Hai; Sadowski, Henry B.

CORPORATE SOURCE: Department of Microbiology, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Molecular Endocrinology (2002), 16(12), 2764-2779

CODEN: MOENEN; ISSN: 0888-8809

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Insulin stimulates signal transducer and activator of transcription 5 (Stat5) activation in insulin receptor (IR)-overexpressing cell lines and in insulin target tissues of mice. Stat5b and insulin receptor substrate 1 (IRS-1) interact with the same auto-phosphorylation site in the IR [phosphotyrosine (pY) 972] in yeast two-hybrid assays, and the IR phosphorylates Stat5b in vitro. These data suggest that Stat5 proteins might be recruited to, and phosphorylated by, the activated IR in vivo. Nevertheless, insulin activates Janus kinases (JAKs) in IR-overexpressing cell lines and in insulin target tissues. To determine whether Stat5 proteins must be recruited to the pY972LSA motif in the IR for insulin-stimulated activation in mammalian cells, the authors generated and tested a series of IR mutants. The L973R/A975D mutation abolishes the ability of the IR to induce Stat5 activation, whereas IRS-1 phosphorylation is unaffected. In contrast, the N969A/P970A mutation in the IR has no effect on Stat5 activation but significantly reduces IRS-1 phosphorylation. In coimmunoprecipitation assays, insulin-stimulated Stat5 activation correlates with Stat5 recruitment to the IR. The authors also find that insulin stimulates tyrosine phosphorylation of JAKs that are constitutively associated with the IR. Expression of dominant-negative (DN) JAKs, the JAK inhibitor suppressor of cytokine signaling 1, or pretreatment with the JAK inhibitor, AG490, reduces, but does not eliminate, insulin-induced Stat5 activation. Expression of the appropriate pair of DN JAKs in each of the singly JAK-deficient cell lines further establishes a component of insulin-stimulated Stat5 activation that is JAK independent. This likely represents phosphorylation of Stat5 proteins by the IR, as the authors find that IR kinase domain phosphorylates Stat5b in vitro on Y699 as efficiently as JAK2. Increasing the concentration of Stat5 proteins in cells favors the direct phosphorylation of Stat5 by the IR kinase where the DN-JAK inhibition of insulin-stimulated Stat5 activation becomes insignificant. At physiological levels of Stat5 however, the authors propose that JAKs and the IR both contribute to the insulin-induced phosphorylation of Stat5.

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:257061 HCAPLUS

DOCUMENT NUMBER: 135:71039

TITLE: A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo

AUTHOR(S): Manchem, Vara Prasad; Goldfine, Ira D.; Kohanski, Ronald A.; Cristobal, Cristina P.; Lum, Robert T.; Schow, Steven R.; Shi, Songyuan; Spevak, Wayne R.; Laborde, Edgardo; Toavs, Deborah K.; Villar, Hugo O.; Wick, Michael M.; Kozlowski, Michael R.

CORPORATE SOURCE: Telik, Inc., South San Francisco, CA, 94080, USA

SOURCE: Diabetes (2001), 50(4), 824-830

CODEN: DIAEAZ; ISSN: 0012-1797

PUBLISHER: American Diabetes Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Insulin resistance, an important feature of type 2 diabetes, is manifested as attenuated insulin receptor (IR) signaling in response to insulin binding. A drug that promotes the initiation of IR signaling by enhancing IR autophosphorylation should, therefore, be useful for treating type 2 diabetes. This report describes the effect of a small molecule IR sensitizer, TLK16998, on IR signaling. This compound activated the tyrosine kinase domain of the IR  $\beta$ -subunit at concentrations of 1  $\mu$ M or less but had no effect on insulin binding to the IR  $\alpha$ -subunit even at much higher

concns. TLK16998 alone had no effect on IR signaling in mouse 3T3-L1 adipocytes but, at concns. as low as 3.2  $\mu\text{mol/l}$ , enhanced the effects of insulin on the phosphorylation of the IR  $\beta$ -subunit and IR substrate 1, and on the amount of phosphatidylinositol 3-kinase that co-immunopptd. with IRS-1. Phosphopeptide mapping revealed that the effect of TLK16998 on the IR was associated with increased tyrosine phosphorylation of the activation loop of the  $\beta$ -subunit tyrosine kinase domain. TLK16998 also increased the potency of insulin in stimulating 2-deoxy-D-glucose uptake in 3T3-L1 adipocytes, with a detectable effect at 8  $\mu\text{mol/l}$  and a 10-fold increase at 40  $\mu\text{mol/l}$ . In contrast, only small effects were observed on IGF-1-stimulated 2-deoxy-D-glucose uptake. In diabetic mice, TLK16998, at a dose of 10 mg/kg, lowered blood glucose levels for up to 6 h. These results suggest, therefore, that small nonpeptide mols. that directly sensitize the IR may be useful for treating type 2 diabetes.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:251038 HCAPLUS

DOCUMENT NUMBER: 133:2960

TITLE: Regulation of mOAT-mediated organic anion transport by okadaic acid and protein kinase C in LLC-PK1 cells  
AUTHOR(S): You, Guofeng; Kuze, Kogo; Kohanski, Ronald A.  
; Amsler, Kurt; Henderson, Scott

CORPORATE SOURCE: Department of Medicine, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Journal of Biological Chemistry (2000), 275(14), 10278-10284

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Organic anion transporters in the kidney proximal tubule play an essential role in eliminating a wide range of organic anions including endogenous compds., xenobiotics, and their metabolites, thereby preventing their potentially toxic effects within the body. We have previously cloned a cDNA encoding an organic anion transporter from mouse kidney (mOAT). In the present study, we assessed the potential for regulation of this transporter by heterologous expression of mOAT in the pig proximal tubule-like cell line, LLC-PK1. We report here that both protein phosphatase (PP1/PP2A) inhibitor, okadaic acid, and protein kinase C (PKC) activators down-regulate mOAT-mediated transport of para-aminohippuric acid (PAH), a prototypic organic anion, in a time- and concentration-dependent manner. However their mechanisms of action for this down-regulation are distinct. Okadaic acid modulated PAH transport, at least in part, through phosphorylation/dephosphorylation of mOAT; phosphoamino acid anal. indicated this phosphorylation occurs on serine. In contrast, PKC activation induced a decrease in the maximum transport velocity ( $V_{\text{max}}$ ) of PAH transport without direct phosphorylation of the transporter protein. Together these results provide the first demonstration that regulation of organic anion transport by mOAT is likely to be tightly controlled directly and indirectly by phosphatase PP1/PP2A and PKC. Our results also suggest that kinases other than PKC are involved in this process.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:725359 HCAPLUS

DOCUMENT NUMBER: 132:48369  
 TITLE: The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase  
 AUTHOR(S): Ball, Helen J.; Melnick, Ari; Shaknovich, Rita; Kohanski, Ronald A.; Licht, Jonathan D.  
 CORPORATE SOURCE: Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Nucleic Acids Research (1999), 27(20), 4106-4113  
 CODEN: NARHAD; ISSN: 0305-1048  
 PUBLISHER: Oxford University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A binding site selection from a CpG island library for the promyelocytic leukemia zinc finger protein (PLZF) identified two high affinity PLZF binding sites. These sequences also bound RAR $\alpha$ /PLZF, a fusion protein formed in chromosomal translocation t(11;17)(q23;q21) associated with acute promyelocytic leukemia. PLZF bound DNA as a slowly migrating complex with an estimated mol. weight of 600 kDa whose formation was dependent on the POZ/dimerization domain of PLZF. The PLZF-DNA complex was unable to form in the presence of cdc2 antibodies. A PLZF-cdc2 interaction was further demonstrated by co-immunopptn. and a biotin-streptavidin pull-down assay. PLZF is a phosphoprotein and immunoppts. with a cdc2-like kinase activity. The PLZF-DNA complex was abolished with the addition of a phosphatase. These studies suggest that the activity of PLZF, a regulator of the cell cycle, may be modulated by cell cycle proteins. RAR $\alpha$ /PLZF did not complex with cdc2, this potentially contributing to its aberrant transcriptional properties and potential role in leukemogenesis.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:652960 HCAPLUS  
 DOCUMENT NUMBER: 131:348403  
 TITLE: Lysozyme degradation by the bovine multicatalytic proteinase complex (proteasome): Evidence for a nonprocessive mode of degradation  
 AUTHOR(S): Wang, Rong; Chait, Brian T.; Wolf, Imrey; Kohanski, Ronald A.; Cardozo, Christopher  
 CORPORATE SOURCE: Departments of Medicine Pharmacology and Biochemistry, The Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Biochemistry (1999), 38(44), 14573-14581  
 CODEN: BICHAW; ISSN: 0006-2960  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The multicatalytic proteinase complex (MPC, proteasome) is composed of 28 subunits organized into four rings surrounding a water-filled canal. The catalytic centers face the inner canal confining protein substrates to an enclosed space. Exptl. findings obtained with MPC from archaebacteria suggest that degradation of proteins by the complex is processive and have led to the proposal that the lengths of the peptides formed during degradation depend on the distances between active sites in the catalytic chamber. To test whether these postulates are valid for the MPC from a higher organism, we examined the size distributions of products formed early vs. late in the course of protein degradation using reduced carboxamidomethylated lysozyme (RCM-lysozyme) and MPC from bovine spleen and pituitary. The

majority of final degradation products ranged in length from 6 to 20 amino acids without a clear predilection for peptides of a particular, uniform size. Our observations suggest that selection of cleavage sites is governed by the amino acid sequence specificity of the MPC catalytic sites rather than the distances between the active sites. Early in the course of degradation, peptides with masses between 5 and 10 kDa accumulated in more than 80-fold molar excess over the MPC, indicating dissociation of large, partially degraded intermediates. Initial cleavages occurred at distances between 10 and 44 amino acids from the N- or C-terminus of the mol. and often involved removal of a fragment from both the N- and C-termini of RCM-lysozyme. Our data indicate that degradation of proteins by MPCs from higher organisms involves a nonprocessive mechanism comprised of multiple, independent cleavages with dissociation of degradation intermediates. A general

model for protein degradation by the MPC is discussed.

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:109764 HCAPLUS

DOCUMENT NUMBER: 130:293210

TITLE: Autophosphorylation Dependent Destabilization of the Insulin Receptor Kinase Domain: Tryptophan-1175 Reports Changes in the Catalytic Cleft

AUTHOR(S): Bishop, Steven M.; Ross, J. B. Alexander; Kohanski, Ronald A.

CORPORATE SOURCE: Department of Biochemistry, The Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Biochemistry (1999), 38(10), 3079-3089

CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein kinases are regulated by conformational or chemical changes which facilitate access of substrates to the active site and promote correct orientations of catalytically essential residues and water mols. The switch between basal and activated states of the insulin receptor's kinase domain (IRKD) results from autophosphorylation. We investigated the effects of IRKD autophosphorylation on the conformational stability by guanidine hydrochloride (GdnHCl) dependent denaturation and by iodide quenching of intrinsic fluorescence. Tryptophan residues of the recombinant soluble IRKD (residues R953-S1355) were excited at a  $\lambda_{\text{ex}}$  of 295 nm, and emission spectra were analyzed for centroid (a characteristic of average polarity of the indole rings' environments) and integrated fluorescence intensity over the  $\lambda_{\text{em}}$  range of 310-420 nm. Denaturation profiles of both apo- and phospho-IRKD forms are complex with at least three distinct unfolding transitions. The first and last transitions were reversible and cooperative and had midpoints at 0.4 or 0.7 M GdnHCl and 2.4 or 2.7 M GdnHCl, resp.; transitions of phospho-IRKD occurred at lower GdnHCl concns. Calcns. of free energy of unfolding suggested a loss of .apprx.2.3 kcal/mol of stabilization for the first transition and .apprx.1.5 kcal/mol for the third transition. CD showed subtle changes in secondary structure over the first transition and global unfolding over the last transition. The first transition reports changes primarily in the local environment of W1175, which is near the catalytic loop and is conserved among protein tyrosine kinases. W1175 is also the dominant fluorophore of the native emission spectrum. Iodide quenching of W1175 was virtually undetectable in the apo-IRKD but significant in the phospho-IRKD, suggesting that W1175 exposure to small solutes is strongly dependent on the conformation of the activation loop. These studies

indicate that autophosphorylation, while exposing the catalytic center, also produces a conformer less stable than the apoenzyme.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:509345 HCAPLUS

DOCUMENT NUMBER: 129:144864

TITLE: Modulators of insulin receptor activity, screening, and therapeutic use

INVENTOR(S): Kauvar, Lawrence M.; Sportsman, Richard; Villar, Hugo O.; Spevak, Wayne R.; Kohanski, Ron A.; Satyam, Apparao; Koehler, Ryan

PATENT ASSIGNEE(S): Terrapin Technologies, Inc., USA

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832017	A2	19980723	WO 1998-US801	19980115
WO 9832017	A3	19990225		
W: AU, BA, CA, CU, GH, GM, GW, ID, JP, LC, SL, YU, ZW				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5830918	A	19981103	US 1997-784857	19970115
US 5851988	A	19981222	US 1997-784854	19970115
US 6329431	B1	20011211	US 1997-916088	19970821
CA 2278023	AA	19980723	CA 1998-2278023	19980115
AU 9860266	A1	19980807	AU 1998-60266	19980115
EP 960335	A2	19991201	EP 1998-903515	19980115
EP 960335	B1	20050525		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512685	T2	20020423	JP 1998-534532	19980115
AT 296446	E	20050615	AT 1998-903515	19980115
US 2002016367	A1	20020207	US 2001-961179	20010921
US 2003078188	A1	20030424	US 2001-999762	20011025
AU 780473	B2	20050324	AU 2002-34362	20020416
AU 2002034362	A5	20020606		
PRIORITY APPLN. INFO.:			US 1997-784854	A 19970115
			US 1997-784855	A 19970115
			US 1997-784857	A 19970115
			US 1997-825269	A 19970327
			US 1997-916088	A 19970821
			WO 1998-US801	W 19980115
			US 1998-88507	B1 19980601

OTHER SOURCE(S): MARPAT 129:144864

AB Methods to identify compds. which have  $\geq 1$  characteristic selected from the group consisting of a composition that (a) modulates the kinase activity of insulin receptor; and/or (b) potentiates the insulin activation of insulin receptor; and/or (c) potentiates the stimulation by insulin of cellular glucose uptake; and/or (d) stimulates the uptake of glucose in cells displaying the insulin receptor; and/or (e) lowers blood glucose in diabetic subjects; and/or (f) stimulates IRS-1 phosphorylation; and/or (g) stimulates PI3 kinase activity; and/or (h) stimulates GLUT-4 translocation; are described. Successful substances having such characteristics alter the conformation of the two-lobed cytoplasmic kinase



domain or preferentially bind sites which have been identified as modulator binding sites in the insulin receptor  $\beta$  chain. Also, modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using

[Ari(A)(R)m]linker]nAr(A)(R)m (Ar = aromatic moiety; A = proton-accepting substituent; R = non-interfering substituent; m = 0-2 n = 1-6; linker = CH<sub>2</sub>, N=N, CH=CH, NHCO, NHCONH or isostere thereof; when n = 1,  $\geq 1$  Ar must comprise  $\geq 2$  fused aromatic rings) (I). I can also be used for structure-activity studies to identify features responsible for the relevant activities.

L4 ANSWER 10 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:429428 HCAPLUS

DOCUMENT NUMBER: 129:185958

TITLE: Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome"

AUTHOR(S): Cardozo, Christopher; Kohanski, Ronald A.

CORPORATE SOURCE: Departments of Medicine and Biochemistry, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Journal of Biological Chemistry (1998), 273(27), 16764-16770

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The multicatalytic proteinase complex (MPC, proteasome) is assembled from 14 nonidentical protein subunits. It expresses five distinct proteolytic activities, including a chymotrypsin-like activity, cleaving after hydrophobic residues, and a branched chain amino acid-preferring component (BrAAP), cleaving preferentially after branched chain residues. Exposure of cells to interferons leads to replacement of the X, Y, and Z subunits by the LMP2, LMP7, and MECL1 subunits. This immunoproteasome is critical to processing of certain antigens. The enzymic basis for enhanced antigen processing has not been determined. To gain insight into this question, we examined sites and relative rates of cleavage of bonds in denatured, reduced, carboxy-amidomethylated lysozyme, a 129-amino acid protein, by MPC from bovine spleen, in which the X, Y, and Z subunits are replaced by LMP2, LMP7, and MECL1. We compared cleavages to those catalyzed by MPC from bovine pituitary, which contains only the X, Y, and Z subunits. We found marked increases in the rates and number of cleavages after branched chain residues in reduced, carboxyamidomethylated lysozyme by the spleen MPC. This was largely due to accelerated cleavages of bonds after a  $\Phi$ -X-Br motif, where  $\Phi$  is a hydrophobic residue, X is a small neutral or polar residue, and Br is a branched chain residue. Inhibitors with these structural properties were selective and potent inhibitors of the BrAAP activity of the spleen MPC. The above findings indicate that alterations in activity and substrate specificity of the BrAAP activity are important factors underlying the altered cleavages after hydrophobic residues associated with incorporation of interferon-inducible subunits. The potential relevance of the findings to antigen-processing functions of MPC is discussed.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:350807 HCAPLUS

DOCUMENT NUMBER: 129:77533  
 TITLE: A binding site for multiple transcriptional activators in the fushi tarazu proximal enhancer is essential for gene expression in vivo  
 AUTHOR(S): Han, Wei; Yu, Yan; Su, Kai; **Kohanski, Ronald A.**; Pick, Leslie  
 CORPORATE SOURCE: Brookdale Center for Developmental and Molecular Biology, Mt. Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Molecular and Cellular Biology (1998), 18(6), 3384-3394  
 CODEN: MCEBD4; ISSN: 0270-7306  
 PUBLISHER: American Society for Microbiology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The Drosophila homeobox gene fushi tarazu (ftz) is expressed in a highly dynamic striped pattern in early embryos. A key regulatory element that controls the ftz pattern is the ftz proximal enhancer, which mediates pos. autoregulation via multiple binding sites for the Ftz protein. In addition, the enhancer is necessary for stripe establishment prior to the onset of autoregulation. We previously identified nine binding sites for multiple Drosophila nuclear proteins in a core 323-bp region of the enhancer. Three of these nine sites interact with the same cohort of nuclear proteins in vitro. We showed previously that the nuclear receptor Ftz-F1 interacts with this repeated module. Here we purified addnl. proteins interacting with this module from Drosophila nuclear exts. Peptide sequences of the zinc finger protein Ttk and the transcription factor Adf-1 were obtained. While Ttk is thought to be a repressor of ftz stripes, we have shown that both Adf-1 and Ftz-F1 activate transcription in a binding site-dependent fashion. These two proteins are expressed ubiquitously at the time ftz is expressed in stripes, suggesting that either may activate striped expression alone or in combination with the Ftz protein. The roles of the nine nuclear factor binding sites were tested in vivo, by site-directed mutagenesis of individual and multiple sites. The three Ftz-F1-Adf-1-Ttk binding sites were found to be functionally redundant and essential for stripe expression in transgenic embryos. Thus, a biochem. anal. identified cis-acting regulatory modules that are required for gene expression in vivo. The finding of repeated binding sites for multiple nuclear proteins underscores the high degree of redundancy built into embryonic gene regulatory networks.

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:686560 HCAPLUS  
 DOCUMENT NUMBER: 127:355530  
 TITLE: Phenylarsine oxide inhibits insulin activation of phosphatidylinositol 3'-kinase  
 AUTHOR(S): Han, Yuan-Ping; **Kohanski, R. A.**  
 CORPORATE SOURCE: The Department of Biochemistry, Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Biochemical and Biophysical Research Communications (1997), 239(1), 316-321  
 CODEN: BBRC99; ISSN: 0006-291X  
 PUBLISHER: Academic  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Two early events downstream of insulin receptor autophosphorylation that are necessary for activation of glucose transport in adipocytes appear to be: (1) The tyrosine phosphorylation of insulin receptor substrate-1

(IRS-1) which (2) recruits and activates phosphatidylinositol 3'-kinase (PI3'-K). Phenylarsine oxide (PAO) has long been known to inhibit glucose transport, without inhibiting insulin receptor auto- or substrate phosphorylation. However, the PAO-sensitive site downstream of these early regulatory events has not been identified. Here we provide evidence that exposure of 3T3-L1 adipocytes to PAO inhibits PI3'-K activation, but it does not decrease either IRS-1 tyrosine-phosphorylation or the recruitment of PI3'-K to IRS-1 after insulin stimulation. PAO is also shown to inhibit PI3'-K activity in vitro. Therefore, since PI3'-K activation is essential for insulin stimulation of glucose transport, our results demonstrate that PI3'-K is a PAO-sensitive target of the insulin signaling pathway regulating glucose transport.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:683014 HCAPLUS

DOCUMENT NUMBER: 128:1387

TITLE: Reactions of [14C]-3,4-Dichloroisocoumarin with Subunits of Pituitary and Spleen Multicatalytic Proteinase Complexes (Proteasomes)

AUTHOR(S): Orlowski, Marian; Cardozo, Christopher; Eleuteri, Anna Maria; Kohanski, Ronald; Kam, Chih-Min; Powers, James C.

CORPORATE SOURCE: Departments of Pharmacology Medicine and Biochemistry, Mount Sinai School of Medicine of the City University of New York, New York, NY, 10029, USA

SOURCE: Biochemistry (1997), 36(45), 13946-13953

CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Exposure to [14C]-3,4-dichloroisocoumarin (DCI) of multicatalytic proteinase complexes (MPC) isolated from bovine pituitary and spleen leads to label incorporation into several  $\beta$ -type subunits, to rapid inactivation of the chymotrypsin-like (ChT-L) activity, and to a slower inactivation of other activities of the MPC. The pituitary and spleen MPCs differ in that the first contains almost exclusively the X, Y, and Z subunits, whereas in the latter these subunits are largely replaced by LMP2, LMP7, and MECL1. Preincubation with two peptidyl aldehyde inhibitors of the ChT-L activity protected the X subunit in the pituitary MPC and unexpectedly the LMP2 subunit in the spleen MPC from label incorporation, despite the greater amino acid sequence homol. of the LMP7 subunit to that of the X subunit. Losses in the yield of amino acids in both subunits, shown by amino acid sequencing, and lability of the DCI-protein bond indicated formation of an acyl derivative by reaction of DCI with the threonine OH group. Brief exposure to [14C]-DCI led to preferential incorporation of label into the LMP2 and X subunits, consistent with the high inactivation rate consts. of the ChT-L activity. Z-LLF-CHO, an inhibitor of ChT-L activity, but not Z-GPFL-CHO, an inhibitor of the branched chain amino acid preferring component, prevented incorporation of radioactivity into the X subunits, whereas both inhibitors prevented label incorporation into LMP2, indicating differences in susceptibility to inhibition between the two components. These and other data are consistent with involvement of the X and LMP2 subunits in expression of the ChT-L activity in the pituitary and spleen MPC, resp., and suggest the catalytic functions of the two other  $\beta$ -subunits.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:361900 HCAPLUS

DOCUMENT NUMBER: 127:92110

TITLE: Cis-Autophosphorylation of Juxtamembrane Tyrosines in the Insulin Receptor Kinase Domain

AUTHOR(S): Cann, Aaron Darius; Kohanski, Ronald A.

CORPORATE SOURCE: Department of Biochemistry, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Biochemistry (1997), 36(25), 7681-7689

CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Receptor tyrosine kinases undergo ligand-induced dimerization that promotes kinase domain trans-autophosphorylation. However, the kinase domains of the insulin receptor are effectively dimerized because of the covalent  $\alpha\beta_2$  holomeric structure. This fact has made it difficult to determine the mol. mechanism of intra-holomeric autophosphorylation, but there is evidence for both cis- and trans-autophosphorylation in the absence and presence of insulin. Here, using the cytoplasmic kinase domain (CKD) of the human insulin receptor, we demonstrate that autophosphorylation in the juxtamembrane (JM) subdomain follows a cis-reaction pathway. JM autophosphorylation was independent of CKD concentration over the range 6 nM-3  $\mu$ M and was characterized kinetically: half-saturation (KATP) was observed at 75  $\mu$ M ATP [5 mM Mn(CH<sub>3</sub>CO<sub>2</sub>)<sub>2</sub>] with a maximal rate of 0.24 mol of PO<sub>4</sub> (mol of CKD)<sup>-1</sup> min<sup>-1</sup>. Pairwise substitutions of Phe for Tyr in the other two autophosphorylation subdomains, generated by site-directed mutagenesis, altered the kinetics of JM autophosphorylation but did not change the pathway from a cis-reaction. Tyr1328,1334 to Phe (in the carboxy-terminal subdomain) yielded <2-fold increase in the efficiency of JM autophosphorylation, whereas Tyr1162,1163 to Phe (in the activation loop subdomain) yielded  $\approx$ 38-fold increased efficiency of JM autophosphorylation, due predominantly to a 23-fold decreased KATP. These findings demonstrate basal state binding of ATP to the CKD leading to cis-autophosphorylation and novel basal state regulatory interactions among the subdomains of the insulin receptor kinase. On the basis of these results and the crystal structure of the conserved catalytic core of this kinase [Hubbard, S. R., et al. (1994) Nature 372, 746], a model is proposed which reconciles the JM cis-reaction and the activation loop cis-inhibition/trans-reaction with the complex kinetics of insulin receptor autophosphorylation [Kohanski, R. A. (1993) Biochem. 32, 5766].

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:343063 HCAPLUS

DOCUMENT NUMBER: 127:14728

TITLE: A tyrosine kinase assay using reverse-phase high-performance liquid chromatography

AUTHOR(S): Cann, Aaron Darius; Wolf, Imre; Kohanski, Ronald A.

CORPORATE SOURCE: Dep. Biochem., Mount Sinai School Medicine, New York, NY, 10029, USA

SOURCE: Analytical Biochemistry (1997), 247(2), 327-332

CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Reverse-phase HPLC can be used as a very precise and accurate routine

assay for peptide phosphorylation by protein kinases that has advantages over other methods. In particular, peptides with native amino acid sequences can be used without the need for radioisotopes. However, reaction conditions that are employed can often present difficulties in recovery and quantitation of phospho- and apo-peptides. Two general problems were encountered: (1) variation in the retention times of peptides and an increasing width of the injection front which can interfere with quantitation both resulted from repeated sample injections. These were caused mostly by the presence of carrier bovine serum albumin used to reduce loss of peptides during the reaction and by high concns. of ATP used to study the kinetics of enzyme catalyzed reactions. These problems were solved by regular washing of the reverse-phase column, thus allowing a broad range of peptide and ATP concns. to be used. (2) The stability of peptides used in the assay was affected by dithiothreitol in combination with  $Mn^{2+}$ . The former is a common reagent of kinase purifications and the latter is often the metal cofactor used in kinase reactions. Minimizing the concentration of dithiothreitol or using  $Mg^{2+}$  resolved

these difficulties. Consideration of these factors is therefore important when using reverse-phase HPLC to monitor peptide phosphorylation in protein tyrosine kinase assays.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:299945 HCAPLUS

DOCUMENT NUMBER: 127:46806

TITLE: Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity

AUTHOR(S): Eleuteri, Anna Maria; Kohanski, Ronald A.; Cardozo, Christopher; Orlowski, Marian

CORPORATE SOURCE: Univ. Camerino, Camerino, 62032, Italy

SOURCE: Journal of Biological Chemistry (1997), 272(18), 11824-11831

CODEN: JBCCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amino acid sequencing of subunits of the multicatalytic proteinase complex (MPC) isolated from bovine spleen showed an almost complete replacement of the X, Y, and Z subunits, constitutively expressed in most tissues, by the interferon- $\gamma$ -inducible LMP7, LMP2, and MECL1 subunits. A comparison with the pituitary MPC found a decreased chymotrypsin-like activity, a depressed peptidylglutamyl-peptide hydrolyzing activity, and a highly active component with properties similar to, but not identical with, that of the pituitary branched chain amino acid-preferring (BrAAP) component. Unlike the pituitary BrAAP component, that of the spleen MPC exhibited a greatly decreased  $K_m$ , a highly increased catalytic efficiency ( $k_{cat}$ ), and a 80-180 times greater specificity constant ( $k_{cat}/K_m$ ) toward substrates with either branched chain or aromatic amino acid residues in the P1 position. Also, unlike the pituitary BrAAP component, that of the spleen was sensitive to inactivation by 3,4-dichloroisocoumarin and sensitive to inhibition by peptidyl-aldehydes with either phenylalaninal or leucinal residues. Several phenylalaninal peptidyl-aldehydes were identified which selectively inhibited components of the spleen but not of the pituitary MPC. Two of the inhibitors are dipeptidyl-aldehydes, two others are tetrapeptidyl-aldehydes with a Pro residue in the P3 position. The

possibility is discussed that the properties and specificity of the spleen MPC are a consequence of the presence of the interferon- $\gamma$ -inducible subunits.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:199678 HCAPLUS

DOCUMENT NUMBER: 126:288328

TITLE: Stat5 is a physiological substrate of the insulin receptor

AUTHOR(S): Chen, Jing; Sadowski, Henry B.; **Kohanski, Ronald A.**; Wang, Lu-Hai

CORPORATE SOURCE: Department of Microbiology, Mount Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1997), 94(6), 2295-2300  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Using the cytoplasmic domain of the insulin receptor (IR) in a yeast two-hybrid screen, the authors identified a cDNA clone encoding the C-terminal 308 amino acids of human Stat5b (Stat5b-Ct). Stat5b-Ct is tyrosine phosphorylated by purified IR kinase domain in vitro. Insulin stimulates tyrosine phosphorylation of overexpressed Stat5b-Ct and endogenous Stat5 in cells overexpressing IR. Stat5 may be a direct target of the IR and, as a member of the Stat family of transcription factors, may play a role in the regulation of gene transcription by insulin. In support of this hypothesis, perfusion of mouse liver with insulin promotes rapid tyrosine phosphorylation of Stat5 and activation of Stat5 DNA binding. Moreover, refeeding of fasted mice leads to rapid tyrosine phosphorylation and stimulation of enhanced DNA-binding activity of Stat5 extracted from liver, skeletal muscle, and adipose tissues. Taken together, the authors' data strongly suggest that IR interacts with and phosphorylates Stat5 in vitro and in tissues physiologically sensitive to insulin.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:309722 HCAPLUS

DOCUMENT NUMBER: 125:3837

TITLE: Purification, identification, and properties of a *Saccharomyces cerevisiae* oleate-activated upstream activating sequence-binding protein that is involved in the activation of POX1

AUTHOR(S): Igor, Yi Luo; Karpichev, Igor V.; **Kohanski, Ronald A.**; Small, Gillian M.

CORPORATE SOURCE: Dep. Cell Biol./Anatomy Dep. Biochem., Mount Sinai Sch. Med., New York, NY, 10029, USA

SOURCE: Journal of Biological Chemistry (1996), 271(20), 12068-12075

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Peroxisomes have a central function in lipid metabolism, and it is well established that these organelles are inducible by many compounds including

fatty acids. Peroxisomes are the sole site for the  $\beta$ -oxidation of fatty acids in yeast. The first and rate-limiting enzyme of this cycle is fatty acyl-CoA oxidase. The gene encoding this enzyme in *Saccharomyces cerevisiae* (POX1) undergoes a complex regulation that is dependent on the growth environment. When this yeast is grown in medium containing oleic acid was the main carbon source peroxisomes are induced and POX1 expression is activated. When cells are grown in the presence of glucose, the expression of POX1 mRNA is repressed, whereas growth on a carbon source such as glycerol or raffinose causes derepression. This rigorous regulation is brought about by the complex interactions between trans-acting factors and cis-elements in the POX1 promoter. Previously the authors characterized regulatory elements in the promoter region of POX1 that are involved in the repression and activation of this gene (Wang, T., Luo, Y., and Small, G. M. (1994) *J. Biol. Chem.* 269, 24480-24485). In this study the authors have purified and identified an oleate-activated transcription factor (Oaflp) that binds to the activating sequence (UAS1) in the POX1 gene. The protein has a predicted mol. mass of approx. 118 kDa.

L4 ANSWER 19 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:956983 HCAPLUS

DOCUMENT NUMBER: 124:1432

TITLE: Tyrosine dephosphorylation of nuclear proteins mimics transforming growth factor  $\beta$ 1 stimulation of  $\alpha$ 2(I) collagen gene expression

AUTHOR(S): Greenwel, Patricia; Hu, Wei; Kohanski, Ronald A.; Ramirez, Francesco

CORPORATE SOURCE: Brookdale Center Molecular Biology, Mt. Sinai School of Medicine, New York, NY, 10029, USA

SOURCE: Molecular and Cellular Biology (1995), 15(12), 6813-19  
CODEN: MCEBD4; ISSN: 0270-7306

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Transforming growth factor  $\beta$ 1 (TGF- $\beta$ 1) exerts a pos. effect on the transcription of genes coding for several extracellular matrix-related products, including collagen I. The authors have previously identified a strong TGF- $\beta$ 1-responsive element (TbRE) in the upstream promoter sequence of the  $\alpha$ 2(I) collagen (COL1A2) gene. The expts. have shown that TGF- $\beta$ 1 stimulates COL1A2 transcription by increasing binding of an Sp1-containing complex (TbRC) to the TbRE. They have also suggested that the change occurs via posttranslational modification of a protein(s) directly or indirectly interacting with Sp1. Here, the authors provide evidence showing that tyrosine dephosphorylation of nuclear proteins mimics the stimulation of COL1A2 transcription by the TGF- $\beta$ 1-activated signaling pathway. Preincubation of nuclear exts. with protein tyrosine phosphatase (PTPase) but not with protein phosphatase type 2A (PP2A), a serine/threonine phosphatase, enhanced binding of the TbRC to the same degree as culturing cells in TGF- $\beta$ 1. Consistent with these in vitro findings, genistein, a tyrosine inhibitor, led to markedly increased COL1A2 gene expression, whereas sodium orthovanadate, a tyrosine phosphatase inhibitor, decreased it substantially. These results were supported by transfection expts. showing that genistein and sodium orthovanadate have opposite effects on TbRE-mediated transcription. Moreover, nuclear proteins isolated from genistein-treated cells were found to interact with the TbRE significantly more than those from untreated cells. Furthermore, pretreatment of cells with sodium orthovanadate virtually abrogated nuclear protein binding to the TbRE, but not to a neighboring cis-acting element unresponsive to TGF- $\beta$ 1. The results of this study, therefore, provide the first correlation between

tyrosine dephosphorylation, increased binding of a transcriptional complex, and TGF- $\beta$ 1 stimulation of gene expression.

L4 ANSWER 20 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:936885 HCAPLUS

DOCUMENT NUMBER: 124:224651

TITLE: Phosphorylation of myosin regulatory light chains by the molluscan twitchin kinase

AUTHOR(S): Heierhorst, Joerg; Probst, William C.; **Kohanski, Ronald A.**; Buku, Angeliki; Weiss, Klaudiusz R.

CORPORATE SOURCE: Mount Siani School of Medicine, City University of New York, New York, NY, USA

SOURCE: European Journal of Biochemistry (1995), 233(2), 426-31

CODEN: EJBCAI; ISSN: 0014-2956

PUBLISHER: Springer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The unusually large ( $\approx 600$  to  $>3000$  kDa) myosin-associated proteins of the titin/twitchin superfamily are considered to be important cytoskeletal rulers for thick filament assembly in muscle. This function is maintained by approx. 60-240 modular fibronectin-type-III and Ig-C2 repeats in these proteins which further contain a protein serine/threonine kinase domain of unknown function. In this study, the bacterially expressed kinase domain of Aplysia twitchin was used to identify a potential physiol. substrate. Addition of the recombinant kinase of Aplysia actomyosin prepns. resulted in the specific phosphorylation of the 19-kDa myosin regulatory light chains. The twitchin kinase phosphorylated purified light chains on Thr15 in a region which shared a high degree of similarity with the phosphorylation site for vertebrate smooth muscle myosin light chain kinase. Peptide analogs of the twitchin substrate sequence and the similar sequence in vertebrate smooth muscle myosin light chains were phosphorylated with good kinetic properties. These data reveal the first potential substrate for any of the giant protein kinases and support a dual role of twitchin in molluscan muscle as a cytoskeletal protein as well as a myosin light chain kinase.

L4 ANSWER 21 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:651898 HCAPLUS

DOCUMENT NUMBER: 123:50261

TITLE: Environments of the four tryptophans in the extracellular domain of human tissue factor: comparison of results from absorption and fluorescence difference spectra of tryptophan replacement mutants with the crystal structure of the wild-type protein

AUTHOR(S): Hasselbacher, C. A.; Rusinova, E.; Waxman, E.; Rusinova, R.; **Kohanski, R. A.**; Lam, W.;

Guha, A.; Du, J.; Lin, T. C.; et al.

CORPORATE SOURCE: Departments Biochemistry, Mount Sinai School Medicine, New York, NY, 10029, USA

SOURCE: Biophysical Journal (1995), 69(1), 20-9

CODEN: BIOJAU; ISSN: 0006-3495

PUBLISHER: Biophysical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The local environments of the four tryptophan residues of the extracellular domain of human tissue factor (sTF) were assessed from difference absorption and fluorescence spectra. The difference spectra were derived by subtracting spectra from single Trp-to-Phe or Trp-to-Tyr replacement mutants from the corresponding spectrum of the wild-type



protein. Each of the mutants was capable of enhancing the proteolytic activity of factor VIIa showing that the mutations did not introduce major structural changes, although the mutants were more susceptible to denaturation by guanidinium chloride. The difference spectra indicate that the Trp residues are buried to different extents within the protein matrix. This evaluation was compared with the x-ray crystal structure of sTF. There is excellent agreement between predictions from the difference spectra and the environments of the Trp residues observed in the x-ray crystal structure, demonstrating that difference absorption and particularly fluorescence spectra derived from functional single-Trp replacement mutants can be used to obtain information about the local environments of individual Trp residues in multi-tryptophan proteins.

L4 ANSWER 22 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:258479 HCAPLUS

TITLE: Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome

AUTHOR(S): Sorbara, Lynn R.; Tang, Zhichun; Cama, Alessandro; Xia, Jinru; Schenker, Esther; Kohanski, Ronald A.; Poretsky, Leonid; Koller, Elizabeth; Taylor, Simeon I.; Dunaif, Andrea

CORPORATE SOURCE: Coll. Med., Pennsylvania State Univ., Hershey, PA, USA  
SOURCE: Metabolism, Clinical and Experimental (1994), 43(12), 1568-74

CODEN: METAAJ; ISSN: 0026-0495

PUBLISHER: Saunders

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Women with polycystic ovary syndrome (PCOS) are markedly insulin-resistant, but the mol. mechanisms of these changes and their relationship to the hyperandrogenic state remain to be clarified. Mutations have recently been identified in the insulin receptor gene of patients with extreme forms of insulin resistance associated with hyperandrogenism (eg, type A insulin resistance), and these mutations account for the insulin resistance in such patients. We performed this study to determine whether mutations in the coding portion of the insulin receptor gene were responsible for insulin resistance in PCOS. Insulin binding studies using cultured skin fibroblasts of three obese (body mass index > 27 kg/m<sup>2</sup>) women with PCOS (i.e., mild hyperandrogenemia and chronic anovulation of unknown etiol.) and documented insulin resistance showed no apparent abnormalities in either the number or affinity of insulin binding sites. Direct sequencing of all 22 exons of the insulin receptor gene from two of the women with PCOS did not reveal any mutations. Furthermore, both alleles of the gene were expressed at equal levels. In a third insulin-resistant PCOS woman, there was no evidence for amutation in the coding portion of the insulin receptor gene as determined by denaturing gradient gel electrophoresis (DGGE). We conclude that the insulin resistance in these PCOS women was caused by a defect extrinsic to the insulin receptor.

L4 ANSWER 23 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:406697 HCAPLUS

DOCUMENT NUMBER: 119:6697

TITLE: A sensitive method to detect defined peptide among those eluted from murine MHC class II molecules

AUTHOR(S): Brumeanu, T. D.; Kohanski, R.; Bona, C. A.; Zaghouani, H.

CORPORATE SOURCE: Dep. Microbiol. and, New York, NY, 10029, USA

SOURCE: Journal of Immunological Methods (1993), 160(1), 65-71

CODEN: JIMMBG; ISSN: 0022-1759

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A sensitive competitive inhibition RIA was developed able to trace pmoles of a defined peptide eluted from major histocompatibility complex (MHC) class II mols. that were subsequently fractionated by RP-HPLC. In this assay a model synthetic peptide corresponding to amino acid residues 110-120 from the hemagglutinin (HA) of PR8 influenza virus, and affinity purified rabbit antibodies specific for this peptide were used. The HA110-120 peptide binds to I-Ed class II mols. on the surface of APCs and is recognized by specific CD4+ T helper cells. The 2PK3 B lymphoma cells (H-2d) were pulsed with HA110-120 peptide or PR8 virus, lysed, the MHC class II mols. extracted, and bound peptides eluted. After separation by

RP-HPLC,

the fractions were tested for inhibition of the binding of rabbit anti-HA110-120 antibodies to peptide coated microtiter plates. A significant inhibitory activity was observed with 1 peak when the cells were pulsed with HA110-120 peptide and 2 peaks when pulsed with PR8 virus. The inhibitory activity was correlated with the presence of HA110-120 peptide as demonstrated by peptide sequencing. The assay is reproducible and sensitive to 1 pmol of antigenic peptide. This assay can be useful to identify microbial peptides with defined structure and antigenicity among the multiple peptides bound to class II mols.

L4 ANSWER 24 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:401355 HCAPLUS

DOCUMENT NUMBER: 119:1355

TITLE: Insulin receptor autophosphorylation. I.  
Autophosphorylation kinetics of the native receptor  
and its cytoplasmic kinase domain

AUTHOR(S): Kohanski, R. A.

CORPORATE SOURCE: Dep. Biochem., Mount Sinai Sch. Med., New York, NY,  
10029, USA

SOURCE: Biochemistry (1993), 32(22), 5766-72

CODEN: BICHAW; ISSN: 0006-2960

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Kinetic anal. of autophosphorylation was done using a non-Michaelis-Menten kinetic model. This model describes autophosphorylation in terms of a fast reaction phase, a slow reaction phase, and a partition function for the two phases. Kinetic parameters determined by this new approach show that insulin stimulates autophosphorylation by promoting (1) a 10-fold increase in the rate constant for the fast phase of the reaction and (2) a 2-fold increase in the partition function favoring the fast phase. Insulin did not significantly affect the binding constant for ATP in this fast phase. Kinetic parameters obtained for the cytoplasmic kinase domain were similar to those obtained for the native insulin receptor in the absence of insulin. The insulin receptor has three subdomains encompassing its seven autophosphorylation sites. The juxtamembrane sites react primarily in the slow kinetic phase, favored by the absence of stimulation and low ATP concns. The carboxy-terminal and central autophosphorylation subdomains react primarily in the fast kinetic phase, favored by raising the ATP concentration and/or the presence of insulin. These observations demonstrate that (1) both ATP and insulin regulate reaction in each autophosphorylation subdomain, (2) insulin stimulation occurs predominantly in the central and carboxy-terminal regions, and (3) autophosphorylation observed with the cytoplasmic kinase domain was similar to native insulin receptor in the absence of insulin. These findings are consistent with conclusions based on the kinetic anal. of autophosphorylation.

L4 ANSWER 25 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:401132 HCAPLUS  
 DOCUMENT NUMBER: 119:1132  
 TITLE: Insulin receptor autophosphorylation. II.  
 Determination of autophosphorylation sites by chemical  
 sequence analysis and identification of the  
 juxtamembrane sites  
 AUTHOR(S): Kohanski, R. A.  
 CORPORATE SOURCE: Dep. Biochem., Mount Sinai Sch. Med., New York, NY,  
 10029, USA  
 SOURCE: Biochemistry (1993), 32(22), 5773-80  
 CODEN: BICHAW; ISSN: 0006-2960  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Autophosphorylation sites of the human insulin receptor were identified by  
 microsequence anal. of 19 discrete tryptic [32P]phosphopeptides, purified  
 from the autophosphorylated cytoplasmic kinase domain (CKD). Seventeen  
 phosphopeptides were generated by cleavage at Arg and/or Lys, but two  
 phosphopeptides were generated reproducibly by anomalous cleavages. Two  
 new sites were identified in the juxtamembrane region of the intact  
 insulin receptor  $\beta$ -subunit (the amino terminus of the CKD), including  
 phosphotyrosins 965 and 972. Three sites in the central region, including  
 phosphotyrosines 1158, 1162, and 1163, were identified from six  
 phosphopeptides; tyrosine at 1158 was the least phosphorylated.  
 Monophosphopeptides contained phosphotyrosine at either residue 1158 or  
 1163, but not at 1162. Bisphosphorylation included phosphotyrosines only  
 at 1162 and 1163. The two autophosphorylation sites near the carboxy  
 terminus were found in seven phosphopeptides, including phosphotyrosines  
 at 1328 and 1334. When mapped by reverse-phase HPLC, these  
 phosphopeptides eluted in the order central domain, first;  
 carboxy-terminal region, second; and juxtamembrane (amino-terminal)  
 domain, last.

L4 ANSWER 26 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:553410 HCAPLUS  
 DOCUMENT NUMBER: 115:153410  
 TITLE: The native  $\alpha 2\beta 2$  tetramer is the only  
 subunit structure of the insulin receptor in intact  
 cells and purified receptor preparations  
 AUTHOR(S): Schenker, Esther; Kohanski, Ronald A.  
 CORPORATE SOURCE: Dep. Biochem., Mount Sinai Sch. Med., New York, NY,  
 10029, USA  
 SOURCE: Archives of Biochemistry and Biophysics (1991),  
 290(1), 79-85  
 CODEN: ABBIA4; ISSN: 0003-9861  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The native subunit structure of the insulin receptor was reinvestigated by  
 two-dimensional nonreducing/reducing gel electrophoresis. Human insulin  
 receptor expressed in murine fibroblasts was a single oligomer, the  
 $\alpha 2\beta 2$  heterotetramer. The structure was assessed using receptor  
 metabolically labeled with [35S]methionine, and using receptor  
 autophosphorylation at two levels of purification: the insulin  
 affinity-purified receptor and the more commonly used wheat germ  
 agglutinin-Sepharose-enriched fraction from whole membrane exts. Lower  
 mol. weight oligomers and free subunits were observed only upon heating the  
 sample prior to electrophoresis. This artifact of sample handling was  
 dependent upon three factors: (1) temperature, (2) time of heating, and (3)  
 impurities typically present in partially purified receptor preps. The

$\alpha 2\beta 2$  tetramer is the only insulin receptor subunit structure native in intact cells and subsequently isolated from cell membranes.

L4 ANSWER 27 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:509637 HCAPLUS  
DOCUMENT NUMBER: 115:109637  
TITLE: Monovalent avidin affinity columns  
AUTHOR(S): Kohanski, Ronald A.; Lane, M. Daniel  
CORPORATE SOURCE: Dep. Biochem., Mt. Sinai Sch. Med., New York, NY, 10029, USA  
SOURCE: Methods in Enzymology (1990), 184(Avidin-Biotin Technol.), 194-200  
CODEN: MENZAU; ISSN: 0076-6879  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The preparation and characteristics of a monovalent avidin-agarose column are described. The isolation of biotin-containing compds. by affinity chromatog. using the monovalent avidin column is described.

L4 ANSWER 28 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:138793 HCAPLUS  
DOCUMENT NUMBER: 114:138793  
TITLE: Primary structure of avian hepatic rhodanese  
AUTHOR(S): Kohanski, Ronald A.; Heinrikson, Robert L.  
CORPORATE SOURCE: Dep. Biochem., Mount Sinai Sch. Med., New York, NY, 10029, USA  
SOURCE: Journal of Protein Chemistry (1990), 9(4), 369-77  
CODEN: JPCHD2; ISSN: 0277-8033  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Rhodanese (EC 2.8.1.1) (I) was purified from chicken liver and its amino acid sequence was determined. I had a specificity activity of 676 IU and a mol. weight of 32,255. The primary structure of 289 amino acids was solved by sequential Edman degradation of overlapping peptides obtained by selected enzymic and chemical cleavages. The N-terminus was blocked, and the C-terminus was heterogeneous. Comparison of the primary structure with bovine liver I showed 212 identically matched amino acids, and the majority of amino acid differences were conservative substitutions. The reaction of I with a 1.4-fold molar excess of [2-<sup>14</sup>C]iodoacetate led to inactivation of the enzyme and carboxymethylation of cysteine-244; this modification was blocked by the substrate, thiosulfate.

L4 ANSWER 29 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:115422 HCAPLUS  
DOCUMENT NUMBER: 114:115422  
TITLE: Control of insulin receptor autophosphorylation by polypeptide substrates. Inhibition and stimulation by interaction with the catalytic subunit  
AUTHOR(S): Kohanski, R. A.; Schenker, Esther  
CORPORATE SOURCE: Dep. Biochem., Mt. Sinai Sch. Med., New York, NY, 10029, USA  
SOURCE: Biochemistry (1991), 30(9), 2406-14  
CODEN: BICHAW; ISSN: 0006-2960  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Autophosphorylation of purified insulin receptor, in the absence of insulin, was stimulated by selected polypeptide substrates. In the presence of 1  $\mu$ M insulin these peptides inhibited autophosphorylation. Stimulation was observed with reduced [S-(carboxamidoethyl)cysteinyl]lysozyme (RCAM-lysozyme) and three peptides generated by CNBr cleavage, V8

proteinase digestion, and/or chemical modification. Two peptide substrates were generated from RCAM-lysozyme which did not stimulate receptor autophosphorylation and were very weak inhibitors. As a control peptide, the simple substrate angiotensin inhibited receptor autophosphorylation in the absence or presence of insulin. However, stimulatory peptide, but not insulin, significantly shifted the concentration dependence for inhibition by angiotensin. The stimulatory peptides also increased autophosphorylation of the cloned cytoplasmic domain of the kinase (R-BIRK). Therefore, stimulation occurs by interaction with the cytoplasmic process of the  $\beta$ -subunit and not through interaction with the insulin binding  $\alpha$ -subunit of the native receptor. Autophosphorylation was analyzed by mapping  $^{32}\text{P}$ -labeled tryptic phosphopeptides from the  $\beta$ -subunit and from R-BIRK. Nearly identical phosphopeptide maps were found, comparing first, basal R-BIRK and basal native receptor, second, peptide- and insulin-stimulated native receptor, and third, peptide-stimulated R-BIRK and insulin-stimulated native receptor. Therefore, R-BIRK functions as a basal-state enzyme and can be stimulated in an insulin-like manner. On the basis of these observations, stimulation by insulin and by peptides yields similar functional results, but by apparently different mechanisms.

L4 ANSWER 30 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:627839 HCAPLUS

DOCUMENT NUMBER: 111:227839

TITLE: Insulin receptor aggregation and autophosphorylation in the presence of cationic polyamino acids

AUTHOR(S): Kohanski, Ronald A.

CORPORATE SOURCE: Dep. Biochem., Mount Sinai Sch. Med., New York, NY, 10029, USA

SOURCE: Journal of Biological Chemistry (1989), 264(35), 20984-91

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aggregation and autophosphorylation of the insulin receptor-protein kinase, from cultured 3T3-L1 adipocytes, were studied in the presence of cationic polyamino acids. Poly-L-lysine and poly-L-arginine produced the following effects with the purified receptor: first, the autophosphorylation rate was increased by polycations. Half-maximal stimulation was proportional to polymer length. The rate enhancement was greater at lower ATP concns. Second, near-endpoint (equilibrium) autophosphorylation was greater in the presence of polycations. Polycations inhibited the reverse reaction: ADP + phosphoreceptor yielding ATP + aporeceptor. Third, the [ $^{32}\text{P}$ ]phosphopeptides generated by trypsin digestion of the  $^{32}\text{P}$ - $\beta$ -subunit, showed that no new autophosphorylation sites resulted from the presence of polycations. Fourth, the polycations, but not insulin, promoted receptor aggregation, and phosphoreceptor aggregated more readily than aporeceptor. Insulin receptor enriched through the wheat germ agglutinin eluate step was compared with purified receptor. Higher concns. of poly-L-arginine were required to stimulate autophosphorylation and to promote aggregation. Finally, several polycation-dependent substrates present in the wheat germ agglutinin eluate co-aggregated with the insulin receptor. Polycation-stimulated receptor autophosphorylation is linked to a lower  $K_{\text{M}}$  for ATP, but substrate phosphorylation may require the aggregation.

L4 ANSWER 31 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:69710 HCAPLUS

DOCUMENT NUMBER: 110:69710

TITLE: Conformational states of the insulin receptor

AUTHOR(S): Schenker, Esther; Kohanski, Ronald A.

CORPORATE SOURCE: Dep. Biochem., Mt. Sinai Sch. Med., New York, NY,  
10029, USA  
SOURCE: Biochemical and Biophysical Research Communications  
(1988), 157(1), 140-5  
CODEN: BBRCA9; ISSN: 0006-291X

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Insulin binding to the  $\alpha$ -subunit of the purified insulin receptor changed the interaction between  $\beta$ -subunits. This conformational change was demonstrated after labeling the receptor's  $\beta$ -subunit by autophosphorylation in the absence of insulin, and then crosslinking the subunits to each other with bis(sulfosuccinimidyl) suberate. The covalent oligomers were resolved by reduction and denaturing gel electrophoresis. Insulin increased the rate of crosslinking, especially the formation of  $\beta$ - $\beta$  dimers. These results support a conformational change following insulin binding, and may reflect the insulin-induced activation of autophosphorylation.

L4 ANSWER 32 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:490494 HCAPLUS  
DOCUMENT NUMBER: 107:90494  
TITLE: Effect of phenylarsine oxide on insulin-dependent  
protein phosphorylation and glucose transport in  
3T3-L1 adipocytes  
AUTHOR(S): Frost, Susan C.; Kohanski, Ronald A.; Lane,  
M. Daniel  
CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205,  
USA  
SOURCE: Journal of Biological Chemistry (1987), 262(20),  
9872-6  
CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Phenylarsine oxide (PAO) blocks insulin-stimulated glucose transport in 3T3-L1 adipocytes and the locus of inhibition is post-receptor. Insulin stimulated the extent of receptor autophosphorylation in solution and in the intact cell by .apprx.4-fold. PAO had no effect on this activity. With reduced and carboxamidomethylated lysozyme as a substrate for the tyrosine-specific receptor, insulin stimulated the rate of receptor kinase-catalyzed substrate phosphorylation by 2-fold; PAO had no effect on this stimulation. However, the insulin-stimulated, serine-specific phosphorylation of 2 endogenous phosphoproteins (pp24 and pp240) in the intact cell was blocked by 25  $\mu$ M PAO. Thus, the inhibition by PAO must be distal to the insulin receptor's protein tyrosine kinase activity.

L4 ANSWER 33 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:603214 HCAPLUS  
DOCUMENT NUMBER: 105:203214  
TITLE: Control of autophosphorylation and substrate  
phosphorylation by the insulin receptor protein kinase  
AUTHOR(S): Lane, M. Daniel; Kohanski, Ronald A.  
CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, USA  
SOURCE: Fernstroem Foundation Series (1986), 7(Mech. Insulin  
Action), 59-73  
CODEN: FFOSDF; ISSN: 0167-7004

DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review, with 18 refs., on the kinetics and role of autophosphorylation in substrate phosphorylation catalyzed by the insulin receptor tyrosine kinase [88201-45-0] in response to insulin [9004-10-8].

L4 ANSWER 34 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:565528 HCAPLUS

DOCUMENT NUMBER: 105:165528

TITLE: Insulin-dependent phosphorylation of the insulin receptor-protein kinase and activation of glucose transport in 3T3-L1 adipocytes

AUTHOR(S): Kohanski, Ronald A.; Frost, Susan C.; Lane, M. Daniel

CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (1986), 261(26), 12272-81

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Intact 3T3-L1 adipocytes were equilibrated with [32P]orthophosphate and then disrupted under denaturing conditions which preserved the phosphorylation state of the insulin [9004-10-8] receptor established in the cell. The insulin receptor, isolated by lectin adsorption and 2-dimensional nonreducing/reducing PAGE, occurred as a single oligomeric species with an apparent  $\alpha\beta_2$  subunit composition. This oligomeric structure was not altered by treating cells with insulin. Only the  $\beta$ -subunit of the receptor was phosphorylated; [32P]phosphoserine and [32P]phosphotyrosine were both identified in the  $\beta$ -subunit from cells in the unstimulated state, but only [32P]phosphotyrosine increased in cells stimulated with insulin. Neither insulin-like growth factor I nor II stimulated insulin receptor  $\beta$ -subunit phosphorylation, although both activated hexose transport. On the addition of insulin, [32P]orthophosphate incorporated into the  $\beta$ -subunit increased 4.5-fold (7-fold with respect to [32P]tyrosine) and was complete within 1 min [half-time ( $t_{1/2}$ ) = 8 s]. Following the removal of insulin from the monolayers, [32P] $\beta$ -subunit fell to the basal level ( $t_{1/2}$  = 2.5 min); there was no lag phase before either transition. The tyrosine protein kinase [80449-02-1] activity, measured in vitro with a model substrate, was higher with immunoaffinity-purified insulin receptor from insulin-stimulated cells than from cells in the basal state. Hexose transport rate, measured using <sup>14</sup>C-labeled 3-O-methylglucose [146-72-5], was half-maximally stimulated at 2 nM insulin. A 1-min latency period followed insulin addition, after which a 7-fold increase in the steady-state rate of hexose uptake was achieved within 5 min. On the removal of insulin, hexose transport continued at the stimulated steady-state rate for 2.5 min and then declined to the basal rate with a  $t_{1/2}$  of 8 min. These kinetic expts. in situ and protein kinase activity measurements in vitro support the hypothesis that  $\beta$ -subunit phosphorylation is an intermediate step linking insulin binding to the increased glucose transport rate.

L4 ANSWER 35 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:163752 HCAPLUS

DOCUMENT NUMBER: 104:163752

TITLE: Posttranslational processing of the insulin proreceptor

AUTHOR(S): Lane, M. Daniel; Ronnett, Gabriele V.; Kohanski, Ronald A.; Simpson, Tracy L.

CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SOURCE: Current Topics in Cellular Regulation (1985), 27 (Modulation Covalent Modif.), 279-92

CODEN: CTCRAE; ISSN: 0070-2137

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review, with 28 refs., on processing of the insulin proreceptor into functional receptor in 3T3-L1 adipocytes and the importance of glycosylation in this process.

L4 ANSWER 36 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:144878 HCAPLUS

DOCUMENT NUMBER: 104:144878

TITLE: Identification and partial purification of the insulin-responsive glucose transporter from 3T3-L1 adipocytes

AUTHOR(S): Schroer, Dean W.; Frost, Susan C.; **Kohanski, Ronald A.**; Lane, M. Daniel; Lienhard, Gustav E.

CORPORATE SOURCE: Dep. Biochem., Dartmouth Med. Sch., Hanover, NH, 03756, USA

SOURCE: Biochimica et Biophysica Acta, Molecular Cell Research (1986), 885(3), 317-26

CODEN: BBAMCO; ISSN: 0167-4889

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The glucose transporter in 3T3-L1 adipocytes has been identified as a polypeptide of average mol. weight 51,000 by its reaction with antibodies raised

against the purified human erythrocyte glucose transporter and by photolabeling with [3H]cytochalasin B. The finding that the antibodies immunopptd. the photolabeled polypeptide demonstrated that both methods detected the same polypeptide. The 3T3-L1 adipocyte glucose transporter has been partially purified. The main steps in the purification procedure were the preparation of salt-washed cellular membranes, Triton X-100 solubilization, and immunoaffinity chromatog. on affinity-purified antibodies against the human erythrocyte transporter. A simple method of affinity purification of these antibodies, which consists of adsorption from serum onto protein-depleted erythrocyte membranes and release with acid, and an assay for the 3T3-L1 adipocyte transporter polypeptide which employs immunoblotting, have been developed.

L4 ANSWER 37 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:125592 HCAPLUS

DOCUMENT NUMBER: 104:125592

TITLE: Kinetic evidence for activating and non-activating components of autophosphorylation of the insulin receptor protein kinase

AUTHOR(S): **Kohanski, Ronald A.**; Lane, M. Daniel

CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SOURCE: Biochemical and Biophysical Research Communications (1986), 134(3), 1312-18

CODEN: BBRC9; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Reduced and carboxamidomethylated-lysozyme (RCAM-lysozyme) is an excellent substrate ( $K_m = 13 \mu M$ ) and a potent inhibitor of insulin receptor protein kinase autophosphorylation ( $K_i = 0.6 \mu M$ ). By using these properties of RCAM-lysozyme, autophosphorylation was resolved into 2 kinetically and functionally distinct components involving formation of phosphotyrosine on the receptor  $\beta$ -subunits. Insulin-stimulated autophosphorylation is independent of autophosphorylation at other sites; activation of insulin receptor-catalyzed substrate phosphorylation is dependent upon this component of autophosphorylation, which is inhibited



by RCAM-lysozyme. Autophosphorylation at saturating RCAM-lysozyme concentration is insensitive to insulin and has little effect on substrate phosphorylation. Thus, only insulin-dependent receptor autophosphorylation is responsible for activation of kinase-catalyzed substrate phosphorylation.

L4 ANSWER 38 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:123217 HCAPLUS  
DOCUMENT NUMBER: 104:123217  
TITLE: Post-translational processing and activation of insulin and EGF proreceptors  
AUTHOR(S): Lane, M. Daniel; Ronnett, Gabriele; Slieker, Lawrence J.; Kohanski, Ronald A.; Olson, Tracy L.  
CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA  
SOURCE: Biochimie (1985), 67(10-11), 1069-80  
CODEN: BICMBE; ISSN: 0300-9084  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review, with 35 refs., on the role of glycosylation on the post-translational processing of the insulin [9004-10-8] and EGF [62229-50-9] proreceptor polypeptides.

L4 ANSWER 39 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:589938 HCAPLUS  
DOCUMENT NUMBER: 103:189938  
TITLE: Synthesis and processing of the insulin proreceptor to form functional insulin receptor  
AUTHOR(S): Lane, M. Daniel; Ronnett, Gabriele V.; Kohanski, Ronald A.; Simpson, Tracy L.  
CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA  
SOURCE: UCLA Symposia on Molecular and Cellular Biology, New Series (1985), 23(Membr. Recept. Cell. Regul.), 397-412  
CODEN: USMBD6; ISSN: 0735-9543  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review, with 26 refs., on the importance of glycosylation in the processing of the insulin [9004-10-8] proreceptor to form functional insulin receptor. Purification of the insulin receptor, posttranslational activation of the proreceptor, and identification of the intermediates in the processing pathway are discussed.

L4 ANSWER 40 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:556541 HCAPLUS  
DOCUMENT NUMBER: 103:156541  
TITLE: Receptor affinity chromatography  
AUTHOR(S): Kohanski, Ronald A.; Lane, M. Daniel  
CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA  
SOURCE: Annals of the New York Academy of Sciences (1985), 447(Biotin), 373-85  
CODEN: ANYAA9; ISSN: 0077-8923  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review with 27 refs. on the chromatog. isolation of the insulin receptor using a bifunctional biotin-hormone conjugate and immobilized avidin to retain the complex between receptor and the bifunctional ligands.

L4 ANSWER 41 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:419252 HCAPLUS

DOCUMENT NUMBER: 103:19252

TITLE: Homogeneous functional insulin receptor from 3T3-L1 adipocytes. Purification using N $\alpha$ B1-(biotinyl- $\epsilon$ -aminocaproyl)insulin and avidin-Sepharose

AUTHOR(S): Kohanski, Ronald A.; Lane, M. Daniel

CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (1985), 260(8), 5014-25

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Insulin receptor was purified 10,000-fold from cultured mouse 3T3-L1 adipocytes in 35% overall yield. The specific activities of 125I-labeled insulin binding and autophosphorylation increased in parallel, following the initial Triton X 100 extraction of membranes. The isolation protocol, performed entirely at pH 8.45, entailed adsorption by avidin-Sepharose CL 4B of a complex formed between Triton X 100-solubilized insulin receptor and N $\alpha$ B1-(biotinyl- $\epsilon$ -aminocaproyl)insulin, and the specific elution of the complex with biotin. The avidin-Sepharose CL 4B was a partially denatured preparation, showing estimated dissociation consts. of 0.2

 $\mu$ M

for biotin and .apprx.1  $\mu$ M for the bifunctional ligand at pH 7, 4°. The bifunctional ligand was characterized by 70% competency in binding to avidin, 100% competency in binding to solubilized insulin receptor, full stimulation of autophosphorylation of the isolated receptor, and maximal stimulation of hexose uptake by intact 3T3-L1 adipocytes. The insulin-binding properties of the insulin receptor were uniform throughout this purification procedure. At pH 8.45, 4°, an average  $K_d$  = 0.72 nM was determined for a single class of noninteracting insulin-binding sites. The apparent autophosphorylation of the  $\beta$ -subunit was also unchanged following affinity chromatog. A single oligomeric structure was established for the purified receptor, composed only of 135,000- and 95,000-dalton subunits whose association was lost by denaturation in the presence of reducing agent. This single structure occurred in the initial Triton X 100 extract. The purified insulin receptor was capable of autophosphorylating the  $\beta$ -subunit and catalyzed phosphorylation of protein substrates.

L4 ANSWER 42 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1984:168791 HCAPLUS

DOCUMENT NUMBER: 100:168791

TITLE: Role of glycosylation in the processing of newly translated insulin proreceptor in 3T3-L1 adipocytes

AUTHOR(S): Ronnett, Gabriele V.; Knutson, Victoria P.; Kohanski, Ronald A.; Simpson, Tracy L.; Lane, M. Daniel

CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (1984), 259(7), 4566-75

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A procedure was developed for the immunopptn. of glycosylated and nonglycosylated forms of the insulin [9004-10-8] receptor and its precursors without prior purification using lectins. 3T3-L1 adipocytes were labeled with [35S]methionine after which 35S-labeled receptor polypeptides

were specifically immunoprecipitated and characterized by SDS-polyacrylamide gel electrophoresis. The first 35S-polyprotein detected was a 190-kilodalton (kDa) glycosylated proreceptor which was rapidly [half-time ( $t_{1/2}$ )  $\approx$  15 min] processed to a 210-kDa intermediate. The latter precursor was more slowly ( $t_{1/2}$   $\approx$  2 h) proteolytically processed to 125-kDa ( $\alpha'$ ) and 83-kDa ( $\beta'$ ) precursors of the mature  $\alpha$ - and  $\beta$ -receptor subunits. Immediately prior to insertion into the plasma membrane, i.e.  $\approx$  3 h after translation, the  $\alpha'$ - and  $\beta'$ -precursor polypeptides were converted to the mature 135-kDa  $\alpha$ - and 95-kDa  $\beta$ -receptor subunits. The characteristics of the oligosaccharide moieties of the receptor precursors and products were investigated. The 210-kDa precursor and its 2 products, the 125-kDa  $\alpha'$ - and 83-kDa  $\beta'$ -species, and the mature  $\alpha$ - and  $\beta$ -receptor subunits bound tightly to wheat germ lectin, whereas the 190-kDa proreceptor species did not. On incubation with endoglycosidase H, both the 210- and 190-kDa species were converted to a 180-kDa species. The 125-kDa  $\alpha'$ - and 83-kDa  $\beta'$ -species were also cleaved by endoglycosidase H, being reduced in size to 97 and 79 kDa, resp. Based on their sensitivity to endoglycosidase H and insensitivity to neuraminidase, the oligosaccharide chains of the receptor precursors (190, 210, 125, and 83 kDa) did not contain terminal sialic acid (or other capping sugars). However, near the time of insertion into the plasma membrane, capping of the  $\alpha'$ - and  $\beta'$ -species by sialic acid occurred, giving rise to the mature 135-kDa  $\alpha$ - and 95-kDa  $\beta$ -receptor subunits, which were partially endoglycosidase H-resistant and neuraminidase-sensitive. When 3T3-L1 adipocytes were treated with tunicamycin, a 180-kDa proreceptor aglycoprotein was synthesized which was incapable of undergoing further processing and proteolytic cleavage to the  $\alpha$ - and  $\beta$  (or  $\alpha'$ - and  $\beta'$ -) subunits. The 180-kDa species, which appeared to be the aglyco-form of the 190-kDa proreceptor generated by endoglycosidase H, was resistant to trypsin in the intact cell and apparently had not reached the cell surface. Thus, the oligosaccharide moieties of the insulin receptor precursor are crucial for proper processing, intracellular translocation, and formation of functionally competent insulin receptor.

L4 ANSWER 43 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1983:433469 HCAPLUS

DOCUMENT NUMBER: 99:33469

TITLE: Binding of insulin to solubilized insulin receptor from human placenta. Evidence for a single class of noninteracting binding sites

AUTHOR(S): Kohanski, Ronald A.; Lane, M. Daniel

CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (1983), 258(12), 7460-8

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Binding of 125I-labeled insulin [9004-10-8] to insulin receptor was studied at equilibrium using plasma membrane protein, from human placenta, solubilized in Triton X-100. Measured at 1 nM [125I]insulin, the amount of radioligand bound specifically was dependent on pH, with the optimal association at 4° occurring in the pH range 8.2-8.7. The Adair equation was employed for anal. of binding isotherms generated at several pH values for concns. of radioligand of 0.01-8.0 nM. Association consts. derived from these analyses showed the same pH dependence described above and were independent of receptor concentration. Hill plots derived from these titrns. consistently yielded Hill coeffs. of 1 and Scatchard plots gave

virtually straight lines. Close correspondence was found between theor. analyses and observations under all exptl. conditions and graphical methods employed. These results are consistent with a single class of noninteracting [<sup>125</sup>I]insulin binding sites on the solubilized insulin receptor.

L4 ANSWER 44 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1982:435084 HCAPLUS

DOCUMENT NUMBER: 97:35084

TITLE: Rhodanese: structure-function relationships relevant to the mechanisms of cyanide detoxication

AUTHOR(S): Keim, Philip; Kohanski, Ronald A.;  
Heinrikson, Robert L.

CORPORATE SOURCE: Dep. Biochem., Univ. Chicago, Chicago, IL, 60637, USA

SOURCE: Antinutr. Nat. Toxicants Foods, [Pap. Symp.] (1981),  
Meeting Date 1979, 331-58. Editor(s): Ory, Robert L.  
Food & Nutr. Press: Westport, Conn.

CODEN: 47ZOAW

DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

AB A review with 61 refs.

L4 ANSWER 45 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:479143 HCAPLUS

DOCUMENT NUMBER: 87:79143

TITLE: A simple quantitative assay of iodine-125-labeled  
 $\alpha$ -bungarotoxin binding to soluble and  
membrane-bound acetylcholine receptor protein

AUTHOR(S): Kohanski, Ronald A.; Andrews, John P.; Wins,  
Pierre; Eldefrawi, Mohyee E.; Hess, George P.

CORPORATE SOURCE: Sect. Biochem. Mol. Biol., Cornell Univ., Ithaca, NY,  
USA

SOURCE: Analytical Biochemistry (1977), 80(2), 531-9

CODEN: ANBCA2; ISSN: 0003-2697

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This method involves the irreversible formation of a complex between <sup>125</sup>I-labeled  $\alpha$ -bungarotoxin [11032-79-4], and the acetylcholine [51-84-3], receptor in either its membrane-bound or purified state. The separation of the labeled toxin-receptor complex from unreacted toxin is accomplished by chromatog. on carboxymethylcellulose cation-exchange resin. The method described was developed to satisfy the following exptl. requirements that could not be dealt with in their entirety by employing any of the published methods: (i) the complete recovery of reacted and unreacted species in relatively small volumes; (ii) an efficient and precise isolation of the specific and irreversible <sup>125</sup>I-labeled  $\alpha$ -bungarotoxin-receptor complex when the complexation reactions demand a large excess of unlabeled  $\alpha$ -bungarotoxin for quenching (a 20-fold molar excess of unlabeled over labeled toxin); (iii) this isolation of the toxin-receptor complex allows one to determine the protein concns. in the samples, a necessity in expts. covering a wide range of receptor concns.; (iv) a consistent low blank for binding site concns. ranging over two or three orders of magnitude; and (v) simplicity and rapidity.

=> => d stat que

L2 57 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PARANG K"/AU OR "PARANG  
KAYKAVOOS"/AU OR "PARANG KEYKAVOVS"/AU)

L3 8 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ABLOOGLU ARARAT J"/AU OR

L4 45 "ABLOOGLU ARARAT JAN"/AU OR "ABLOOGU ARARAT"/AU) NOT L2  
 SEA FILE=HCAPLUS ABB=ON PLU=ON ("KOHANSKI R"/AU OR "KOHANSKI  
 R A"/AU OR "KOHANSKI RON"/AU OR "KOHANSKI RON A"/AU OR  
 "KOHANSKI RONALD"/AU OR "KOHANSKI RONALD A"/AU) NOT (L2 OR L3)  
 L5 22 SEA FILE=HCAPLUS ABB=ON PLU=ON ("COURTNEY A"/AU OR "COURTNEY  
 A D"/AU OR ("COURTNEY ALIYA"/AU OR "COURTNEY ALIYA D"/AU)) NOT  
 (L2 OR L3 OR L4)

=>

=>

=> d ibib abs 15 1-22

L5 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2005:1035398 HCAPLUS  
 TITLE: Requisite role for complement C5 and the C5a receptor  
 in granulomatous response to mycobacterial glycolipid  
 trehalose 6,6'-dimycolate  
 AUTHOR(S): Borders, C. W.; Courtney, A.; Ronen, K.;  
 Laborde-Lahoz, M. Pilar; Guidry, T. V.; Hwang, S.-A.;  
 Olsen, M.; Hunter, R. L., Jr.; Hollmann, T. J.;  
 Wetsel, R. A.; Actor, J. K.  
 CORPORATE SOURCE: Medical School, University of Texas-Houston, Houston,  
 TX, USA  
 SOURCE: Scandinavian Journal of Immunology (2005), 62(2),  
 123-130  
 CODEN: SJIMAX; ISSN: 0300-9475  
 PUBLISHER: Blackwell Publishing Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The development of pulmonary granulomatous lesions during mycobacterial  
 infection is a complex phenomenon, in part caused by responses elicited  
 towards the surface glycolipid trehalose 6,6'-dimycolate (TDM; cord  
 factor). The mol. mechanisms underlying granuloma formation following  
 challenge with TDM are not yet completely understood. The present study  
 defines pathol. differences in acute response to Mycobacterium  
 tuberculosis TDM in C57BL/6 mice and mice lacking the C5a receptor  
 (C5aR-/-). Mice were i.v. injected with TDM prepared in  
 water-in-oil-in-water emulsion and examined for histol. response and changes  
 in proinflammatory cytokines and chemokines in lung tissue. Control C5a  
 receptor-sufficient mice demonstrated a granulomatous response that peaked  
 between days 4 and 7. Increased production of macrophage inflammatory  
 protein-1 alpha (MIP-1 $\alpha$ ), interleukin-1 $\beta$  (IL-1 $\beta$ ) and CXC  
 chemokine KC (CXCL1) correlated with development of granulomas, along with  
 modest change in tumor necrosis factor-alpha (TNF- $\alpha$ ). In contrast,  
 the C5aR-/- mice revealed markedly exacerbated inflammatory response. The  
 receptor-deficient mice also demonstrated a lack of coherent granulomatous  
 response, with severe edema present and instances of lymphocytic cuffing  
 around pulmonary vessels. Lung weight index was increased in the C5aR-/-  
 mice, correlating with increased MIP-1 $\alpha$ , KC, IL-1 $\beta$  and  
 TNF- $\alpha$  over that identified in the congenic C5aR-sufficient controls.  
 Correlate expts. performed in C5-deficient (B10.D2-H2d H2-T18c Hco/oSnJ)  
 mice revealed similar results, leading to the conclusion that C5 plays a  
 significant role in mediation of chemotactic and activation events that  
 are the basis for maturation of granulomatous responses to TDM.  
 REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:266327 HCAPLUS

DOCUMENT NUMBER: 138:380914  
TITLE: Chemical Approaches to Reversible Protein Phosphorylation  
AUTHOR(S): Cole, Philip A.; **Courtney, Aliya D.**; Shen, Kui; Zhang, Zhongsen; Qiao, Yingfeng; Lu, Wei; Williams, Daniel M.  
CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA  
SOURCE: Accounts of Chemical Research (2003), 36(6), 444-452  
CODEN: ACHRE4; ISSN: 0001-4842  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
AB A review. Protein phosphorylation catalyzed by protein kinases plays a critical role in cellular signaling. Here we review several chemical approaches to understanding protein kinases and the consequences of protein phosphorylation. We discuss the design of bisubstrate analog inhibitors based on a dissociative transition state, the development of reagents for crosslinking protein kinases with their substrates, the chemical rescue of mutant protein tyrosine kinases, and the application of expressed protein ligation to understanding protein phosphorylation.  
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:851034 HCAPLUS  
DOCUMENT NUMBER: 138:45018  
TITLE: Deformation and bonding in a puckered Re-C square net  
AUTHOR(S): Merschrod S., Erika F.; **Courtney, Aliya**; Hoffmann, Roald  
CORPORATE SOURCE: Dep. Chemistry Chemical Biology, Cornell Center Materials Res., Cornell Univ., Ithaca, NY, 14853-1301, USA  
SOURCE: Zeitschrift fuer Anorganische und Allgemeine Chemie (2002), 628(12), 2757-2763  
CODEN: ZAACAB; ISSN: 0044-2313  
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Sc5Re2C7 contains unusual Re-C puckered "square" nets, isolated C3 units, and scandium ions. Its electron count drives the peculiar distortion of the Re-C nets, resulting in quite different Re-C and Re-Re bonding along each direction. Indeed, some of the Re-C interactions emerge as stronger than double bonds. The puckering, in turn, enables a bonding role for the scandium atoms in addition to their function as electron donors to the nets and the isolated carbide units.  
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2000:515071 HCAPLUS  
DOCUMENT NUMBER: 133:248858  
TITLE: p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism  
AUTHOR(S): Lau, Ontario D.; **Courtney, Aliya D.**; Vassilev, Alex; Marzilli, Lisa A.; Cotter, Robert J.; Nakatani, Yoshihiro; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (2000), 275(29), 21953-21959  
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB P300/CBP-associated factor (PCAF) is a histone acetyltransferase that plays an important role in the remodeling of chromatin and the regulation of gene expression. It has been shown to catalyze preferentially acetylation of the  $\epsilon$ -amino group of lysine 14 in histone H3. In this study, the kinetic mechanism of PCAF was evaluated with a 20-amino acid peptide substrate derived from the amino terminus of histone H3 (H3-20) and recombinant bacterially expressed PCAF catalytic domain (PCAFcat). The enzymol. behavior of full-length PCAF and PCAFcat were shown to be similar. PCAF-catalyzed acetylation of the substrate H3-20 was shown to be specific for Lys-14, analogous to its behavior with the full-length histone H3 protein. Two-substrate kinetic anal. displayed an intersecting line pattern, consistent with a ternary complex mechanism for PCAF. The dead-end inhibitor analog desulfo-CoA was competitive vs. acetyl-CoA and noncompetitive vs. H3-20. The dead-end analog inhibitor H3-20 K14A was competitive vs. H3-20 and uncompetitive vs. acetyl-CoA. The potent bisubstrate analog inhibitor H3-CoA-20 was competitive vs. acetyl-CoA and noncompetitive vs. H3-20. Taken together, these inhibition patterns support an ordered BiBi kinetic mechanism for PCAF in which acetyl-CoA binding precedes H3-20 binding. Viscosity expts. suggest that diffusional release of product is not rate-determining for PCAF catalysis. These results provide a mechanistic framework for understanding the detailed catalytic behavior of an important subset of the histone acetyltransferases and have significant implications for mol. regulation of and inhibitor design for these enzymes.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:267237 HCAPLUS

DOCUMENT NUMBER: 124:310185

TITLE: An assessment of the possible reasons for differential tolerance to fluroxypyr in selected populations of Galium aparine

AUTHOR(S): Hill, A. L.; Courtney, A. D.; Harvey, B. M. R.

CORPORATE SOURCE: Agriculture and Food Science Centre, Queen's University, Belfast, BT9 5PX, UK

SOURCE: Weed Research (1996), 36(1), 15-20  
CODEN: WEREAT; ISSN: 0043-1737

PUBLISHER: Blackwell

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In an investigation of the possible reasons for tolerance to fluroxypyr by G. aparine, a wide range of variation in total herbicide retention was exhibited by 9 diverse populations from throughout Europe. Although these differences in fluroxypyr retention became negligible when considered on a unit area basis, a two-fold difference was maintained per unit dry matter. There was no difference in fluroxypyr uptake between a fluroxypyr-tolerant and a fluroxypyr-susceptible population, and differences in translocation between the two populations did not seem to explain the differential

tolerance. Differential metabolic detoxification may be the main reason for the variation in response to fluroxypyr by populations of *G. aparine*.

L5 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:501849 HCAPLUS  
DOCUMENT NUMBER: 121:101849  
TITLE: The significance of crop density on the tolerance of irrigated crops to pendimethalin in the Sudan  
AUTHOR(S): Tom, S. El; **Courtney, A. D.**  
CORPORATE SOURCE: Dep. Appl. Plant Sci., Queen's Univ. Belfast, BT9 5PX, UK  
SOURCE: Brighton Crop Protection Conference--Weeds (1993), (VOL. 2), 647-8  
CODEN: BCPWE2; ISSN: 0955-1514  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The effect of crop d. on crop tolerance to pendimethalin was tested in two field trials in the Sudan. Each of the crops sorghum, oats and pigeon pea showed increased mortality during establishment with increasing d. The effects were most significant in sorghum, the most sensitive crop to pendimethalin. This response is contrary to the more often recorded effect of d. where crop tolerance is increased by higher crop stands.

L5 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:250369 HCAPLUS  
DOCUMENT NUMBER: 116:250369  
TITLE: Cost-effectiveness of weed control in cereals - systems based on thresholds and reduced rates  
AUTHOR(S): Proven, M. J.; **Courtney, A.**; Picton, J.; Davies, D. H. K.; Whiting, A. J.  
CORPORATE SOURCE: Agric. Dev. Advis. Serv., Drayton Exp. Husb. Farm., Stratford upon Avon/Warwickshire, CV37 9RQ, UK  
SOURCE: Brighton Crop Protection Conference--Weeds (1991), (Vol. 3), 1201-8  
CODEN: BCPWE2; ISSN: 0955-1514  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A series of trials was established in farm cereal crops on 10 sites throughout the United Kingdom in the 1987/88 season. The experiment was designed to test in practice systems of weed control which placed differing degrees of reliance on weed threshold models developed at Long Ashton Research Station. It also studied the effectiveness of systems which reduced herbicide inpt by halving the product application rates. Weed populations were monitored, both to determine the need for treatment in threshold-managed systems and, by comparison with untreated areas, to assess herbicide efficacy. Over a wide range of soil types and locations, on typical arable farms, the risk-averse thresholds were exceeded on about 80% of occasions. The reduction in efficacy when herbicide rate was reduced by 50% from that recommended on the product label was, over a wide range of situations, small. Grain yield was generally unaffected by frequency of herbicide use or by herbicide rate. As a direct consequence, the most cost-effective strategies were those which involved the least expenditure on herbicides.

L5 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:250357 HCAPLUS  
DOCUMENT NUMBER: 116:250357  
TITLE: The relative influence of genetic variation and provenance on the morphology and herbicide response of selected populations of *Galium aparine*



AUTHOR(S): Hill, A. L.; **Courtney, A. D.**  
 CORPORATE SOURCE: Agric. Bot. Dep., Queens Univ. Belfast, Belfast, BT9 5PX, UK  
 SOURCE: Brighton Crop Protection Conference--Weeds (1991), (Vol. 3), 1015-22  
 CODEN: BCPWE2; ISSN: 0955-1514  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Seeds of Galium aparine, collected from locations in 5 European countries, were grown in Germany and Northern Ireland. Plants grown from seed from these sites were then compared along with plants from the original seed collection. A significant effect of provenance, population and an interaction between the 2 were found with respect to seed size, percentage germination, and some seedling characters. Significant population differences in response to fluroxypyr were unaffected by the provenance of the seeds.

L5 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1990:419342 HCAPLUS  
 DOCUMENT NUMBER: 113:19342  
 TITLE: The effect of crop density on herbicide efficacy and yield response in continuous spring barley  
 AUTHOR(S): Easson, D. L.; **Courtney, A. D.**  
 CORPORATE SOURCE: Agric. Res. Inst. North. Ireland, Hillsborough, BT26 6DR, UK  
 SOURCE: Brighton Crop Protection Conference--Weeds (1989), (1), 137-42  
 CODEN: BCPWE2; ISSN: 0955-1514  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A spring barley experiment was carried out in which herbicide (Advance; Twin-Tak; Seritox 50; Ally) and crop d. treatments were imposed on two cultivars on the same plots for four years. In the absence of herbicide broad-leaved weed nos. progressively increased from 106 m<sup>-2</sup> to 194 m<sup>-2</sup> over the four years. This contrasts with the Poa annua population, which exhibited a general decline on all treatments. The herbicide treatments reduced broad-leaved weed nos. and progressively increased yields. Reducing the crop d. influenced weed biomass rather than weed nos. with the highest response to herbicides occurring at the lowest crop d. The herbicide treatments showed significantly different yield responses which appear to be attributable to factors other than weed control efficacy.

L5 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1988:506460 HCAPLUS  
 DOCUMENT NUMBER: 109:106460  
 TITLE: A comparison of herbicides for weed control in fiber flax  
 AUTHOR(S): **Courtney, A. D.**  
 CORPORATE SOURCE: Agric. Bot. Res. Div., Dep. Agric. N. Ireland, Belfast, BT9 5PX, UK  
 SOURCE: Annals of Applied Biology (1988), 112(Suppl.), 50-1  
 CODEN: AABIAV; ISSN: 0003-4746  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Of 6 preemergence herbicides, Butisan S 500, aclonifen 3000, and Tristar 1104 kg/ha, were the most effective, controlling weeds and increasing the yield of fiber flax by 38, 34, and 32%, resp. Postemergence Ally 3 g/ha or Vulcan (bromoxynil 240 + clopyralid 50 g/ha) increased the yield by 29 and 28%, resp.

L5 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:631307 HCAPLUS

DOCUMENT NUMBER: 107:231307

TITLE: Weed incidence and yield response to herbicides in spring barley (*Hordeum vulgare*) on farm sites in Northern Ireland

AUTHOR(S): Courtney, A. D.; Johnston, R. T.

CORPORATE SOURCE: Agric. Bot. Res. Div., Dep. Agric. North. Ireland, Belfast, BT9 5PX, UK

SOURCE: Record of Agricultural Research (1987), 35, 11-15  
CODEN: RARIAQ; ISSN: 0375-0698

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In an investigation conducted at 41 farm sites between 1978 and 1981, no significant yield response was recorded to application of herbicides (MCPA, MCPA-dichlorprop mixture, ioxynil-bromoxynil-mecoprop mixture) to spring barley, but a regression anal. indicated a significant reduction in yield due to an increase in the number of weeds. The average weed population

was

184 weeds/m<sup>2</sup>. The most frequent species was *Stellaria media* followed by *Polygonum persicaria* and annual grass weeds.

L5 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:511005 HCAPLUS

DOCUMENT NUMBER: 107:111005

TITLE: A comparison of herbicide regimes for weed control in fiber flax

AUTHOR(S): Courtney, A. D.

CORPORATE SOURCE: Agric. Bot. Res. Div., Dep. Agric. N. Ireland, Belfast, BT9 5PX, UK

SOURCE: Tests of Agrochemicals and Cultivars (1987), 8, 84-5  
CODEN: TACUDC; ISSN: 0951-4309

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The standard unincorporated trifluralin treatment failed to give adequate control of either dicotyledonous or grass weeds. Metazachlor was the best treatment against grass weeds but some initial effects on crop establishment were observed, suggesting that crop tolerance may not be sufficient. Each of the sulfonyl urea treatments even at the lowest rates produced excellent control of the main weed species present at the two sites, *Polygonum persicaria*, *Galeopsis tetrahit*, *Spergula arvensis*, *Ranunculus repens*, and *Chamomilla suaveolens*. The bromoxynil + clopyralid treatment caused distortion of the crop and, with bentazon, gave inadequate weed control. Effects on crop yield were not statistically significant.

L5 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:80241 HCAPLUS

DOCUMENT NUMBER: 106:80241

TITLE: A comparison of herbicide regimes for weed control in fiber flax

AUTHOR(S): Courtney, A. D.

CORPORATE SOURCE: Agric. Bot. Res. Div., Dep. Agric. North. Ireland, Belfast, BT9 5PX, UK

SOURCE: Tests of Agrochemicals and Cultivars (1986), 7, 88-9  
CODEN: TACUDC; ISSN: 0951-4309

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Preemergence treatments only gave consistent weed control in flax when used in sequence with Pardner (bromoxynil) or Vulcan (bromoxynil-

clopyralid mixture). Early postemergence application of Finesse (metsulfuron-chlorsulfuron mixture) [76363-65-0] also gave good control. Control of *Polygonum aviculare* was improved by the use in sequence of Pardner. At 960 g/ha, Chandor [8070-92-6] caused basal callus formation and fracture of some stems. At 20 g/ha, Finesse caused severe crop stunting. Both Pardner and Vulcan caused some temporary distortion in crop growth.

L5 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:124975 HCAPLUS

DOCUMENT NUMBER: 104:124975

TITLE: Pre-harvest retting of flax: uptake, translocation and efficacy of glyphosate applied to flax in a dry year

AUTHOR(S): Harvey, B. M. R.; Crothers, S. H.; Courtney, A. D.

CORPORATE SOURCE: Agric. Bot. Res. Div., Dep. Agric. North. Ireland, Belfast, BT9 5PX, UK

SOURCE: Record of Agricultural Research (1985), 33, 87-93  
CODEN: RARIAQ; ISSN: 0375-0698

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The uptake, translocation, and efficacy of glyphosate [1071-83-6] in promoting the preharvest retting of flax were studied in the abnormally dry summer of 1984. Cultivar Hera was sprayed with glyphosate (1.44 kg/ha) 12 days after the mid-point of flowering, when the soil moisture deficit (SMD) was 114 mm. <sup>14</sup>C-labeled glyphosate was applied to the upper leaves of the main stem immediately after spraying and the distribution of <sup>14</sup>C was determined at 20, 48 and 120 h after treatment. More than 90% had been taken ≤48 h after application, and by 120 h 86% of the applied glyphosate had been translocated out of the treated leaves. Most of the translocated glyphosate (66%) accumulated in the capsules. Cultivars Ariane, Natasja, and Regina were sprayed at 13, 12, and 15 days, resp., after the mid-point of flowering (SMD 117 mm). No varietal differences in uptake or translocation of <sup>14</sup>C-glyphosate were found. Rainfall reduced the SMD to 86 mm at the end of the second week after spraying and by the 4th week all varieties had desiccated to <18% moisture content. Thus, the slow desiccation of Hera was not due to poor uptake of glyphosate or to poor translocation out of the treated leaves. The absorbed glyphosate remained potentially active and caused desiccation when rainfall was sufficient to relieve plant moisture stress.

L5 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1983:84803 HCAPLUS

DOCUMENT NUMBER: 98:84803

TITLE: Preharvest retting of flax: a light microscope study of the effects of glyphosate treatment on the maturation of stem tissues

AUTHOR(S): Fraser, T. W.; Courtney, A. D.; Harvey, B. M. R.

CORPORATE SOURCE: Plant Pathol. Res. Div., Dep. Agric. Northern Ireland, Belfast, BT9 5PX, UK

SOURCE: Annals of Applied Biology (1982), 101(3), 533-7  
CODEN: AABIAV; ISSN: 0003-4746

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A range of glyphosate [1071-83-6] treatments was applied to flax at 3 stages of flowering. Spraying at a rate equivalent to 1.4 kg/ha at the start of flowering gave satisfactorily uniform premature desiccation and was selected for a light-microscopic investigation of the effects of the

herbicide on stem tissues. During normal maturation, increase in fiber cell wall thickness, lignification of the fibers, and differentiation of the secondary xylem continued for 3-5 wk after the beginning of flowering. This differentiation was halted by the application of glyphosate. Three wk after treatment various types of tissue damage were observed. In some sections epidermal and cortical cells showed the most damage, this being consistent with herbicide uptake at the stem surface. In other sections phloem and associated parenchyma cells showed the most damage. Disintegration of phloem and cortical cells occurred in some treated stem segments and caused separation of the fiber bundles from surrounding tissues. This resembled the release of fiber bundles which results from conventional postharvest retting. The potential of glyphosate application to flax as a preharvest retting technique is discussed.

L5 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1982:594511 HCAPLUS

DOCUMENT NUMBER: 97:194511

TITLE: An evaluation of the selective herbicidal activity of soil sterilants based on methyl isothiocyanate

AUTHOR(S): Wilson, Ruth E.; Courtney, A. D.

CORPORATE SOURCE: Dep. Agric. Bot., Queen's Univ. Belfast, Belfast, BT9 5PX, UK

SOURCE: Theory Pract. Use Soil Appl. Herbic., Symp. (1981), 291-8. Eur. Weed Res. Soc.: Paris, Fr.

CODEN: 48SBAX

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Soil samples were stored at 278 K for 4 wk to induce cold stratification of weed seed, treated with Dazomet (I) [533-74-4] at 10, 20, or 40 g/m<sup>2</sup>, and placed on seed trays. I decreased seedling emergence to 63, 41, and 23% of controls resp. Emergence in nonstratified samples was decreased to 53, 76, and 14% of controls, resp. which shows that 20 g I/m<sup>2</sup> stimulated germination of non-stratified weed seed. In seed soaking treatments, using metham-sodium [137-42-8], a wide variation in species tolerance was observed. Broad-leaved dock (*Rumex obtusifolius*) was very tolerant, while barley (*Hordeum vulgare*), perennial ryegrass (*Lolium perenne*), wild oat (*Avena fatua*), and rough-stalked meadow grass (*Poa trivialis*) were very susceptible. Sublethal concns. of metham-Na stimulated germination, especially in *Lepidium sativum*. Thus, both methyl isothiocyanate [556-61-6] generators affected germination in analogous ways, consisting of concomitant inhibition and stimulation which may involve breakdown products.

L5 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1981:582194 HCAPLUS

DOCUMENT NUMBER: 95:182194

TITLE: Evaluation of DPX 4189 for selective weed control in grassland

AUTHOR(S): McAteer, S.; Courtney, A. D.

CORPORATE SOURCE: Dep. Agric. Bot., Queen's Univ., Belfast, UK

SOURCE: Tests of Agrochemicals and Cultivars (1981), 2, 48-9  
CODEN: TACUDC; ISSN: 0951-4309

DOCUMENT TYPE: Journal

LANGUAGE: English

AB DPX 4189 [64902-72-3] (20 or 40 g/ha) decreased the dry matter yield of *Lolium perenne*, *L. multiflorum*, *Festuca pratensis*, and *F. prandinacea*. *Dactylis glomerata* was only moderately sensitive to DPX 4189.

L5 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1981:436995 HCAPLUS

DOCUMENT NUMBER: 95:36995  
 TITLE: The effect of herbicides on the dry matter yield and regrowth elongation of an established Lolium perenne (ryegrass) sward  
 AUTHOR(S): Courtney, A. D.; Johnson, R. M.  
 CORPORATE SOURCE: Field Bot. Res. Div., Dep. Agric. North. Ireland, Belfast, BT9 5PX, UK  
 SOURCE: Proceedings - British Crop Protection Conference--Weeds (1980), 15(2), 589-94  
 CODEN: PBCWDF; ISSN: 0144-1604  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB When applied at recommended rates, the herbicides asulam [3337-71-1], mecoprop [7085-19-0] and dicamba [1918-00-9] with mecoprop produced no significant effects on annual dry matter (d.m.) yields of perennial ryegrass; even in seasons when the swards were subject to considerable drought stress, severe depressions of yield occurred at some individual harvests. The effects of the herbicide treatments were reflected in a prolonged reduction in regrowth elongation which appeared to be most pronounced for mecoprop and dicamba with mecoprop, and was still apparent in some instance 12 wks after spraying. This effect on elongation appeared to involve an interaction with drought stress and the incidence of rainfall.


L5 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:479533 HCAPLUS  
 DOCUMENT NUMBER: 87:79533  
 TITLE: An extended season of herbicides application for the control of Senecio jacobaea  
 AUTHOR(S): Courtney, A. D.; Johnston, R.  
 CORPORATE SOURCE: Field Bot. Res. Div., Dep. Agric., Belfast, UK  
 SOURCE: Proceedings of the British Weed Control Conference (1976), 13, Vol. 2, 611-18  
 CODEN: BWCPAI; ISSN: 0571-6144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Ragwort (S. jacobaea) was controlled in 2 pastures by a variety of herbicides, such as 2,4-D amine [2008-39-1], dicamba-mecoprop mixture [58051-22-2], DMM dicamba-mecoprop-MCPA mixture [39283-71-1] etc. Timing of the application was crucial. June application gave poor result.

L5 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1976:415161 HCAPLUS  
 DOCUMENT NUMBER: 85:15161  
 TITLE: Time of herbicide application for the control of docks (Rumex obtusifolius) in a grassland conservation system  
 AUTHOR(S): Courtney, A. D.; Johnston, R. T.  
 CORPORATE SOURCE: Dep. Agric. Northern Ireland, Belfast, UK  
 SOURCE: Proceedings of the British Weed Control Conference (1974), 12, Vol. 2, 751-60  
 CODEN: BWCPAI; ISSN: 0571-6144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB The herbicides asulam (I) [3337-71-1], mecoprop [7085-19-0], and dicamba-mecoprop mixture [58051-22-2] for dock control and grass yield were most effective when applied 7-14 day intervals in July-August. Among the 3 agents tested, mecoprop had the highest yield of grass, although it was inferior in dock control.

L5 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1971:508864 HCAPLUS

DOCUMENT NUMBER: 75:108864

TITLE: Control of Rumex species in northern Ireland and the influence of herbicidal treatment on herbage yield and composition

AUTHOR(S): Courtney, A. D.

CORPORATE SOURCE: Minist. Agric. North. Ireland, UK

SOURCE: Proc. Brit. Weed Contr. Conf., 10th (1971), Meeting Date 1970, Volume 2, 488-94. Brit. Crop Prot. Counc.: London, Engl.  
CODEN: 23NHA3

DOCUMENT TYPE: Conference

LANGUAGE: English

AB At 4 sites in N. Ireland a range of herbicide treatments was applied to control mature Rumex species in grassland. Counts of dock shoot nos. indicated that a dicamba-mecoprop mixture (1.5 lb total acid equiv (a.e.)/acre) gave the greatest degree of persistent control. Also good were mecoprop (3.2 lb a.e./ac), dichlorprop (3.2 lb a.e. acre) and asulam/mecoprop mixture (1 lb a.e. + 0.8 lb a.e. acre). Where the docks were making a considerable contribution to the dry matter yield, sample cuts of the herbage from these areas indicated that the grass content of the cuts increased when the docks were controlled but did not immediately compensate for the production of the docks.

L5 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1971:462439 HCAPLUS

DOCUMENT NUMBER: 75:62439

TITLE: Herbicides for weed control in flax

AUTHOR(S): Courtney, A. D.

CORPORATE SOURCE: Minist. Agric. North. Ireland, UK

SOURCE: Proc. Brit. Weed Contr. Conf., 10th (1971), Meeting Date 1970, Volume 2, 537-44. Brit. Crop Prot. Counc.: London, Engl.  
CODEN: 23NHA3

DOCUMENT TYPE: Conference

LANGUAGE: English

AB In trials of pre-and postemergence herbicides for weed control in flax, the preemergence treatments have in general proved more effective. The evidence to date suggests that the wettable powder 50% weight/weight formulation of linuron at 0.75 lb/acre, or 1.0 lb/acre on heavier soils, is safe and except in dry seasons gives satisfactory control of most species including redshank (Polygonum persicaria). Lenacil (80% weight/weight wettable powder) at 0.8 lb/acre did not give noticeably superior weed control to linuron at 0.75 lb/acre, however, the mixture of linuron + lenacil (0.5 + 0.4 lb/acre) gave generally comparable control to linuron at 0.75 lb/acre and may have an advantage with respect to crop safety as

evidenced by the one trial in 1970.

=> => d stat que l7 1-64  
'1-64' IS NOT VALID HERE

=> d stat que

```
L1      161 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("COLE PHIL"/AU OR "COLE
        PHILIP"/AU OR "COLE PHILIP A"/AU OR "COLE PHILIP ARTHUR"/AU)
        OR COLE P/AU OR COLE P A/AU
L2      57 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("PARANG K"/AU OR "PARANG
        KAYKAVOOS"/AU OR "PARANG KEYKAVOVS"/AU)
L3      8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ABLOOGLU ARARAT J"/AU OR
        "ABLOOGLU ARARAT JAN"/AU OR "ABLOOGU ARARAT"/AU) NOT L2
L4      45 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("KOHANSKI R"/AU OR "KOHANSKI
        R A"/AU OR "KOHANSKI RON"/AU OR "KOHANSKI RON A"/AU OR
        "KOHANSKI RONALD"/AU OR "KOHANSKI RONALD A"/AU) NOT (L2 OR L3)
L5      22 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("COURTNEY A"/AU OR "COURTNEY
        A D"/AU OR ("COURTNEY ALIYA"/AU OR "COURTNEY ALIYA D"/AU)) NOT
        (L2 OR L3 OR L4)
L6      151 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT (L2 OR L3 OR L4 OR L5)
L7      64 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6 AND (BISUB? OR INHIBITOR
        OR KINASE)
```

=> d ibib abs l7 1-64

```
L7      ANSWER 1 OF 64  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:      2005:973022  HCAPLUS
TITLE:                  p300/CBP-associated Factor Drives DEK into
                        Interchromatin Granule Clusters
AUTHOR(S):              Cleary, Joanne; Sitwala, Kajal V.; Khodadoust, Michael
                        S.; Kwok, Roland P. S.; Mor-Vaknin, Nirit; Cebrat,
                        Marek; Cole, Philip A.; Markovitz, David M.
CORPORATE SOURCE:      Department of Internal Medicine, Division of
                        Infectious Diseases, University of Michigan, Ann
                        Arbor, MI, 48109-0640, USA
SOURCE:                 Journal of Biological Chemistry (2005), 280(36),
                        31760-31767
                        CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER:              American Society for Biochemistry and Molecular
                        Biology
DOCUMENT TYPE:          Journal
LANGUAGE:               English
```

AB DEK is a mammalian protein that has been implicated in the pathogenesis of autoimmune diseases and cancer, including acute myeloid leukemia, melanoma, glioblastoma, hepatocellular carcinoma, and bladder cancer. In addition, DEK appears to participate in multiple cellular processes, including transcriptional repression, mRNA processing, and chromatin remodeling. Sub-nuclear distribution of this protein, with the attendant functional ramifications, has remained a controversial topic. Here we report that DEK undergoes acetylation in vivo at lysine residues within the first 70 N-terminal amino acids. Acetylation of DEK decreases its affinity for DNA elements within the promoter, which is consistent with the involvement of DEK in transcriptional repression. Furthermore, deacetylase inhibition results in accumulation of DEK within interchromatin granule clusters (IGCs), sub-nuclear structures that contain RNA processing factors. Overexpression of P/CAF acetylase drives DEK into IGCs, and addition of a newly developed, synthetic, cell-permeable

P/CAF **inhibitor** blocks this movement. To our knowledge, this is the first reported example of acetylation playing a direct role in relocation of a protein to IGCs, and this may explain how DEK can function in multiple pathways that take place in distinct sub-nuclear compartments. These findings also suggest that DEK-associated malignancies and autoimmune diseases might be amenable to treatment with agents that alter acetylation.

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:736697 HCAPLUS

TITLE: Probing conformational changes of the PCAF/GCN5 histone acetyltransferase

AUTHOR(S): Zheng, Yujun; Mamdani, Fatemah; Toptygin, Dimitri; Brand, Ludwig; Stivers, James T.; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, 21205, USA

SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), BIOL-198. American Chemical Society: Washington, D. C.

CODEN: 69HFCL

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)

LANGUAGE: English

AB PCAF and GCN5 are histone acetyltransferase (HAT) paralogs which play roles in the remodeling of chromatin in health and disease. Previously, a conformationally-flexible loop in the catalytic domain had been observed in the X-ray structures of GCN5 in different liganded states. Here, the conformation and dynamics of this PCAF/GCN5 alpha5-beta6 loop was investigated in solution using tryptophan fluorescence. A mutant PCAF HAT domain (PCAFWloop) was created in which the natural tryptophan (Trp514) remote from the alpha5-beta6 loop was replaced with tyrosine and a glutamate within the loop (Glu641) was substituted with tryptophan. This PCAFWloop protein showed catalytic parameters within 3-fold of those of the wild-type PCAF catalytic domain suggesting that the loop mutation was not deleterious for HAT activity. While saturating CoASH induced a 30% quenching of Trp fluorescence in PCAFWloop, binding of the high affinity **bisubstrate** analog H3-CoA-20 led to a 2-fold fluorescence increase. These different effects correlate with the different alpha5-beta6 loop conformations seen previously in X-ray structures. Based on stopped-flow fluorescence studies, H3-CoA-20 binding to PCAFWloop proceeds via a rapid association step followed by a slower conformational change involving loop movement. Fluorescence lifetime measurements support a model in which the alpha5-beta6 loop in the H3-CoA-20/PCAF complex exists in a narrower ensemble of conformations compared to the free enzyme. The relevance of loop dynamics to PCAF/GCN5 catalysis and substrate specificity is discussed.

L7 ANSWER 3 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:626824 HCAPLUS

DOCUMENT NUMBER: 143:224887

TITLE: Fluorescence Analysis of a Dynamic Loop in the PCAF/GCN5 Histone Acetyltransferase

AUTHOR(S): Zheng, Yujun; Mamdani, Fatemah; Toptygin, Dimitri; Brand, Ludwig; Stivers, James T.; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine,



SOURCE: Baltimore, MD, 21205, USA  
Biochemistry (2005), 44(31), 10501-10509  
CODEN: BICHAW; ISSN: 0006-2960  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB PCAF and GCN5 are histone acetyltransferase (HAT) paralogs which play roles in the remodeling of chromatin in health and disease. Previously, a conformationally flexible loop in the catalytic domain had been observed in the X-ray structures of GCN5 in different liganded states. Here, the conformation and dynamics of this PCAF/GCN5  $\alpha 5$ - $\beta 6$  loop was investigated in solution using tryptophan fluorescence. A mutant human PCAF HAT domain (PCAFWloop) was created in which the natural tryptophan (Trp-514) remote from the  $\alpha 5$ - $\beta 6$  loop was replaced with tyrosine and a glutamate within the loop (Glu-641) was substituted with tryptophan. This PCAFWloop protein exhibited catalytic parameters within 3-fold of those of the wild-type PCAF catalytic domain, suggesting that the loop mutation was not deleterious for HAT activity. While saturating CoASH induced a 30% quenching of Trp fluorescence in PCAFWloop, binding of the high-affinity bisubstrate analog H3-CoA-20 led to a 2-fold fluorescence increase. These different effects correlate with the different  $\alpha 5$ - $\beta 6$  loop conformations seen previously in X-ray structures. On the basis of stopped-flow fluorescence studies, binding of H3-CoA-20 to PCAFWloop proceeds via a rapid association step followed by a slower conformational change involving loop movement. Time-resolved fluorescence measurements support a model in which the  $\alpha 5$ - $\beta 6$  loop in the H3-CoA-20-PCAFWloop complex exists in a narrower ensemble of conformations compared to free PCAFWloop. The relevance of loop dynamics to PCAF/GCN5 catalysis and substrate specificity are discussed.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:793226 HCAPLUS  
DOCUMENT NUMBER: 142:329022  
TITLE: Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. [Erratum to document cited in CA140:385639]  
AUTHOR(S): Farrell, Christopher J.; Lee, Jae Myun; Shin, Eui-Cheol; Cebrat, Marek; Cole, Philip A.; Hayward, S. Diane  
CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA  
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2004), 101(37), 13694  
CODEN: PNASA6; ISSN: 0027-8424  
PUBLISHER: National Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB In Materials and Methods, two latent membrane protein 1 (LMP1) primers, two  $\beta$ -actin primers, and one LMP1 oligonucleotide probe are mislabeled. The correct primers were used in the expts., so the conclusions are not affected. The correct sequences are as follows: PCR primers: LMP1, 5'-ATGGAACGCGACCTTGAGAG-3' and 5'-CCAAGGTACAATGCCTGTCC-3'; and  $\beta$ -actin, 5'-CGTGGGGCGGCCAGGCACCA-3' and 5'-TTGGCCTTGGGGTTCAGGGGGG-3'; and oligonucleotide probe: LMP1, 5'-CCCCTCTCCTCTCCATAGG-3'.

L7 ANSWER 5 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:761209 HCAPLUS  
DOCUMENT NUMBER: 142:108224  
TITLE: Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation  
AUTHOR(S): Ott, Melanie; Dorr, Alexander; Hetzer-Egger, Claudia; Kaehele, Katrin; Schnolzer, Martina; Henklein, Peter; **Cole, Phil**; Zhou, Ming-Ming; Verdin, Eric  
CORPORATE SOURCE: Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, 94103, USA  
SOURCE: Novartis Foundation Symposium (2004), 259(Reversible Protein Acetylation), 182-196  
CODEN: NFSYF7; ISSN: 1528-2511  
PUBLISHER: John Wiley & Sons Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The HIV transcriptional activator Tat enhances the processivity of RNA polymerase II by recruiting the CyclinT1/CDK9 complex to the TAR RNA element. In addition, Tat synergizes with the histone acetyltransferase p300 and is acetylated by p300 at a single lysine residue (K50) in the TAR RNA binding domain. We have recently reported that this post-translational modification is necessary for the interaction and transcriptional synergy of Tat with the transcriptional coactivator PCAF. We have further studied the relevance of Tat acetylation during HIV transcription and generated antibodies specific for acetylated Tat (AcTat). Microinjection of anti-AcTat antibodies inhibited Tat-mediated transactivation in cells. Similarly, the specific p300 **inhibitor** Lys-CoA and short inhibitory RNAs specific for p300 suppressed Tat transcriptional activity. Full-length synthetic AcTat bound to TAR RNA and CyclinT1 with high affinity, but formation of the Tat-TAR-CyclinT1 ternary complex was inhibited when K50 was acetylated. Our data collectively show that Tat acetylation by p300 defines a critical step in Tat transactivation that serves to disrupt the Tat/TAR/CyclinT1 complex and helps in recruiting PCAF to the elongating RNA polymerase II.  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:420513 HCAPLUS  
DOCUMENT NUMBER: 141:133547  
TITLE: **Bisubstrate** analogue structure-activity relationships for p300 histone acetyltransferase **inhibitors**  
AUTHOR(S): Sagar, Vatsala; Zheng, Weiping; Thompson, Paul R.; **Cole, Philip A.**  
CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(12), 3383-3390  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:133547  
AB P300 and CBP are important histone acetyltransferases (HATs) that regulate gene expression and may be anti-cancer drug targets. Based on a previous lead compound, Lys-CoA, we have used solid phase synthesis to generate a series of 11 new analogs and evaluated these compds. as HAT **inhibitors**. Increased spacing between the CoA moiety and the

lysyl moiety generally decreases inhibitory potency. We have found two substituted derivs. that show about 4-fold increased potency compared to the parent compound Lys-CoA. These structure-activity studies allow for a greater understanding of the optimal requirements for potent inhibition of HAT enzymes and pave the way for a novel class of anti-cancer therapeutics.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:362593 HCAPLUS

DOCUMENT NUMBER: 141:119139

TITLE: Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A

AUTHOR(S): Hines, Aliya C.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2951-2954

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:119139

AB An ATP-peptide conjugate was synthesized as a bisubstrate analog inhibitor of the serine/threonine kinase protein kinase A. The compound was found to be a linear, competitive inhibitor with respect to ATP substrate, exhibiting a  $K_i$  of 3.8  $\mu$ M. The compound was noncompetitive with respect to peptide substrate. The inhibitor was shown to be selective for protein kinase A vs. the closely related protein kinase C as well as tyrosine kinase Csk. This anal. provides new evidence for the dissociative transition state of protein serine/threonine kinases and illustrates a simple method to convert a low affinity peptide substrate to a selective and moderately potent inhibitor for these enzymes.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:316124 HCAPLUS

DOCUMENT NUMBER: 140:385639

TITLE: Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide

AUTHOR(S): Farrell, Christopher J.; Lee, Jae Myun; Shin, Eui-Cheol; Cebrat, Marek; Cole, Philip A.; Hayward, S. Diane

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2004), 101(13), 4625-4630

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with cancers in immunocompromised populations. Antiviral drugs targeted

against lytic viral replication have limited efficacy in these disease settings. EBV infection of peripheral blood mononuclear cells induces growth proliferation and the EBV latency Epstein-Barr virus-encoded nuclear antigen (EBNA)2 transcriptional transactivator (TAT) is essential for this response. EBNA2 targets the cellular DNA-binding protein CBF1 to mimic activated Notch signaling. A 10-aa peptide from the CBF1 interaction domain of EBNA2 was synthesized as a fusion with the protein transduction domain of HIV-1 TAT. The EBNA2-TAT peptide blocked EBNA2-CBF1 interaction in an in vitro GST affinity assay and labeling with fluorescein confirmed that the EBNA2-TAT peptide efficiently entered cultured B cells. Neither EBNA2-TAT, nor a mutant peptide with a 2-aa substitution that was unable to block the EBNA2-CBF1 interaction, significantly affected the growth of non-EBNA2-expressing EBV(-) B cells or Burkitt's lymphoma Akata cells. However, treatment of an EBV-immortalized lymphoblastoid cell line with the EBNA2-TAT peptide stopped cell growth and reduced cell viability. RT-PCR analyses of gene expression in the peptide-treated lymphoblastoid cell line cultures revealed that EBNA2-TAT treatment down-regulated the EBNA2-responsive viral LMP1 and LMP2 genes and cellular CD23, intercellular adhesion mol. 1, BATF, and Cdk1 genes while up-regulating expression of the cyclin-dependent kinase inhibitor p21. EBV-induced outgrowth of B cells from cultured peripheral blood mononuclear cells was also blocked in a dose-responsive manner by the EBNA2-TAT peptide. This study suggests that cell-permeable EBNA2 peptides may have potential as novel anti-EBV therapeutics.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:301649 HCAPLUS

DOCUMENT NUMBER: 141:309475

TITLE: Selective HAT **inhibitors** as mechanistic tools for protein acetylation

AUTHOR(S): Zheng, Yujun; Thompson, Paul R.; Cebrat, Marek; Wang, Ling; Devlin, Meghann K.; Alani, Rhoda M.; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21218, USA

SOURCE: Methods in Enzymology (2004), 376(Chromatin and Chromatin Remodeling Enzymes, Part B), 188-199  
CODEN: MENZAU; ISSN: 0076-6879

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histone acetyltransferases (HATs) regulate gene expression by the targeted acetylation of histones and other proteins. The use of selective HAT **inhibitors** was introduced as mechanistic tools to probe the catalytic features of HATs and their roles in various cellular pathways. The design, synthesis, and applications of these **inhibitors** in different biol. contexts are described. It is hoped that HAT **inhibitors** might ultimately serve useful clin. role in the treatment of cancer and other diseases.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:254163 HCAPLUS

DOCUMENT NUMBER: 140:387787

TITLE: Regulation of the p300 HAT domain via a novel

activation loop

AUTHOR(S): Thompson, Paul R.; Wang, Dongxia; Wang, Ling; Fulco, Marcella; Pediconi, Natalia; Zhang, Dianzheng; An, Woojin; Ge, Qingyuan; Roeder, Robert G.; Wong, Jiemin; Levrero, Massimo; Sartorelli, Vittorio; Cotter, Robert J.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Nature Structural & Molecular Biology (2004), 11(4), 308-315

CODEN: NSMBCU; ISSN: 1545-9993

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The transcriptional coactivator p300 is a histone acetyltransferase (HAT) whose function is critical for regulating gene expression in mammalian cells. However, the mol. events that regulate p300 HAT activity are poorly understood. We evaluated autoacetylation of the p300 HAT protein domain to determine its function. Using expressed protein ligation, the p300 HAT protein domain was generated in hypoacetylated form and found to have reduced catalytic activity. This basal catalytic rate was stimulated by autoacetylation of several key lysine sites within an apparent activation loop motif. This post-translational modification and catalytic regulation of p300 HAT activity is conceptually analogous to the activation of most protein **kinases** by autophosphorylation. We therefore propose that this autoregulatory loop could influence the impact of p300 on a wide variety of signaling and transcriptional events.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:958238 HCAPLUS

DOCUMENT NUMBER: 140:89809

TITLE: Conversion of a Tyrosine **Kinase** Protein Substrate to a High Affinity Ligand by ATP Linkage

AUTHOR(S): Shen, Kui; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of the American Chemical Society (2003), 125(52), 16172-16173

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:89809

AB Protein **kinases** often show low affinity for their protein substrates, which makes it difficult to study **kinase**-substrate interactions. Here, the authors show using expressed protein ligation with the signaling protein Src that it is feasible to install a covalently linked ATP moiety into the tail of Src, generating a semisynthetic protein with a high affinity for its cognate tyrosine **kinase**, Csk. It is also established that this Src-ATP conjugate can be used to selectively pull down Csk from a complex protein mixture. This work outlines a general strategy for identifying an unknown **kinase** that is responsible for the phosphorylation of a protein substrate on a site of interest.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:829216 HCAPLUS

DOCUMENT NUMBER: 140:195198

TITLE: Protein tyrosine **kinases** Src and Csk: a tail's taleAUTHOR(S): **Cole, Philip A.**; Shen, Kui; Qiao, Yingfeng; Wang, Dongxia

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Current Opinion in Chemical Biology (2003), 7(5), 580-585

CODEN: COCBF4; ISSN: 1367-5931

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review and discussion. Csk and Src are 2 protein tyrosine **kinases** with similar amino acid sequences but very different structures and functions. Csk catalyzes a tail phosphorylation reaction on Src and thereby restrains Src's activity and oncogenic potential. Comparative anal. of the domain interactions in these enzymes provides a lesson in signaling diversity and mechanisms of enzyme regulation. The mol. basis of the specificity of Csk targeting the Src tail appears to involve both local and long-range interactions and illustrates the complexity of selective targeting in post-translational modification.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:673327 HCAPLUS

DOCUMENT NUMBER: 139:334684

TITLE: Novel **bisubstrate** analog **inhibitors** of serotonin N-acetyltransferase: the importance of being neutralAUTHOR(S): Zheng, Weiping; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Bioorganic Chemistry (2003), 31(5), 398-411

CODEN: BOCMBM; ISSN: 0045-2068

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:334684

AB Linker modified novel **bisubstrate** analog **inhibitors** for serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) have been designed and synthesized. Examination of these **inhibitors** with AANAT in vitro suggested the following points: (i) linker hydrogen bonding makes only modest contributions to the affinity of **bisubstrate** analog **inhibitors** studied; (ii) greater than or equal to four methylene groups between the indole and the CoA (CoASH) moieties are required for a **bisubstrate** analog **inhibitor** to achieve strong AANAT inhibition; (iii) the AANAT active site appears not to accommodate pos. charged linkers as well as neutral ones; and (iv) substrate amine pKa depression may constitute one strategy for AANAT substrate recognition and catalysis. The results reported here have enhanced our understanding of AANAT substrate recognition/catalysis, and are important for novel **inhibitor** design. Since AANAT belongs to the GCN5-related N-acetyltransferase (GNAT) superfamily, our exptl. strategies should find applications for other acetyltransferases.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:631384 HCAPLUS  
 TITLE: Chemical approaches to sorting out protein phosphorylation  
 AUTHOR(S): Cole, Philip A.  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, 21205, USA  
 SOURCE: Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), COMP-224. American Chemical Society: Washington, D. C.

CODEN: 69EKY9  
 DOCUMENT TYPE: Conference; Meeting Abstract  
 LANGUAGE: English

AB Reversible protein phosphorylation represents a major mechanism for cell signal transduction. We will summarize a few recent technologies developed and applied in our lab to understand the function of protein **kinases** in various contexts. In particular, we will discuss the design and application of **bisubstrate** analogs as protein **kinase inhibitors**, the chemical rescue of mutant tyrosine **kinases**, and the use of expressed protein ligation in protein phosphorylation anal.

L7 ANSWER 15 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:624989 HCAPLUS  
 DOCUMENT NUMBER: 139:257962  
 TITLE: Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation  
 AUTHOR(S): Kaehicke, Katrin; Dorr, Alexander; Hetzer-Egger, Claudia; Kiermer, Veronique; Henklein, Peter; Schnoelzer, Martina; Loret, Erwann; Cole, Philip A.; Verdin, Eric; Ott, Melanie  
 CORPORATE SOURCE: Deutsches Krebsforschungszentrum, Heidelberg, D-69120, Germany  
 SOURCE: Molecular Cell (2003), 12(1), 167-176  
 CODEN: MOCEFL; ISSN: 1097-2765  
 PUBLISHER: Cell Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The HIV transcriptional activator Tat is acetylated by p300 at a single lysine residue in the TAR RNA binding domain. We have generated monoclonal and polyclonal antibodies specific for the acetylated form of Tat (AcTat). Microinjection of anti-AcTat antibodies inhibited Tat-mediated transactivation in cells. Similarly, the p300 **inhibitor** Lys-CoA and siRNA specific for p300 suppressed Tat transcriptional activity. Full-length synthetic AcTat bound to TAR RNA with the same affinity as unacetylated Tat, but formation of a Tat-TAR-CyclinT1 ternary complex was completely inhibited in the presence of AcTat. We propose that Tat acetylation may help in dissociating the Tat cofactor CyclinT1 from TAR RNA and serve to transfer Tat onto the elongating RNA polymerase II.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:500681 HCAPLUS  
 DOCUMENT NUMBER: 140:52742

TITLE: Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300

AUTHOR(S): Cebrat, Marek; Kim, Cheol M.; Thompson, Paul R.; Daugherty, Matthew; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA

SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(15), 3307-3313  
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Lys-CoA (1) is a selective **inhibitor** of p300 histone acetyltransferase (HAT) but shows poor pharmacokinetic properties because of its multiply charged phosphates. In an effort to overcome this limitation, truncated derivs. of 1 were designed, synthesized and tested as p300HAT **inhibitors** as well as substrates for the CoA biosynthetic bifunctional enzyme phosphopantetheine adenylyltransferase-dephospho-CoA **kinase** (PPAT/DPCK). Lys-pantetheine (3) and Lys-phosphopantetheine (2) showed no detectable p300HAT inhibition whereas 3'-dephospho-Lys-CoA (5) was a modest p300 **inhibitor** with IC50 of 1.6  $\mu$ M (compared to IC50 of .apprx.50 nM for 1 blocking p300). Compound 2 was shown to be an efficient substrate for PPAT whereas 5 was a very poor DPCK substrate. Further anal. with 3'-dephospho-Me-SCoA (7) indicated that DPCK shows relatively narrow capacity to accept substrates with sulfur substitution. While these results suggest that truncated derivs. of 1 will be of limited value as lead agents for p300 blockade in vivo, they augur well for prodrug versions of CoA analogs that do not require 3'-phosphate substitution for efficient binding to their targets, such as the GCN-5 related N-acetyltransferases.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:106602 HCAPLUS

DOCUMENT NUMBER: 139:65326

TITLE: The Role of C-terminal Tyrosine Phosphorylation in the Regulation of SHP-1 Explored via Expressed Protein Ligation

AUTHOR(S): Zhang, Zhongsen; Shen, Kui; Lu, Wei; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (2003), 278(7), 4668-4674  
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The protein tyrosine phosphatase SHP-1 plays a variety of roles in the "neg." regulation of cell signaling. The mol. basis for the regulation of SHP-1 is incompletely understood. Whereas SHP-1 has previously been shown to be phosphorylated on two tail tyrosine residues (Tyr536 and Tyr564) by several protein tyrosine **kinases**, the effects of these phosphorylation events have been difficult to address because of the intrinsic instability of the linkages within a protein tyrosine



phosphatase. Using expressed protein ligation, we have generated semisynthetic SHP-1 proteins containing phosphotyrosine mimetics at the Tyr536 and Tyr564 sites. Two phosphonate analogs were installed, phosphonomethylenephénylalanine (Pmp) and difluorophosphonomethylenephénylalanine (F2Pmp). Incorporation of Pmp at the 536 site led to 4-fold stimulation of the SHP-1 tyrosine phosphatase activity whereas incorporation at the 564 site led to no effect. Incorporation of F2Pmp at the 536 site led to 8-fold stimulation of the SHP-1 tyrosine phosphatase activity and 1.6-fold at the 564 site. A combination of size exclusion chromatog., phosphotyrosine peptide stimulation studies, and site-directed mutagenesis led to the structural model in which tyrosine phosphorylation at the 536 site engages the N-Src homol. 2 domain in an intramol. fashion relieving basal inhibition. In contrast, tyrosine phosphorylation at the 564 site has the potential to engage the C-Src homol. 2 domain intramolecularly, which can modestly and indirectly influence catalytic activity. The finding that phosphonate modification at each of the 536 and 564 sites can promote interaction with the Grb2 adaptor protein indicates that the intramol. interactions fostered by post-translational modifications of tyrosine are not energetically strong and susceptible to intermol. competition.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:859524 HCAPLUS

DOCUMENT NUMBER: 138:87174

TITLE: Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes  
AUTHOR(S): Bandyopadhyay, Debdutta; Okan, Nihal A.; Bales, Elise; Nascimento, Lucia; Cole, Philip A.; Medrano, Estela E.

CORPORATE SOURCE: Huffington Center on Aging and Department of Molecular and Cellular Biology and Dermatology, Baylor College of Medicine, Houston, TX, 77030, USA

SOURCE: Cancer Research (2002), 62(21), 6231-6239  
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The histone acetyltransferases p300 and cAMP-responsive element-binding protein-binding protein (CBP) are required for the execution of critical biol. functions such as proliferation, differentiation, and apoptosis. Both proteins are believed to regulate the activity of a large number of general and cell-specific transcription factors. Here we demonstrate a dramatic decrease in the total cellular levels of p300 and CBP with increasing population doublings of human normal melanocytes. We show that one consequence of p300 depletion is transcriptional down-regulation of the cyclin E gene, caused by deacetylation of histones at its promoter. The cyclin E promoter was activated by p300 and the histone deacetylase inhibitor trichostatin A. Conversely, the cyclin E promoter was repressed by wild-type Retinoblastoma tumor suppressor p105 protein (pRB) and by a dominant neg. p300 mutant (DN p300) that lacks histone acetyltransferase activity. We also provide evidence of the alternative recruitment of p300 and histone deacetylase 1 to the cyclin E promoter in proliferating and senescent melanocytes, resp. The biol. significance of these results was established by showing that block of p300 activity by overexpression of DN p300 or by Lys-CoA, a specific chemical inhibitor of p300, resulted in growth inhibition, down-regulation of cyclin E, and activation of the senescence-associated  $\beta$ -galactosidase marker in human melanocytes and melanoma cells. Together, these results

provide evidence for the essential role of p300 in the regulation of proliferation and senescence in cells from melanocytic origin.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:859143 HCAPLUS

DOCUMENT NUMBER: 138:200902

TITLE: Structure of the GCN5 histone acetyltransferase bound to a **bisubstrate inhibitor**

AUTHOR(S): Poux, Arienne N.; Cebrat, Marek; Kim, Cheol M.; **Cole, Philip A.**; Marmorstein, Ronen

CORPORATE SOURCE: The Wistar Institute, and Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(22), 14065-14070  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histone acetyltransferases (HATs) use acetyl CoA to acetylate target lysine residues within histones and other transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequence and substrate preference. Several HAT proteins have been implicated in human cancer. We have previously reported on the preparation of peptide-CoA conjugate **inhibitors** with distinct specificities for the p300/CBP [cAMP response element binding protein (CREB)-binding protein] or GCN5 HAT subfamilies. Here we report on the crystal structure of the GCN5 HAT bound to a peptide-CoA conjugate containing CoA covalently attached through an isopropionyl linker to Lys-14 of a 20-aa N-terminal fragment of histone H3. Surprisingly, the structure reveals that the H3 portion of the **inhibitor** is bound outside of the binding site for the histone substrate and that only five of the 20 aa residues of the **inhibitor** are ordered. Rearrangements within the C-terminal region of the GCN5 protein appear to mediate this peptide displacement. Mutational and enzymic data support the hypothesis that the observed structure corresponds to a late catalytic intermediate. The structure also provides a structural scaffold for the design of HAT-specific **inhibitors** that may have therapeutic applications for the treatment of HAT-mediated cancers.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:798434 HCAPLUS

DOCUMENT NUMBER: 138:102774

TITLE: Substrate Conformational Restriction and CD45-catalyzed Dephosphorylation of Tail Tyrosine-phosphorylated Src Protein

AUTHOR(S): Wang, Dongxia; Esselman, Walter J.; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (2002), 277(43), 40428-40433

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

DOCUMENT TYPE: Biology  
 LANGUAGE: Journal  
 English

AB Hydrolysis of the tail phosphotyrosine in Src family members is catalyzed by the protein-tyrosine phosphatase CD45, activating Src family-related signaling pathways. Using purified recombinant phospho-Src (P-Src) (amino acid residues 83-533) and purified recombinant CD45 catalytic (cytoplasmic) domain (amino acid residues 565-1268), we have analyzed the kinetic behavior of dephosphorylation. A time course of phosphatase activity showed the presence of a burst phase. By varying the concentration of P-Src, it was shown that the amplitude of this burst phase increased linearly with respect to P-Src concentration. Approx. 2% of P-Src was shown to

be

rapidly dephosphorylated followed by a slower linear phase. A P-Src protein substrate containing a functional point mutation in the Src homol. domain 2 (SH2) led to more rapid dephosphorylation catalyzed by CD45, and this reaction showed only a single linear kinetic phase. These results were interpreted in terms of a model in which P-Src exists in a relatively slow dynamic equilibrium between "closed" and "open" conformational forms. Combined mutations in the SH2 and SH3 domain or the addition of an SH3 domain ligand peptide enhanced the accessibility of P-Src to CD45 by biasing P-Src to a more open form. Consistent with this model, a phosphotyrosine peptide that behaved as an SH2 domain binding ligand showed .apprx.100-fold greater affinity for unphosphorylated Src vs. P-Src. Surprisingly, P-Src possessing combined SH3 and SH2 functional inactivating point mutations was dephosphorylated by CD45 more slowly compared with P-Src completely lacking SH3 and SH2 domains. Addnl. data suggest that the SH3 and SH2 domains can inhibit accessibility of the P-Src tail to CD45 by interactions other than direct phosphotyrosine binding by the SH2 domain. Taken together, these results suggest how activation of Src family member signaling pathways by CD45 may be influenced by the presence or absence of ligand interactions remote from the tail.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:794219 HCAPLUS

DOCUMENT NUMBER: 137:307009

TITLE: Chemical ligation of proteins via amide bond through transthioesterification/cleavage reaction for NMR and protein-chip applications

INVENTOR(S): Muir, Tom W.; Cole, Philip A.; Friedman, Jeffrey M.; Sondhi, Dolan; Severinov, Konstantine

PATENT ASSIGNEE(S): The Rockefeller University, USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont. of U.S. Ser. No. 191,890.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002151006	A1	20021017	US 2001-904117	20010712
US 6875594	B2	20050405		
PRIORITY APPLN. INFO.:			US 1997-65391P	P 19971113
			US 1998-93990P	P 19980724
			US 1998-191890	B1 19981113

AB The present invention relates to methods for chemical ligating two oligopeptides end to end with an amide bond, wherein at least one of the oligopeptides is a product of recombinant expression. The present invention further relates to segmental isotopic labeling of recombinant protein domains, and segmental expression of recombinant protein domains or subunits and subsequent ligation and uses thereof. The present invention also relates to use of these methods for producing protein-chip compns. and uses thereof. The present invention provides a method of cleaving a recombinantly expressed protein from an intein and ligating the protein to a peptide containing an N-terminal cysteine having an unoxidized sulfhydryl side chain which comprises contacting the protein with the peptide in a reaction solution comprising a conjugated thiophenol, thereby forming a C-terminal thioester of the recombinant protein which spontaneously rearranges intramolecularly to form an amide bond linking the protein to the peptide. Accordingly, this invention relates to a method of ligating a recombinantly expressed protein to an oligopeptide. Utilizing a particular reagent, i.e., a thiophenol, to cleave the recombinantly expressed protein from its manufacturing process, and in the presence of the oligopeptide to which it is to be ligated, the desired ligation reaction occurs without the necessity for conversion to the necessary  $\alpha$ -thioester prior to ligation with the oligopeptide. It is also a further object of the present invention to provide a method for NMR spectroscopy using proteins segmentally labeled by the provided method. Appending a phosphotyrosine tail to Csk, highly homologous to Src but lacks a C-terminal tyrosine-containing tail, resulted in a new conformation involving an intramol. interaction between the SH2 domain and the tail phosphotyrosine. This report also describes the development of procedures which for the first time allow two folded recombinant protein domains to be efficiently linked together by in vitro chemical ligation reactions. This strategy was used to prepare NMR quantities of the Abelson protein tyrosine **kinase** regulatory apparatus, Abl-SH(32), in which only one domain was uniformly labeled with  $^{15}\text{N}$ . The in vitro chemical ligation strategy called for the generation of a recombinant Abl-SH3 domain activated at its C-terminus as a  $\alpha$ -thioester, and a recombinant Abl-SH2 domain containing an N-terminal cysteine residue. These two folded protein domains, when combined under physiol. conditions,, chemoselectively reacted via the well established native chemical ligation reaction to form an amide linkage at the ligation junction.

L7 ANSWER 22 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:618077 HCAPLUS  
 TITLE: Histone acetyltransferases: From structure to function and synthetic **inhibitors**  
 AUTHOR(S): Marmorstein, Ronen; Clements, Adrienne; Poux, Adrienne; Yan, Yuan; Cebrat, Marek; Kim, Cheol M.; Lo, Wan-Sheng; Berger, Shelly; **Cole, Philip A.**  
 CORPORATE SOURCE: Structural Biology Program, The Wistar Institute, Philadelphia, PA, 19104-4268, USA  
 SOURCE: Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (2002), MEDI-225. American Chemical Society: Washington, D. C.  
 CODEN: 69CZPZ  
 DOCUMENT TYPE: Conference; Meeting Abstract  
 LANGUAGE: English

AB Histone acetyltransferases (HATs) acetylate specific lysine residues in histones to promote gene activation, and the deregulation of several HATs has been implicated in human cancer making them attractive therapeutic targets. We have determined structures of members of the Gcn5/PCAF and MYST subfamily of HATs and have characterized their function in vitro to probe

the mechanism of histone substrate binding specificity and catalysis. Our studies show that HATs contain a structurally conserved domain that mediates CoA-binding and catalysis, although we find that the mode of catalysis differs dramatically between the Gcn5/PCAF and MYST HATs. The two HAT subfamilies contain a similar structural scaffold for histone binding and sequence divergence within this scaffold appears to contribute to histone substrate specificity. The structure of Gcn5 bound to a **bisubstrate inhibitor** provides further insights into the mechanism of catalysis by these enzymes and provides a scaffold for the design of HAT-specific inhibitors.

L7 ANSWER 23 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:471979 HCAPLUS

DOCUMENT NUMBER: 137:195985

TITLE: Csk, a critical link of G protein signals to actin cytoskeletal reorganization

AUTHOR(S): Lowry, William E.; Huang, Jianyun; Ma, Yong-Chao; Ali, Shariq; Wang, Dongxia; Williams, Daniel M.; Okada, Masato; Cole, Philip A.; Huang, Xin-Yun

CORPORATE SOURCE: Department of Physiology, Weill Medical College, Cornell University, New York, NY, 10021, USA

SOURCE: Developmental Cell (2002), 2(6), 733-744

CODEN: DCEEBE; ISSN: 1534-5807

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heterotrimeric G proteins can signal to reorganize the actin cytoskeleton, but the mechanism is unclear. Here we report that, in tyrosine kinase Csk-deficient mouse embryonic fibroblast cells, G protein ( $G\beta\gamma$ ,  $G\alpha_{12}$ ,  $G\alpha_{13}$ , and  $G\alpha_q$ )-induced, and G protein-coupled receptor-induced, actin stress fiber formation was completely blocked. Reintroduction of Csk into Csk-deficient cells restored the G protein-induced actin stress fiber formation. Chemical rescue expts. with catalytic mutants of Csk demonstrated that the catalytic activity of Csk was required for this process. Furthermore, we uncovered that  $G\beta\gamma$  can both translocate Csk to the plasma membrane and directly increase Csk kinase activity. Our genetic and biochem. studies demonstrate that Csk plays a critical role in mediating G protein signals to actin cytoskeletal reorganization.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:435236 HCAPLUS

DOCUMENT NUMBER: 137:136733

TITLE: Serotonin N-acetyltransferase: Mechanism and inhibition

AUTHOR(S): Zheng, Weiping; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Current Medicinal Chemistry (2002), 9(12), 1187-1199

CODEN: CMCH7; ISSN: 0929-8673

PUBLISHER: Bentham Science Publishers

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 76 refs. Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase) (I) catalyzes the rate-limiting step in the biosynthesis of the circadian hormone, melatonin, from serotonin. Although melatonin was identified 40 yr ago, relatively little is known

about its (patho)physiol. roles, and a solid scientific foundation is still lacking for most therapeutic applications currently claimed for melatonin. The development of potent, specific, and cell-permeable **inhibitors** for I should constitute an important strategy to address these issues. These **inhibitors** are also potential therapeutics for various sleep/mood disorders. This review focuses on the efforts toward developing in vitro and in vivo I **inhibitors**, including basic mechanistic studies on I, which have played an important role in design.

REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:404517 HCAPLUS

DOCUMENT NUMBER: 137:151733

TITLE: Investigation of the roles of catalytic residues in serotonin N-acetyltransferase

AUTHOR(S): Scheibner, Kara A.; De Angelis, Jacqueline; Burley, Stephen K.; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (2002), 277(20), 18118-18126

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase (AANAT)) is a critical enzyme in the light-mediated regulation of melatonin production and

circadian rhythm. It is a member of the GNAT (GCN-5-related N-acetyltransferase) superfamily of enzymes, which catalyze a diverse array of biol. important acetyl transfer reactions from antibiotic resistance to chromatin remodeling. In this study, the authors probed the functional properties of two histidines (His 120 and His 122) and a tyrosine (Tyr 168) postulated to be important in the mechanism of AANAT based on prior x-ray structural and biochem. studies. Using a combination of steady-state kinetic measurements of microviscosity effects and pH dependence on the H122Q, H120Q, and H120Q/H122Q AANAT mutants, the authors show that His 122 (with an apparent pKa of 7.3) contributes .apprx.6-fold to the acetyltransferase chemical step as either a remote catalytic base or hydrogen bond donor. Furthermore, His 120 and His 122 appear to contribute redundantly to this function. By anal. of the Y168F AANAT mutant, it was demonstrated that Tyr 168 contributes .apprx.150-fold to the acetyltransferase chemical step and is responsible for the basic limb of the pH-rate profile with an apparent (subnormal) pKa of 8.5. Paradoxically, Y168F AANAT showed 10-fold enhanced apparent affinity for acetyl-CoA despite the loss of a hydrogen bond between the Tyr phenol and the CoA sulfur atom. The x-ray crystal structure of Y168F AANAT bound to a **bisubstrate** analog **inhibitor** showed no significant structural perturbation of the enzyme compared with the wild-type complex, but revealed the loss of dual **inhibitor** conformations present in the wild-type complex. Taken together with kinetic measurements, these crystallog. studies allow the authors to propose the relevant structural conformations related to the distinct alkyltransferase and acetyltransferase reactions catalyzed by AANAT. These findings have significant implications for understanding GNAT catalysis and the design of potent and selective **inhibitors**.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:335834 HCAPLUS

DOCUMENT NUMBER: 137:241811

TITLE: Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms

AUTHOR(S): Subbaramaiah, Kotha; Cole, Philip A.; Dannenberg, Andrew J.

CORPORATE SOURCE: Department of Medicine, New York Presbyterian Hospital-Cornell and Strang Cancer Prevention Center, New York, NY, 10021, USA

SOURCE: Cancer Research (2002), 62(9), 2522-2530  
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Treatment with retinoic acid (RA) or carnosol, two structurally unrelated compds. with anticancer properties, inhibited phorbol ester (PMA)-mediated induction of activator protein-1 (AP-1) activity and cyclooxygenase-2 (COX-2) expression in human mammary epithelial cells. The induction of COX-2 transcription by PMA was mediated by increased binding of AP-1 to the cAMP response element (CRE) of the COX-2 promoter. Inhibition of the histone acetyltransferase activity of CREB-binding protein (CBP)/p300 blocked the induction of COX-2 by PMA. Treatment with carnosol but not RA blocked increased binding of AP-1 to the COX-2 promoter. Because AP-1 binding was unaffected by RA, we investigated whether RA inhibited COX-2 transcription via effects on the coactivator CBP/p300. Treatment with RA stimulated an interaction between RA receptor- $\alpha$  and CBP/p300; a corresponding decrease in the interaction between CBP/p300 and c-Jun was observed. Importantly, overexpressing CBP/p300 or dominant-neg. RA receptor- $\alpha$  relieved the suppressive effect of RA on PMA-mediated stimulation of the COX-2 promoter. To elucidate the mechanism by which carnosol inhibited COX-2 transcription, its effects on protein kinase C (PKC) signaling were determined. Carnosol but not RA inhibited the activation of PKC, ERK1/2, p38, and c-Jun NH2-terminal kinase mitogen-activated protein kinase. Overexpressing c-Jun but not CBP/p300 reversed the suppressive effect of carnosol on PMA-mediated stimulation of COX-2 promoter activity. Thus, RA acted by a receptor-dependent mechanism to limit the amount of CBP/p300 that was available for AP-1-mediated induction of COX-2. By contrast, carnosol inhibited the induction of COX-2 by blocking PKC signaling and thereby the binding of AP-1 to the CRE of the COX-2 promoter. Taken together, these results show that small mols. can block the activation of COX-2 transcription by distinct mechanisms.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:326837 HCAPLUS

DOCUMENT NUMBER: 137:75166

TITLE: Proton Demand Inversion in a Mutant Protein Tyrosine Kinase Reaction

AUTHOR(S): Williams, Daniel M.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of the American Chemical Society (2002),

124(21), 5956-5957  
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB In contrast to previous studies that have shown that the neutral phenol serves as the nucleophile for WT Csk-promoted phosphorylation of a tyrosine-containing substrate, the phenolate ion acts as primary nucleophile for the D314N Csk-catalyzed reaction. Rate comparisons of D314N Csk-promoted phosphotransfer using a series of fluorotyrosine-containing peptide substrates reveal a near zero  $\beta_{\text{nuc}}$ , consistent with a dissociative mechanism of phosphotransfer. These combined results argue against a hydroxy nucleophile-to-phosphate proton transfer occurring prior to an associative transition state of phosphoryl transfer.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:271977 HCAPLUS  
DOCUMENT NUMBER: 136:310176  
TITLE: Preparation of peptide CoA conjugates as **inhibitors** of histone acetyltransferases (HATs)

INVENTOR(S): **Cole, Philip A.**; Soccio, Raymond E.; Lau, Ontario D.; Khalil, Ehab M.; Kundu, Tapas K.; Roeder, Robert G.

PATENT ASSIGNEE(S): The Rockefeller University, USA

SOURCE: U.S., 20 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6369030	B1	20020409	US 1999-451034	19991129

PRIORITY APPLN. INFO.: US 1999-451034 19991129

OTHER SOURCE(S): MARPAT 136:310176

AB The design, synthesis, and application of peptide CoA conjugates as selective HAT **inhibitors** for the transcription factors p300 and PCAF are described. Two **inhibitors** (Lys-CoA for p300, H3-CoA-20 for PCAF) were found to be potent ( $\text{IC}_{50}$  .apprx. 0.5  $\mu\text{M}$ ) and selective (.apprx. 200-fold) in blocking p300 and PCAF HAT activity. These **inhibitors** were used to show quant. that PCAF and p300 display additive but not synergistic HAT activity when present in mixts. Lys-CoA was used to directly demonstrate the importance of p300 HAT activity in enhancing chromatin template mediated transcription in vitro.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 29 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:207764 HCAPLUS  
DOCUMENT NUMBER: 137:17102

TITLE: X-ray Crystallographic Studies of Serotonin N-acetyltransferase Catalysis and Inhibition

AUTHOR(S): Wolf, Eva; De Angelis, Jacqueline; Khalil, Ehab M.; **Cole, Philip A.**; Burley, Stephen K.

CORPORATE SOURCE: Laboratories of Molecular Biophysics, The Rockefeller University, New York, NY, 10021, USA



SOURCE: Journal of Molecular Biology (2002), 317(2), 215-224  
CODEN: JMOBAK; ISSN: 0022-2836  
PUBLISHER: Elsevier Science  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The structure of serotonin N-acetyltransferase (also known as arylalkylamine N-acetyltransferase; AANAT) bound to a potent **bisubstrate** analog **inhibitor** has been determined at 2.0 Å resolution using a two-edge (Se, Br) multiwavelength anomalous diffraction (MAD) experiment. This acetyl-CoA dependent enzyme is a member of the GCN5-related family of N-acetyltransferases (GNATs), which share four conserved sequence motifs (A-D). In serotonin N-acetyltransferase, motif A adopts an  $\alpha/\beta$  conformation characteristic of the phylogenetically invariant cofactor binding site seen in all previously characterized GNATs. Motif B displays a significantly lower level of conservation among family members, giving rise to a novel  $\alpha/\beta$  structure for the serotonin binding slot. Utilization of a brominated CoA-S-acetyl-tryptamine-**bisubstrate** analog **inhibitor** and the MAD method permitted conclusive identification of two radically different conformations for the tryptamine moiety in the catalytic site (cis and trans). A second high-resolution x-ray structure of the enzyme bound to a **bisubstrate** analog **inhibitor**, with a longer tether between the acetyl-CoA and tryptamine moieties, demonstrates only the trans conformation. Given a previous proposal that AANAT can catalyze an alkyltransferase reaction in a conformationally altered active site relative to its acetyltransferase activity, it is possible that the two conformations of the **bisubstrate** analog observed crystallog. correspond to these alternative reaction pathways. Our findings may ultimately lead to the design of analogs with improved AANAT inhibitory properties for in vivo applications.  
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:902976 HCAPLUS  
DOCUMENT NUMBER: 136:181211  
TITLE: CBP/p300 and muscle differentiation: no HAT, no muscle  
AUTHOR(S): Polesskaya, A.; Naguibneva, I.; Fritsch, L.; Duquet, A.; Ait-Si-Ali, S.; Robin, P.; Vervisch, A.; Pritchard, L. L.; Cole, P.; Harel-Bellan, A.  
CORPORATE SOURCE: CNRS UPR 9079, Institut Andre Lwoff, Villejuif, 94800, Fr.  
SOURCE: EMBO Journal (2001), 20(23), 6816-6825  
CODEN: EMJODG; ISSN: 0261-4189  
PUBLISHER: Oxford University Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Terminal differentiation of muscle cells follows a precisely orchestrated program of transcriptional regulatory events at the promoters of both muscle-specific and ubiquitous genes. Two distinct families of transcriptional co-activators, GCN5/PCAF and CREB-binding protein (CBP)/p300, are crucial to this process. While both possess histone acetyl-transferase (HAT) activity, previous studies have failed to identify a requirement for CBP/p300 HAT function in myogenic differentiation. We have addressed this issue directly using a chemical **inhibitor** of CBP/p300 in addition to a neg. transdominant mutant. Our results clearly demonstrate that CBP/p300 HAT activity is critical for myogenic terminal differentiation. Furthermore, this requirement is restricted to a subset of events in the differentiation program: cell fusion and specific gene expression. These data help to define the

requirements for enzymic function of distinct coactivators at different stages of the muscle cell differentiation program.

REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:859343 HCAPLUS

DOCUMENT NUMBER: 136:98372

TITLE: Novel Mechanism of Regulation of the Non-receptor Protein Tyrosine **Kinase** Csk: Insights from NMR Mapping Studies and Site-directed Mutagenesis

AUTHOR(S): Shekhtman, Alexander; Ghose, Ranajeet; Wang, Dongxia; **Cole, Philip A.**; Cowburn, David

CORPORATE SOURCE: The Rockefeller University, New York, NY, 10021-6399, USA

SOURCE: Journal of Molecular Biology (2001), 314(1), 129-138  
CODEN: JMOBAK; ISSN: 0022-2836

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Csk (C-terminal Src **kinase**), a protein tyrosine **kinase**, consisting of the Src homol. 2 and 3 (SH2 and SH3) domains and a catalytic domain, phosphorylates the C-terminal tail of Src-family members, resulting in down-regulation of the Src family **kinase** activity. The Src family **kinases** share 37 % homol. with Csk but, unlike Src-family **kinases**, the catalytic domain of Csk alone is weakly active and can be stimulated in trans by interacting with the Csk-SH3 domain, suggesting a mode of intra-domain regulation different from that of Src family **kinases**. The structural determinants of this intermol. interaction were studied by NMR and site-directed mutagenesis techniques. Chemical shift perturbation of backbone nuclei (<sup>1</sup>H and <sup>15</sup>N) has been used to map the Csk catalytic domain binding site on the Csk-SH3. The exptl. determined interaction surface includes three structural elements: the N-terminal tail, a small part of the RT-loop, and the C-terminal SH3-SH2 linker. Site-directed mutagenesis revealed that mutations in the SH3-SH2 linker of the wild-type Csk decrease Csk **kinase** activity up to fivefold, whereas mutations in the RT-loop left Csk **kinase** activity largely unaffected. We conclude that the SH3-SH2 linker plays a major role in the activation of the Csk catalytic domain. (c) 2001 Academic Press.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:839353 HCAPLUS

DOCUMENT NUMBER: 136:336067

TITLE: Chromatin-dependent cooperativity between constitutive and inducible activation domains in CREB

AUTHOR(S): Asahara, Hiroshi; Santoso, Buyung; Guzman, Ernesto; Du, Keyong; **Cole, Philip A.**; Davidson, Irwin; Montminy, Marc

CORPORATE SOURCE: Peptide Biology Laboratories, Salk Institute for Biological Studies, La Jolla, CA, 92037-1002, USA

SOURCE: Molecular and Cellular Biology (2001), 21(23), 7892-7900

CODEN: MCEBD4; ISSN: 0270-7306

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The cAMP-responsive factor CREB induces target gene expression via

constitutive (Q2) and inducible (KID, for **kinase**-inducible domain) activation domains that function synergistically in response to cellular signals. KID stimulates transcription via a phospho (Ser133)-dependent interaction with the coactivator paralogs CREB binding protein and p300, whereas Q2 recruits the TFIID complex via a direct association with hTAFII 130. Here the authors investigate the mechanism underlying cooperativity between the Q2 domain and KID in CREB by in vitro transcription assay with naked DNA and chromatin templates containing the cAMP-responsive somatostatin promoter. The Q2 domain was highly active on a naked DNA template, and Ser133 phosphorylation had no addnl. effect on transcriptional initiation in crude exts. Q2 activity was repressed on a chromatin template, however, and this repression was relieved by the phospho (Ser133) KID-dependent recruitment of p300 histone acetyltransferase activity to the promoter. In chromatin immunopptn. assays of NIH 3T3 cells, cAMP-dependent recruitment of p300 to the somatostatin promoter stimulated acetylation of histone H4. Correspondingly, overexpression of hTAFII130 potentiated CREB activity in cells exposed to cAMP, but had no effect on reporter gene expression in unstimulated cells. The authors propose that cooperativity between the KID and Q2 domains proceeds via a chromatin-dependent mechanism in which recruitment of p300 facilitates subsequent interaction of CREB with TFIID.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:832382 HCAPLUS

DOCUMENT NUMBER: 136:114346

TITLE: Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling

AUTHOR(S): Lu, Wei; Gong, Delquin; Bar-Sagi, Dafna; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Molecular Cell (2001), 8(4), 759-769  
CODEN: MOCEFL; ISSN: 1097-2765

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The regulation of protein tyrosine phosphatase (PTPase) SHP-2 is proposed to involve tyrosine phosphorylation on two tail tyrosine residues. Using "expressed protein ligation", nonhydrolyzable phosphotyrosine analogs were introduced at known phosphorylation sites in SHP-2. Biochem. anal. suggests that a phosphonate at Tyr542 interacts intramolecularly with the N-terminal SH2 domain to relieve basal inhibition of the PTPase, whereas a phosphonate at Tyr-580 stimulates the PTPase activity by interaction with the C-terminal SH2 domain. Microinjection expts. indicate that a single phosphorylation of Tyr-542 of SHP-2 is sufficient to activate the MAP **kinase** pathway in living cells. These studies support a novel mechanism explaining how tyrosine phosphorylation of a PTPase is important in signal transduction.

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:678637 HCAPLUS

DOCUMENT NUMBER: 136:2189

TITLE: Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase

activity  
 AUTHOR(S): Thompson, Paul R.; Kurooka, Hisanori; Nakatani, Yoshihiro; **Cole, Philip A.**  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD, 21205, USA  
 SOURCE: Journal of Biological Chemistry (2001), 276(36), 33721-33729  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The p300/cAMP response element-binding protein-binding protein (CBP) family members include human p300 and cAMP response element-binding protein-binding protein, which are both important transcriptional coactivators and histone acetyltransferases. Although the role of these enzymes in transcriptional regulation has been extensively documented, the mol. mechanisms of p300 and CBP histone acetyltransferase catalysis are poorly understood. Herein, the authors describe the first detailed kinetic characterization of p300 using full-length purified recombinant enzyme. These studies have employed peptide substrates to systematically examine the substrate specificity requirements and the kinetic mechanism of this enzyme. The importance of nearby pos. charged residues in lysine targeting was demonstrated. The strict structural requirement of the lysine side chain was shown. The catalytic mechanism of p300 was shown to follow a ping-pong kinetic pathway and viscosity expts. revealed that product release and/or a conformational change were likely rate-limiting in catalysis. Detailed anal. of the p300 selective **inhibitor** Lys-CoA the results showed that it exhibited slow, tight-binding kinetics.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 35 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:637152 HCAPLUS  
 TITLE: Chemical approaches to tyrosine phosphorylation  
 AUTHOR(S): **Cole, Philip A.**  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, 21205, USA  
 SOURCE: Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001 (2001), BIOL-141. American Chemical Society: Washington, D. C.  
 CODEN: 69BUZP  
 DOCUMENT TYPE: Conference; Meeting Abstract  
 LANGUAGE: English

AB Protein tyrosine **kinases** catalyze the transfer of a phosphoryl group from ATP to the tyrosine side chains of proteins and play important roles in signal transduction. We will report on our progress to apply a variety of chemical synthesis and kinetic methods to elucidate the structure, function, and regulation of tyrosine **kinases** and the substrates that they phosphorylate. Relevance of our findings to cell signalling and/or drug design will be discussed.

L7 ANSWER 36 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:604186 HCAPLUS  
 DOCUMENT NUMBER: 135:315182  
 TITLE: Protein Tyrosine **Kinase** Csk-Catalyzed Phosphorylation of Src Containing Unnatural Tyrosine Analogues  
 AUTHOR(S): Wang, Dongxia; **Cole, Philip A.**

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences,  
Johns Hopkins University School of Medicine,  
Baltimore, MD, 21205, USA

SOURCE: Journal of the American Chemical Society (2001),  
123(37), 8883-8886

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Using expressed protein ligation, five unnatural tyrosine analogs (amino-phenylalanine, homotyrosine, 2-methyl-tyrosine, ( $\alpha$ S, $\beta$ R)- $\beta$ -methyl-tyrosine, and 2,6-difluoro-tyrosine) were incorporated into Src in place of the natural tail tyrosine residue. These semisynthetic substrates were evaluated as Csk substrates or allosteric activators. It appears that the tyrosine phenol hydroxyl is unlikely to be contributing significantly to Src's ground-state binding affinity for Csk. It has been observed that stabilizing tyrosine conformers can further optimize Src's already high substrate efficiency. These latter findings contrast similar studies with synthetic peptide substrates and highlight the value of investigation of protein **kinase** substrate selectivity with protein substrates.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:561080 HCAPLUS

DOCUMENT NUMBER: 135:192000

TITLE: Probing the mechanism of enzymatic phosphoryl transfer with a chemical trick

AUTHOR(S): Thompson, Paul R.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences,  
Johns Hopkins University, Baltimore, MD, 21205, USA

SOURCE: Proceedings of the National Academy of Sciences of the  
United States of America (2001), 98(15), 8170-8171  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 25 refs. and commentary on the research of Cho et al. (PNAS 2001, 98, 8525-8530). Nucleophilic substitutions at phosphorus comprise one of the most important classes of reactions in biol. Phosphate diester substitution reactions are catalyzed by nucleases and polymerases and are critical in DNA replication and transcription. Phosphate monoester (phosphoryl transfer) reactions are catalyzed by GTPases, ATPases, protein and small mol. **kinases**, and protein and small mol. phosphatases. These enzymes play diverse roles in energy regulation, cell signaling, ion and small mol. transport, and nucleotide synthesis. There have been intensive efforts to try to understand the details of phosphoryl transfer reactions extending from nonenzymic (or enzyme model) systems to the mechanisms of the enzymic reactions, as exemplified by the study by Cho et al. in the current issue of PNAS. Cho et al. have determined the crystal structure of phosphoserine phosphatase (PSP) bound to BeF<sub>3</sub><sup>-</sup>; and compared it to the structure of a related protein CheY, also bound to BeF<sub>3</sub><sup>-</sup>. The paper by Cho et al. underscores the utility of studying smaller, less complicated proteins as tools to gain insights into the mol. mechanisms of larger, structurally related proteins that may be multidomain, highly regulated or difficult to obtain in sufficient quantities for biochem. studies.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:457578 HCAPLUS

DOCUMENT NUMBER: 135:189742

TITLE: **Bisubstrate** Ketone Analogues as Serotonin  
N-Acetyltransferase **Inhibitors**AUTHOR(S): Kim, Cheol Min; **Cole, Philip A.**CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences,  
Johns Hopkins University School of Medicine,  
Baltimore, MD, 21205, USASOURCE: Journal of Medicinal Chemistry (2001), 44(15),  
2479-2485

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Serotonin N-acetyltransferase, also called the melatonin rhythm enzyme, is thought to play an important regulatory role in circadian rhythm in animals and people. A series of analogs were synthesized in which indole and CoA were linked via ketone tethers as designed **inhibitors** of this enzyme. These compds. were tested against purified serotonin N-acetyltransferase. The parent ketone compound was as potent as an amide linked compound studied previously, suggesting that there are no key hydrogen bonds to the nitrogen atom of the corresponding substrate necessary for tight inhibition. Reduction of the parent ketone afforded the diastereomeric carbinol mixture which showed reduced inhibitory potency, arguing against tetrahedral analog mimicry as an important inhibitory theme. Several conformationally constrained ketone analogs were synthesized and investigated, and the results indicated that directing the orientation of the two substrates within the **bisubstrate** system could be used to maximize enzyme inhibition.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 39 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:362203 HCAPLUS

DOCUMENT NUMBER: 135:73233

TITLE: Mechanistic studies on the alkyltransferase activity  
of serotonin N-acetyltransferaseAUTHOR(S): Zheng, Weiping; Scheibner, Kara A.; Ho, Anthony K.;  
**Cole, Philip A.**CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The  
Johns Hopkins University School of Medicine,  
Baltimore, MD, 21205, USA

SOURCE: Chemistry &amp; Biology (2001), 8(4), 379-389

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:73233

AB Background: Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) catalyzes the first, rate-limiting step in the biosynthesis of the circadian hormone melatonin (5-methoxy-N-acetyltryptamine) from serotonin. Our recent discovery that, in addition to catalyzing the acetyl transfer from acetyl-CoA (acetyl-CoASH) to serotonin, AANAT is also a robust catalyst for the alkyl transfer reaction between CoASH and N-bromoacetyltryptamine has not only opened up a new way to develop cell-permeable AANAT acetyltransferase **inhibitors** that are valuable in vivo tools in helping elucidate melatonin's (patho)physiol. roles, but has also raised a question - how does AANAT

accelerate the alkyl transfer reaction. In this study, mechanistic aspects of the AANAT-catalyzed alkyl transfer reaction were explored by employing CoASH and a series of N-haloacetyltryptamines that were also evaluated for their AANAT acetyltransferase inhibitory activities. Results: Investigation of various N-haloacetyltryptamine analogs showed a similar leaving group effect on the enzymic and non-enzymic reaction rates. Steady-state kinetic analyses demonstrated that AANAT alkyltransferase obeys a sequential, ternary complex mechanism, with random substrate binding. Rate vs. pH profiles revealed the catalytic importance of an ionizable group with pKa .apprx. 7. All those N-haloacetyltryptamines that serve as substrates of AANAT alkyltransferase are also potent (low micromolar) in vitro inhibitors against AANAT acetyltransferase activity. In particular, N-chloroacetyltryptamine was also shown to be a potent inhibitor of intracellular melatonin production in a pineal cell culture assay. Conclusions: This is the first detailed investigation of the alkyltransferase activity associated with an acetyltransferase. Our results indicate that AANAT does not accelerate the alkyl transfer reaction by simple approximation effect as previously proposed for the similar alkyl transfer reaction catalyzed by other acyltransferases. This study has general implications for developing novel inhibitors by taking advantage of the promiscuous alkyltransferase activity associated with several acyltransferases.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 40 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:334042 HCAPLUS

DOCUMENT NUMBER: 135:118539

TITLE: Kinase chips hit the proteomics era

AUTHOR(S): Williams, D. M.; Cole, P. A.

CORPORATE SOURCE: Dept of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Trends in Biochemical Sciences (2001), 26(5), 271-273

CODEN: TBSCDB; ISSN: 0376-5067

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB The title research of Zhu, H. et al (Nat. Genet. 26, pg. 283-289, 2000) is reviewed with commentary and 15 refs. Protein kinase chips, in which kinases are tested for their ability to phosphorylate immobilized substrates, have been developed and used to evaluate the protein kinases encoded by the yeast genome. This new technol. promises to be a valuable addition to the biochemists' and cell biologists' arsenal for evaluating the substrate selectivity and function of protein kinases in cell signaling.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 41 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:44827 HCAPLUS

DOCUMENT NUMBER: 134:233500

TITLE: Molecular Determinants for Csk-Catalyzed Tyrosine Phosphorylation of the Src Tail

AUTHOR(S): Wang, Dongxia; Huang, Xin-Yun; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Biochemistry (2001), 40(7), 2004-2010

CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Phosphorylation of a critical tail tyrosine residue in Src modulates its three-dimensional structure and protein tyrosine **kinase** activity. The protein tyrosine **kinase** Csk is responsible for catalyzing the phosphorylation of this key Src tyrosine residue, but the detailed mol. basis for Src recognition and catalysis is poorly understood. In this study, we investigate this phosphorylation event using purified recombinant Csk and Src proteins and mutants. It was shown that the apparent *k*<sub>cat</sub> and *K*<sub>m</sub> values for Csk phosphorylation of catalytically impaired Src (dSrc) are similar to the parameters for Csk-catalyzed phosphorylation of the Src family member Lck. The SH3 (Src homol. 3) and SH2 (Src homol. 2) domains of dSrc were fully dispensable with respect to rapid phosphorylation, indicating that the catalytic domain and tail of dSrc are sufficient for the high efficiency of dSrc as a substrate. Of the eight Src tail residues examined, only the fully conserved Glu (Y-3 position) and Gln (Y-1 position) investigated by alanine scanning mutagenesis caused large redns. (10-40-fold) in dSrc substrate efficiency. The Y-3 Glu requirement was stringent as conservative replacements with Asp or Gln were no better than Ala whereas replacement of the Y-1 Gln with Ile was readily tolerated. Interestingly, en bloc replacement of the tail with a seven amino acid consensus sequence derived from a peptide library anal. was no better than the wild-type sequence. Surprisingly, the dSrc Y527F protein, although not a Csk substrate, enhanced Csk-catalyzed phosphorylation of dSrc. These results and other data suggest that Src dimerization (or higher order oligomerization) is important for high-efficiency Csk-catalyzed phosphorylation of the Src tail.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:878500 HCAPLUS

DOCUMENT NUMBER: 134:204291

TITLE: Chemical rescue of a mutant protein-tyrosine **kinase**

AUTHOR(S): Williams, Daniel M.; Wang, Dongxia; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Journal of Biological Chemistry (2000), 275(49), 38127-38130

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein-tyrosine **kinases** contain a catalytic loop Arg residue located either two or four positions downstream of a highly conserved Asp residue. In this study, the role of this Arg (Arg-318) in the protein-tyrosine **kinase** C-terminal Src **kinase** (Csk) was investigated. The observed *k*<sub>cat</sub> for phosphorylation of the random copolymer poly(Glu,Tyr) substrate by Csk R318A is .apprx.3000-fold smaller compared with that of wild type Csk, whereas the *K*<sub>m</sub> values for ATP and poly(Glu,Tyr) are only mildly affected. The *k*<sub>cat</sub> value for poly(Glu,Tyr) phosphorylation by the Csk double mutant A316R,R318A is 100-fold greater than the *k*<sub>cat</sub> value for the single R318A mutant, suggesting that an Arg positioned at the alternative location fulfills a similar function as in



wild type. Csk R318A **kinase** activity can also be partially recovered by several exogenous small mols. including guanidinium and imidazole. These mols. contain key features whose roles in catalysis can be rationalized from a known x-ray structure of the insulin receptor tyrosine **kinase**. Imidazole is the best of these activators, enhancing phosphorylation rates by Csk R318A up to 100-fold for poly(Glu,Tyr) and significantly stimulating Csk R318A phosphorylation of the physiol. substrate Src. This chemical rescue of mutant protein **kinase** activity might find applications in cell signal transduction expts.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 43 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:241819 HCAPLUS

DOCUMENT NUMBER: 133:70560

TITLE: HATs off: selective synthetic **inhibitors** of the histone acetyltransferases p300 and PCAF

AUTHOR(S): Lau, Ontario D.; Kundu, Tapas K.; Soccio, Raymond E.; Ait-Si-Ali, Slimane; Khalil, Ehab M.; Vassilev, Alex; Wolffe, Alan P.; Nakatani, Yoshihiro; Roeder, Robert G.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Molecular Cell (2000), 5(3), 589-595  
CODEN: MOCEFL; ISSN: 1097-2765

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histone acetyltransferases (HATs) play important roles in the regulation of gene expression. In this report, we describe the design, synthesis, and application of peptide CoA conjugates as selective HAT **inhibitors** for the transcriptional coactivators p300 and PCAF. Two **inhibitors** (Lys-CoA for p300 and H3-CoA-20 for PCAF) were found to be potent ( $IC_{50} \approx 0.5 \mu M$ ) and selective (.apprx.200-fold) in blocking p300 and PCAF HAT activities. These **inhibitors** were used to probe enzymic and transcriptional features of HAT function in several assay systems. These compds. should be broadly useful as biol. tools for evaluating the roles of HATs in transcriptional studies and may serve as lead agents for the development of novel antineoplastic therapeutics.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 44 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:84845 HCAPLUS

DOCUMENT NUMBER: 132:121541

TITLE: Crystal structure of a Ras-Sos complex and its use in rational drug design

INVENTOR(S): Boriack-Sjodin, Ann; Margarit, S. Mariana; Bar-Sagi, Dafna; Cole, Philip; Kuriyan, John

PATENT ASSIGNEE(S): The Rockefeller University, USA

SOURCE: PCT Int. Appl., 224 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000005258	A1	20000203	WO 1999-US16348	19990720
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6156526	A	20001205	US 1998-119794	19980721
AU 9953179	A1	20000214	AU 1999-53179	19990720
PRIORITY APPLN. INFO.:				
			US 1998-119794	A2 19980721
			WO 1999-US16348	W 19990720
AB A detailed 3-dimensional structure for the complex formed between Ras and the Son of sevenless (Sos) protein is provided. Specifically, x-ray crystallog. data are provided for the complex of a C-terminally truncated form of human H-Ras (residues 1-166) with the guanine nucleotide-exchange factor region of human Sos1 (residues 564-1049). The crystals of this complex have a space group of I422 and unit cell dimensions of a = 142.7 Å, b = 142.7 Å, and c = 207.9 Å. The structure reveals that Sos interacts extensively with Ras and stabilizes it in a nucleotide-free state by displacing the residues that coordinate the magnesium ion and the phosphate groups of the nucleotide and by partially occluding the magnesium binding site. The structure also suggests a pathway for the rebinding of nucleotides to Ras, with consequent release of Sos, a process that is crucial for the functioning of Sos as a nucleotide exchanger rather than a binding inhibitor. The interaction between these 2 proteins plays a key role in the regulation of cell proliferation, and the present invention therefore provides procedures for identifying agents that can inhibit tumor proliferation through the use of rational drug design predicated on the crystals and crystallog. data disclosed.				
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L7 ANSWER 45 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1999:748305 HCAPLUS  
 DOCUMENT NUMBER: 132:456  
 TITLE: **Inhibitors of serotonin N-acetyltransferase**  
 INVENTOR(S): **Cole, Philip A.; Khalil, Ehab**  
 PATENT ASSIGNEE(S): The Rockefeller University, USA  
 SOURCE: U.S., 40 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5990094	A	19991123	US 1998-14340	19980127
PRIORITY APPLN. INFO.:			US 1998-14340	19980127
GI				



AB Compds. and pharmaceutical compns. which inhibit serotonin N-acetyltransferase enzyme and modulate the serotonin-melatonin pathway are described. Potent **inhibitors** of serotonin N-acetyltransferase serve as biol. tools that help reveal biol. functions for melatonin and pineal serotonin in vivo. Ultimately, they can even serve as therapeutic agents for a variety of different conditions, perhaps by allowing pineal serotonin and melatonin to be artificially regulated. A synthetic **bisubstrate** compound (I), which incorporated the indole and CoA moieties of the two substrates (acetyl-CoA and tryptamine), was an extremely potent serotonin N-acetyltransferase **inhibitor**, the IC<sub>50</sub> of 150 mM being near the expected range to be effective for in vivo studies.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 46 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:728878 HCAPLUS

DOCUMENT NUMBER: 132:44826

TITLE: Mechanism-based inhibition of the melatonin rhythm enzyme: pharmacologic exploitation of active site functional plasticity

AUTHOR(S): Khalil, Ehab M.; De Angelis, Jacqueline; Ishii, Makoto; Cole, Philip A.

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, The Rockefeller University, New York, NY, 10021, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1999), 96(22), 12418-12423  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Serotonin N-acetyltransferase is the enzyme responsible for the diurnal rhythm of melatonin production in the pineal gland of animals and humans. **Inhibitors** of this enzyme active in cell culture have not been reported previously. The compound N-bromoacetyltryptamine was shown to be a potent **inhibitor** of this enzyme in vitro and in a pineal cell

culture assay ( $IC_{50} \approx 500$  nM). The mechanism of inhibition is suggested to involve a serotonin N-acetyltransferase-catalyzed alkylation reaction between N-bromoacetyltryptamine and reduced CoA, resulting in the production of a tight-binding **bisubstrate analog inhibitor**. This alkyltransferase activity is apparently catalyzed at a functionally distinct site compared with the acetyltransferase activity active site on serotonin N-acetyltransferase. Such active site plasticity is suggested to result from a subtle conformational alteration in the protein. This plasticity allows for an unusual form of mechanism-based inhibition with multiple turnovers, resulting in "mol. fratricide.". N-bromoacetyltryptamine should serve as a useful tool for dissecting the role of melatonin in circadian rhythm as well as a potential lead compound for therapeutic use in mood and sleep disorders.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 47 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:474360 HCAPLUS

DOCUMENT NUMBER: 131:254182

TITLE: Domain interactions in protein tyrosine **kinase**  
Csk

AUTHOR(S): Sondhi, Dolan; **Cole, Philip A.**

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, The Rockefeller  
University, New York, NY, 10021, USA

SOURCE: Biochemistry (1999), 38(34), 11147-11155  
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Csk (C-terminal Src **kinase**) is a protein tyrosine **kinase** that phosphorylates Src family member C-terminal tails, resulting in down-regulation of Src family members. It is composed of three principal domains: an SH3 (Src homol. 3) domain, an SH2 (Src homol. 2) domain, and a catalytic domain. The impact of the noncatalytic domains on **kinase** catalysis was investigated. The Csk catalytic domain was expressed in Escherichia coli as a recombinant glutathione S-transferase-fusion protein and demonstrated to have 100-fold reduced catalytic efficiency. Production of the catalytic domain by proteolysis of full-length Csk afforded a similar rate reduction. This suggested that the reduction in catalytic efficiency of the recombinant catalytic domain was intrinsic to the sequence and not an artifact related to faulty expression. This rate reduction was similar for peptide and protein substrates and was due almost entirely to a reduced  $k_{cat}$  rather than to effects on substrate  $K_m$ s. Viscosity expts. on the catalytic fragment **kinase** reaction demonstrated that the chemical (phosphoryl transfer) step had a reduced rate. While the Csk SH2 domain had no intermol. effect on the **kinase** activity of the Csk catalytic domain, the SH3 domain and SH3-SH2 fragment led to a partial rescue (4-5-fold) of the lost **kinase** activity. This rescue was not achieved with two other SH3 domains (lymphoid cell **kinase**, Abelson **kinase**). The extrapolated  $K_d$  of interaction for the Csk catalytic domain with the Csk SH3 domain was 2.2  $\mu M$  and that of the Csk catalytic domain with the Csk SH3-SH2 fragment was 8.8  $\mu M$ . Taken together, these findings suggest that there is likely an intramol. interaction between the catalytic and SH3 domains in full-length Csk that is important for efficient catalysis. By employing a Csk SH3 specific type II polyproline helix peptide and carrying out site-directed mutagenesis, it was established that the SH3 surface that interacts with the catalytic domain was distinct from the surface that binds type II polyproline helix peptides. This finding suggests a novel mode of protein-protein interaction for an SH3 domain.

The implications for Csk substrate selectivity, regulation, and function are discussed.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 48 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:397260 HCAPLUS

DOCUMENT NUMBER: 131:196270

TITLE: Chemical approaches to the study of protein tyrosine **kinases** and their implications for mechanism and **inhibitor** design

AUTHOR(S): **Cole, Philip A.**; Sondhi, Dolan; Kim, Kyonghee

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, The Rockefeller University, New York, NY, 10021, USA

SOURCE: Pharmacology & Therapeutics (1999), 82(2-3), 219-229  
CODEN: PHTHDT; ISSN: 0163-7258

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein tyrosine **kinases** are critical enzymes for signal transduction. Using C-terminal Src **kinase** (Csk) as a model system, we discuss progress in three main areas. First, we describe our efforts to measure the transition state of the reaction using peptide substrates containing fluorotyrosine analogs. It is shown that the Bronsted nucleophile coefficient for the reaction is near zero (similar to the nonenzymic reaction) and the required nucleophile is the neutral phenol (rather than the more chemical reactive phenoxide anion). By studying the **kinase** reaction in the reverse direction, a Bronsted leaving group coefficient of -0.3 was measured, indicative of protonation of the departing phenol in the transition state. Taken together, these results strongly support a dissociative transition state mechanism for the **kinase** activity. These findings set constraints on the design of transition state analog **inhibitors**. Second, we describe efforts toward defining the specificity of Csk for peptide and protein substrates. The main findings are that local amino acids surrounding a phosphorylated tyrosine can influence recognition, but that long-range interactions probably are more important in a physiol. protein substrate. These findings underscore the complexities in how protein **kinases** select protein substrates. Third, we describe a new method in protein engineering that has been applied to the study of protein **kinases**. The method, expressed protein ligation, allows a general approach for ligating synthetic peptides to recombinant proteins. Using expressed protein ligation, obtaining site-specifically phosphorylated proteins and proteins with the incorporation of biophys. probes becomes relatively straightforward. We have used this method to generate a tail phosphorylated, conformationally altered Csk that showed an unexpected increase in **kinase** activity.

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:306632 HCAPLUS

DOCUMENT NUMBER: 131:73935

TITLE: Synthesis of (2S,3R)- $\beta$ -methyltyrosine catalyzed by tyrosine phenol-lyase

AUTHOR(S): Kim, Kyonghee; **Cole, Philip A.**

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, Rockefeller University, New York, NY, 10021, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(8),

1205-1208  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 131:73935  
AB A one-step enzymic synthesis of the conformationally restrained tyrosine analog (2S,3R)- $\beta$ -methyltyrosine is reported. This synthesis extends the preparative chemical associated with tyrosine phenol-lyase. The  $\beta$ -methyltyrosine derivative was shown to be an efficient protein tyrosine **kinase** substrate, suggesting that conformational restraint may ultimately be used to enhance tyrosine **kinase** recognition of substrates.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 50 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:748871 HCAPLUS  
DOCUMENT NUMBER: 130:106804  
TITLE: Indoleamine analogs as probes of the substrate selectivity and catalytic mechanism of serotonin N-acetyltransferase  
AUTHOR(S): Khalil, Ehab M.; De Angelis, Jacqueline; **Cole, Philip A.**  
CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, Rockefeller University, New York, NY, 10021, USA  
SOURCE: Journal of Biological Chemistry (1998), 273(46), 30321-30327  
CODEN: JBCHA3; ISSN: 0021-9258  
PUBLISHER: American Society for Biochemistry and Molecular Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase (AANAT)) catalyzes the reaction of serotonin (or tryptamine) with acetyl-CoA to form N-acetylserotonin (or N-acetyltryptamine) and is responsible for the melatonin circadian rhythm in vertebrates. This study evaluates a series of indoleamine analogs as alternate substrates of AANAT. 3-Indolepropylamine and 3-indolebutylamine were chemical synthesized and found to be processed by AANAT, although 20- and 60-fold less efficiently compared with the natural substrate serotonin, resp. Racemic  $\alpha$ -methyltryptamine and N $\omega$ -methyltryptamine were also shown to be substrates for AANAT, again with reduced kcat and kcat/Km compared with serotonin. The enzyme did exhibit .apprx.9:1 stereoselectivity for the R-enantiomer of  $\alpha$ -methyltryptamine vs. the S-enantiomer. By measuring the enzymic rates vs. increasing buffer microviscosity, it was demonstrated that diffusional release of product is most likely the principal rate-determining step for the enzymic transformation of tryptamine (which has similar kcat and kcat/Km compared with serotonin). Anal. of kcat and kcat/Km vs. pH for the poor substrate N $\omega$ -methyltryptamine showed that an ionizable group on the enzyme with pKa .apprx. 7, required to be in its deprotonated form, may be important in catalysis. The  $\alpha$ -methyltryptamine analog  $\alpha$ -trifluoromethyltryptamine was not processed by the enzyme, but served as a modest competitive **inhibitor**. Taken together with the pH-rate anal., these results favor a model in which the serotonin substrate binds to the enzyme as the pos. charged ammonium salt, and nucleophilicity of the amine is important in enzyme-catalyzed acetyl transfer.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 51 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:431209 HCAPLUS

DOCUMENT NUMBER: 129:172344

TITLE: Kinetic analysis of a protein tyrosine kinase reaction transition state in the forward and reverse directions

AUTHOR(S): Kim, Kyonghee; Cole, Philip A.

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, Rockefeller University, New York, NY, 10021, USA

SOURCE: Journal of the American Chemical Society (1998), 120(28), 6851-6858

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein tyrosine kinases catalyze the transfer of the  $\gamma$ -phosphoryl group from ATP to tyrosine residues in proteins and are important enzymes in cell signal transduction. We have investigated the catalytic phosphoryl transfer transition state of a protein tyrosine kinase reaction catalyzed by Csk by analyzing a series of fluorotyrosine-containing peptide substrates. It was established for five such fluorotyrosine-containing peptide substrates that there is good agreement between the tyrosine analog phenol pKa and the ionizable group responsible for the basic limb of a pH rate profile anal. This indicates that the substrate tyrosine phenol must be neutral to be enzymically active. Taken together with previous data indicating a small  $\beta$ nucleophile coefficient (0-0.1), these results strongly support a dissociative transition state for phosphoryl transfer. In addition, the  $\beta$ leaving group coefficient was measured for the reverse protein tyrosine kinase reaction and shown to be -0.3. This value is in good agreement with a previously reported nonenzymic model phosphoryl transfer reaction carried out under acidic conditions (pH 4) and is most readily explained by a transition state with significant proton transfer to the departing phenol.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 52 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:378466 HCAPLUS

DOCUMENT NUMBER: 129:118455

TITLE: Expressed protein ligation: A general method for protein engineering

AUTHOR(S): Muir, Tom W.; Sondhi, Dolan; Cole, Philip A.

CORPORATE SOURCE: Laboratory of Synthetic Protein Chemistry, Rockefeller University, New York, NY, 10021, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1998), 95(12), 6705-6710

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A protein semisynthesis method-expressed protein ligation-is described that involves the chemoselective addition of a peptide to a recombinant protein. This method was used to ligate a phosphotyrosine peptide to the C terminus of the protein tyrosine kinase C-terminal Src kinase (Csk). By intercepting a thioester generated in the recombinant protein with an N-terminal cysteine containing synthetic peptide, near quant. chemical ligation of the peptide to the protein was achieved. The semisynthetic tail-phosphorylated Csk showed evidence of an intramol. phosphotyrosine-Src homol. 2 interaction and an unexpected increase in

catalytic phosphoryl transfer efficiency toward a physiol. relevant substrate compared with the non-tail-phosphorylated control. This work illustrates that expressed protein ligation is a simple and powerful new method in protein engineering to introduce sequences of unnatural amino acids, posttranslational modifications, and biophys. probes into proteins of any size.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 53 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:373235 HCAPLUS

DOCUMENT NUMBER: 129:132919

TITLE: A Potent **Inhibitor** of the Melatonin Rhythm Enzyme

AUTHOR(S): Khalil, Ehab M.; **Cole, Philip A.**

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, Rockefeller University, New York, NY, 10021, USA

SOURCE: Journal of the American Chemical Society (1998), 120(24), 6195-6196

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Inhibitors** of melatonin biosynthesis could not only help improve our understanding of circadian rhythm but they might also have therapeutic roles in mood and sleep disorders. The key enzyme to be targeted in this regard is serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT), also called the melatonin rhythm enzyme. This paper reports the synthesis and activity of the first potent and specific **inhibitor** of AANAT. This **inhibitor** is a **bisubstrate** analog which contains covalently linked components of serotonin and acetyl-CoA.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 54 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:79094 HCAPLUS

DOCUMENT NUMBER: 128:241144

TITLE: Kinetic analysis of the catalytic mechanism of serotonin N-acetyltransferase (EC 2.3.1.87)

AUTHOR(S): De Angelis, Jacqueline; Gastel, Jonathan; Klein, David C.; **Cole, Philip A.**

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, The Rockefeller University, New York, NY, 10021, USA

SOURCE: Journal of Biological Chemistry (1998), 273(5), 3045-3050

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT, EC 2.3.1.87) is the penultimate enzyme in melatonin biosynthesis. This enzyme is of special biol. interest because large changes in its activity drive the large night/day rhythm in circulating melatonin in vertebrates. In this study, the kinetic mechanism of AANAT action was studied using a bacterially expressed glutathione S-transferase (GST)-AANAT fusion protein. The enzymol. behaviors of GST-AANAT and cleaved AANAT were essentially identical. Two-substrate kinetic anal. generated an intersecting line pattern characteristic of a ternary complex mechanism.



The dead end **inhibitor** analog desulfo-CoA was competitive vs. acetyl-CoA and noncompetitive vs. tryptamine. Tryptophol was not an alternative substrate but was a dead end competitive **inhibitor** vs. tryptamine and an uncompetitive **inhibitor** vs. acetyl-CoA, indicative of an ordered binding mechanism requiring binding of acetyl-CoA first. N-Acetyl-tryptamine, a reaction product, was a noncompetitive **inhibitor** vs. tryptamine and uncompetitive with respect to acetyl-CoA. Taken together, these results support an ordered BiBi ternary complex (sequential) kinetic mechanism for AANAT and provide a framework for **inhibitor** design.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 55 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:794353 HCAPLUS

DOCUMENT NUMBER: 128:125196

TITLE: Peptide and Protein Phosphorylation by Protein Tyrosine Kinase Csk: Insights into Specificity and Mechanism

AUTHOR(S): Sondhi, Dolan; Xu, Wenqing; Songyang, Zhou; Eck, Michael J.; Cole, Philip A.

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, Rockefeller University, New York, NY, 10021, USA

SOURCE: Biochemistry (1998), 37(1), 165-172  
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Csk (C-terminal Src **kinase**) is a protein tyrosine **kinase** that phosphorylates Src family member C-terminal tails, resulting in down-regulation of Src family members. The mol. basis of Csk's substrate specificity and catalytic mechanism with a protein substrate was investigated. Using a peptide library approach, preferential amino acids which are unrelated to the conserved Src C-terminal sequence were identified. The validity of these preferences was confirmed by synthesizing a short consensus peptide and demonstrating its high catalytic efficiency with Csk. These results underscore the difficulties of relying on amino acids neighboring tyrosine in protein sequences as predictors of protein **kinase** substrate specificity for in vivo anal. In addition, a catalytically inactive version of the Src family member, Lck (lymphoid cell **kinase**), was expressed, purified, and evaluated as a Csk substrate. It was proven to be the most catalytically efficient substrate yet identified for Csk. The high efficiency of purified Csk phosphorylating a pure, unphosphorylated Src family member argues against the importance of an SH2-phosphotyrosine docking interaction or the involvement of extra recruitment proteins in facilitating Csk phosphorylation of Src family members. Kinetic studies revealed that the chemical step is at least partially rate-determining in Csk-mediated phosphoryl transfer to the Lck protein. Other properties including preferences for Mn over Mg, thio effects, and Kms for ATP also correlate fairly well between protein and peptide phosphorylation. The lack of a significant impact of increased salt on the Km for Lck phosphorylation differs from Csk-mediated poly(Glu,Tyr) phosphorylation, and argues against the importance of electrostatic effects in the Csk-Lck binding interaction. The failure of the Lck phosphorylation product (phosphotyrosine-505) to significantly inhibit Csk phosphorylation of Lck is consistent with a catalytic model involving multidomain structural interactions between substrate and enzyme.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 56 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:720443 HCAPLUS  
 DOCUMENT NUMBER: 127:328275  
 TITLE: Measurement of a Bronsted Nucleophile Coefficient and Insights into the Transition State for a Protein Tyrosine **Kinase**  
 AUTHOR(S): Kim, Kyonghee; **Cole, Philip A.**  
 CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, Rockefeller University, New York, NY, 10021, USA  
 SOURCE: Journal of the American Chemical Society (1997), 119(45), 11096-11097  
 CODEN: JACSAT; ISSN: 0002-7863  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The Bronsted nucleophile coefficient ( $\beta_{\text{nuc}}$ ), a measure of the role of the nucleophile in the transition state, has never before been determined on an ATP-dependent **kinase**. Here, we measure this value on the protein tyrosine **kinase** Csk-catalyzed phosphorylation of a peptide substrate family. At  $0.08 \pm 0.06$ , the  $\beta_{\text{nuc}}$  is in good agreement with those of analogous non-enzymic reactions and strongly suggests a transition state with dissociative character. Furthermore, the attacking nucleophile in the enzyme reaction is shown to be the neutral tyrosine phenol, not the phenoxide anion. These findings set conceptual constraints on protein **kinase inhibitor** design and regulation.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 57 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:127316 HCAPLUS  
 DOCUMENT NUMBER: 126:141322  
 TITLE: Divalent Ion Effects and Insights into the Catalytic Mechanism of Protein Tyrosine **Kinase** Csk  
 AUTHOR(S): Grace, Miranda R.; Walsh, Christopher T.; **Cole, Philip A.**  
 CORPORATE SOURCE: Laboratory of Bio-Organic Chemistry, Rockefeller University, New York, NY, 0021, USA  
 SOURCE: Biochemistry (1997), 36(7), 1874-1881  
 CODEN: BICHAW; ISSN: 0006-2960  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Csk (C-terminal Src **kinase**) is a protein tyrosine **kinase** which catalyzes the transfer of the  $\gamma$ -phosphoryl group of ATP to the tyrosine hydroxyl of proteins in the presence of a divalent ion. Previous work with poly(Glu,Tyr) as the tyrosine-containing substrate and Mn as the divalent ion defined a ternary complex mechanism with ADP product release partially rate-determining [Cole, P. A., et al. (1994) J. Biol. Chemical 269, 30880-30887]. In this current study, ionic strength and divalent ion effects were probed. Increasing ionic strength led to a dramatic rise in the poly(Glu,Tyr) [4:1 poly(glutamate:tyrosine)]  $K_m$  and had little effect on the ATP  $K_m$  or  $k_{\text{cat}}$  in Csk-mediated phosphoryl transfer. This finding allowed the dead-end peptide **inhibitor** EDNEFTA to be characterized as a linear competitive **inhibitor** of poly(Glu,Tyr) and a linear noncompetitive **inhibitor** of ATP. Taken together with previous data, the overall kinetic mechanism could now be assigned as random substrate binding, ternary complex. Compared to Mn, Mg was shown to sustain phosphoryl transfer with a 2.5-fold higher  $k_{\text{cat}}$  but  $K_m$ 's for

ATP and poly(Glu,Tyr) that were some 15-20-fold higher. An elevated ADP  $K_i$  and microviscosity effects were most suggestive of a kinetic mechanism with fast ADP release, and the chemical step fully rate-determining in the Mg-dependent reaction. Steady-state kinetic analyses of Csk reactions with Co and Ni in addition to Mg and Mn on wild-type and D314E Csk with ATP and ATPyS [adenosine 5'-O-(3-thiotriphosphate)] as substrates were performed. The  $k_{cat}$  thio effects [ $k_{cat}(\text{ATP})/k_{cat}(\text{ATPyS})$ ] were inversely correlated with metal thiophilicity in both wild-type and D314E mutant Csk reactions, although the relation was less pronounced in the latter. These results appear to underscore the role of  $\gamma$ -phosphoryl hydrogen bonding/salt bridging in the wild-type Csk reaction transition state, which is somewhat perturbed in the D314E Csk reaction. In the case of the Ni reaction, the  $k_{cat}$  thio effect was reduced to about 2 in the wild-type and D314E mutant Csk reactions. Relevance with regard to the degree of nucleophilic attack in the transition state, i.e., associative vs. dissociative character of phosphoryl transfer, is discussed.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 58 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:825203 HCAPLUS

DOCUMENT NUMBER: 123:221576

TITLE: The role of the catalytic base in the protein tyrosine kinase Csk

AUTHOR(S): Cole, Philip A.; Grace, Miranda R.; Phillips, Robert S.; Burn, Paul; Walsh, Christopher T.  
CORPORATE SOURCE: Dep. Biol. Chem. Mol. Pharmacol., Harvard Med. Sch., Boston, MA, 02115, USA

SOURCE: Journal of Biological Chemistry (1995), 270(38), 22105-8

PUBLISHER: CODEN: JBCHA3; ISSN: 0021-9258  
American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A potential distinguishing feature between protein tyrosine kinases and homologous serine/threonine kinases is the function of the catalytic base in these enzymes. In this study, the authors show that a peptide containing the unnatural amino acid trifluorotyrosine shows remarkably similar efficiency as a substrate of the tyrosine kinase Csk (C-terminal Src kinase) compared with the corresponding tyrosine-containing peptide despite a 4-unit change in the phenolic pKa. These results argue against the importance of early tyrosine deprotonation by a catalytic base in Csk. To further explore the role of the proposed catalytic base, the Csk mutant protein D314E was produced. This mutant displayed a significant reduction in  $k_{cat}$  (approx. 104) but relatively little effect on substrate  $K_m$  values compared with wild-type Csk. Examination of the thio effect ( $k_{cat}$ -ATP/ $k_{cat}$ -adenosine 5'-O-(thiotriphosphate)) for D314E Csk led to the suggestion that a role of aspartate 314 may be to enhance the reactivity of the  $\gamma$ -phosphate of ATP toward electrophilic attack. These results may have significant impact on protein tyrosine kinase inhibitor design.

L7 ANSWER 59 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:675132 HCAPLUS

DOCUMENT NUMBER: 121:275132

TITLE: Evaluation of the catalytic mechanism of recombinant human Csk (C-terminal Src kinase) using nucleotide analogs and viscosity effects


AUTHOR(S): Cole, Philip A.; Burn, Paul; Takacs, Bela;

Walsh, Christopher T.  
CORPORATE SOURCE: Dep. Biological Chem. Mol. Pharmacol., Harvard Medical  
School, Boston, MA, 02115, USA  
SOURCE: Journal of Biological Chemistry (1994), 269(49),  
30880-7  
CODEN: JBCHA3; ISSN: 0021-9258  
PUBLISHER: American Society for Biochemistry and Molecular  
Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB In this study, the authors have investigated the tyrosine **kinase**  
reaction catalyzed by purified human recombinant Csk (C-terminal Src  
**kinase**). Poly(Glu,Tyr) 4:1 was used as the tyrosine-containing  
substrate. Both ATP and poly(Glu,Tyr) were shown to be well behaved  
saturable substrates for recombinant Csk, with Km values that were in  
reasonable agreement with literature values reported for the  
non-recombinant enzyme and with kcat about 40 min<sup>-1</sup>. A sequential kinetic  
mechanism is suggested by a steady state kinetic anal. **Inhibitor**  
studies with ADP and  $\beta,\gamma$ -imidoadenosine 5'-triphosphate were  
performed, and these results provided evidence against the possibility  
that ordered binding of peptide prior to ATP occurs. While a suitable  
competitive **inhibitor** of poly(Glu,Tyr) has not yet been  
identified, other evidence pointed to a rapid equilibrium random mechanism.  
Csk utilized adenosine 5'-O-(3-thiotriphosphate) in place of ATP. The  
phosphorothioyl transfer occurred with a kcat about 15-20-fold lower than  
the ATP reaction but with similar Km values. Deuterium solvent isotope  
effects on kcat were small for both reactions in a pH-independent range,  
consistent with the possibility that proton transfer is asym. in the  
reaction transition state. Using viscosity effects, ADP product release  
was suggested to be partially rate determining for catalysis in the standard  
ATP reaction. A comparison of the Csk kinetic mechanism with that of protein  
**kinase A** is discussed.


L7 ANSWER 60 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1994:162322 HCAPLUS  
DOCUMENT NUMBER: 120:162322  
TITLE: Estimates of trace element intakes in Chinese farmers  
AUTHOR(S): Chen, Fan; **Cole, Philip**; Wen, Lifang; Mi,  
Zhibao; Trapido, Edward J.  
CORPORATE SOURCE: Sylvester Compr. Cancer Cent., Univ. Miami, Miami, FL,  
33136, USA  
SOURCE: Journal of Nutrition (1994), 124(2), 196-201  
CODEN: JONUAI; ISSN: 0022-3166  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Epidemiol. data on the average daily human dietary intake of the trace  
elements nickel, cadmium, molybdenum and silicon are scarce worldwide,  
primarily because foods consumed vary widely over days and seasons.  
Available full year food allocation records for farmers in rural areas of  
China provide an unique opportunity to estimate dietary trace elements. In  
1988, the authors measured the concns. of zinc, copper, iron, cadmium,  
nickel, molybdenum, silicon and selenium in different foods by using food  
samples collected from 232 villages (distributed among 21 communes).  
These measurements, combined with the food consumption information from  
existing food allocation records in each commune for an entire year,  
allowed the authors to estimate the average daily consumption of these trace  
elements by Chinese farmers. With one exception (an association of zinc and  
esophageal cancer), the variation of dietary trace elements did not show  
any association with mortality from several common diseases. The ests. for

some of the dietary trace elements from some subpopulations were either less or more than current recommendations. No increases in mortality were found, however, from diseases normally associated with either dietary deficiencies or excesses of these elements.

L7 ANSWER 61 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1994:26181 HCAPLUS  
 DOCUMENT NUMBER: 120:26181  
 TITLE: Synthetic and enzymic studies with potential alternate substrates for human placental aromatase: 10 $\beta$ -trifluoroacetyl and 10 $\beta$ -allyl steroids  
 AUTHOR(S): Jaworski, Krzysztof; Cole, Philip A.; Robinson, Cecil H.  
 CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205-2185, USA  
 SOURCE: Bioorganic Chemistry (1993), 21(3), 330-41  
 CODEN: BOCMBM; ISSN: 0045-2068  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



I



II, R = CH=CH<sub>2</sub>

III, R = C $\equiv$ CH

AB The 10 $\beta$ -trifluoroacetyl (I) and 10 $\beta$ -allyl (II) analogs of androstenedione were studied as potential alternate substrates for aromatase. The hitherto undescribed I was prepared via the reaction of trifluoromethyltrimethylsilane with a 19-oxo steroid. There was no conversion of I to estrogen by aromatase, although I was a competitive inhibitor. Furthermore II was not epoxidized significantly by the enzyme, leaving open the mechanism of suicide inactivation of aromatase by the propargyl steroid III.


L7 ANSWER 62 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1991:530530 HCAPLUS  
 DOCUMENT NUMBER: 115:130530  
 TITLE: A chemical portrait of and inhibitor development for cytochrome P-450 aromatase  
 AUTHOR(S): Cole, Philip Arthur  
 CORPORATE SOURCE: Johns Hopkins Univ., Baltimore, MD, USA  
 SOURCE: (1991) 359 pp. Avail.: Univ. Microfilms Int., Order No. DA9113651  
 From: Diss. Abstr. Int. B 1991, 51(12, Pt. 1), 5843  
 DOCUMENT TYPE: Dissertation  
 LANGUAGE: English  
 AB Unavailable

L7 ANSWER 63 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1990:586943 HCAPLUS  
 DOCUMENT NUMBER: 113:186943  
 TITLE: Mechanism and inhibition of cytochrome P-450 aromatase

AUTHOR(S): Cole, Philip A.; Robinson, Cecil H.  
 CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA  
 SOURCE: Journal of Medicinal Chemistry (1990), 33(11), 2933-42  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review, with many refs., on the mechanism of the aromatase activity of cytochrome P 450 and its inhibition. Competitive **inhibitors**, suicide inactivators, and affinity labels are examined and future directions for the design of mechanism-based **inhibitors** are discussed.

L7 ANSWER 64 OF 64 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1990:528512 HCAPLUS  
 DOCUMENT NUMBER: 113:128512  
 TITLE: Conversion of a 3-desoxysteroid to 3-desoxyestrogen by human placental aromatase  
 AUTHOR(S): Cole, Philip A.; Bean, Joseph M.; Robinson, Cecil H.  
 CORPORATE SOURCE: Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA  
 SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1990), 87(8), 2999-3003  
 CODEN: PNASA6; ISSN: 0027-8424  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Human placental aromatase is a cytochrome P 450 enzyme system which converts androgens to estrogens by 3 successive oxidative reactions. The first 2 steps have been shown to be hydroxylations at the androgen 19-C but the third step remains unknown. A leading theory for the third step involves ferric peroxide attack on the 19-oxo group to produce a 19,19-hydroxyferric peroxide intermediate and subsequent collapse to estrogen. Previously, a nonenzymic peroxide model reaction based on the above-mentioned theory was developed, and the importance of 3-ketone enolization in facilitating aromatization was demonstrated. This study discusses the synthesis and nonenzymic and enzymic study of a 3-desoxy-2,4-diene-19-oxo androgen analog. This compound was a potent nonenzymic model substrate and competitive **inhibitor** of aromatase ( $K_i = 73 \text{ nM}$ ). Furthermore, in an unprecedented event, this compound served as a substrate for aromatase, with conversion to the corresponding 3-desoxyestrogen.

=> => d stat que 122  
 L15 STR




NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L17 125972 SEA FILE=REGISTRY SSS FUL L15  
L18 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
GGCAT IS MCY AT 18  
GGCAT IS PCY AT 19  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L19 6 SEA FILE=REGISTRY SUB=L17 SSS FUL L18  
L22 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L19

=>  
=>

=> d ibib abs hitstr l22 1-4

L22 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:622866 HCAPLUS

DOCUMENT NUMBER: 143:243964

TITLE: Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: Molecular yardsticks for analyzing catalytic mechanism and inhibitor design  
AUTHOR(S): Hines, Aliya C.; Parang, Keykavous; Kohanski, Ronald A.; Hubbard, Stevan R.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Bioorganic Chemistry (2005), 33(4), 285-297  
CODEN: BOCMBM; ISSN: 0045-2068

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bisubstrate analogs have the potential to provide enhanced specificity for protein kinase inhibition and tools to understand catalytic mechanism. Previous efforts led to the design of a peptide-ATP conjugate bisubstrate analog utilizing aminophenylalanine in place of tyrosine and a thioacetyl

linker to the  $\gamma$ -phosphate of ATP which was a potent inhibitor of the insulin receptor kinase (IRK). In this study, the authors have examined the contributions of various electrostatic and structural elements in the bisubstrate analog to IRK binding affinity. Three types of changes (seven specific analogs in all) were introduced: a Tyr isostere of the previous aminophenylalanine moiety, modifications of the spacer between the adenine and the peptide, and deletions and substitutions within the peptide moiety. These studies allowed a direct evaluation of the hydrogen bond strength between the anilino nitrogen of the bisubstrate analog and the enzyme catalytic base Asp and showed that it contributes 2.5 kcal/mol of binding energy, in good agreement with previous predictions. Modifications of the linker length resulted in weakened inhibitory affinity, consistent with the geometric requirements of an enzyme-catalyzed dissociative transition state. Alterations in the peptide motif generally led to diminished inhibitory potency, and only some of these effects could be rationalized based on prior kinetic and structural studies. Taken together, these results suggest that a combination of mechanism-based design and empirical synthetic manipulation will be necessary in producing optimized protein kinase bisubstrate analog inhibitors.

IT 329783-44-0P 863099-24-5P 863099-25-6P  
863099-26-7P 863099-27-8P



RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(bisubstrate analog; peptide bisubstrate analog probes preparation and inhibition of insulin receptor protein tyrosine kinase)

RN 329783-44-0 HCAPLUS


CN L-Aspartic acid, N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-4-[[6-(5'-adenylyloxy)-4,6-dihydroxy-4,6-dioxido-1-oxo-5-oxa-3-thia-4,6-diphosphahex-1-yl]amino]-L-phenylalanyl-L-methionyl-L-asparaginyll-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







PAGE 1-C




PAGE 2-A



PAGE 2-B




PAGE 2-C




RN 863099-24-5 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B




RN 863099-25-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 863099-26-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C





PAGE 2-A




RN 863099-27-8 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.







PAGE 1-C




PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:958238 HCAPLUS

DOCUMENT NUMBER: 140:89809  
 TITLE: Conversion of a Tyrosine Kinase Protein Substrate to a High Affinity Ligand by ATP Linkage  
 AUTHOR(S): Shen, Kui; Cole, Philip A.  
 CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA  
 SOURCE: Journal of the American Chemical Society (2003), 125(52), 16172-16173  
 CODEN: JACSAT; ISSN: 0002-7863  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 140:89809

AB Protein kinases often show low affinity for their protein substrates, which makes it difficult to study kinase-substrate interactions. Here, the authors show using expressed protein ligation with the signaling protein Src that it is feasible to install a covalently linked ATP moiety into the tail of Src, generating a semisynthetic protein with a high affinity for its cognate tyrosine kinase, Csk. It is also established that this Src-ATP conjugate can be used to selectively pull down Csk from a complex protein mixture. This work outlines a general strategy for identifying an unknown kinase that is responsible for the phosphorylation of a protein substrate on a site of interest.

IT 643760-38-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(ATP linkage to Src-based peptide and expressed protein ligation to convert Csk tyrosine kinase substrate to high-affinity ligand/inhibitor for selective kinase pull down)


RN 643760-38-7 HCAPLUS

CN L-Leucine, L-cysteiny-L-glutaminy-L-4-[[6-(5'-adenylyloxy)-4,6-dihydroxy-4,6-dioxido-1-oxo-5-oxa-3-thia-4,6-diphosphahex-1-yl]amino]-L-phenylalanyl-L-glutaminy-L-prolylglycyl-L- $\alpha$ -glutamyl-L-asparaginy-L- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:713377 HCAPLUS  
 DOCUMENT NUMBER: 135:253738  
 TITLE: Bisubstrate inhibitors of kinases  
 INVENTOR(S): Courtney, Aliya; Cole, Philip A.; Parang, Keykavous;  
 Abloogu, Ararat; Kohanski, Ron  
 PATENT ASSIGNEE(S): Johns Hopkins University, USA  
 SOURCE: PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070770	A2	20010927	WO 2001-US8886	20010321
WO 2001070770	A3	20020704		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 2002031820 A1 20020314 US 2001-811870 20010321  
 PRIORITY APPLN. INFO.: US 2000-190799P P 20000321

AB Protein kinase inhibitors have applications as anti-cancer therapeutic agents and biol. tools in cell signalling. Potent and selective bisubstrate inhibitors for the insulin receptor tyrosine kinase are based on a phosphoryl transfer mechanism involving a dissociative transition

state. One such inhibitor is synthesized by linking ATPyS to a peptide substrate analog via a two-carbon spacer. The compound is a high-affinity competitive inhibitor against both nucleotide and peptide substrate and shows a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirms the key design features inspired by a dissociative transition state, and reveal that the linker takes part in the octahedral coordination of an active site  $Mg^{2+}$  ion. A Kemptide-ATPyS compound was also prepared. This compound was an inhibitor of protein kinase A.

IT **329783-44-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(insulin receptor tyrosine kinase inhibitor; bisubstrate inhibitors of kinases)

RN 329783-44-0 HCAPLUS


CN L-Aspartic acid, N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-4-[[6-(5'-adenylyloxy)-4,6-dihydroxy-4,6-dioxido-1-oxo-5-oxa-3-thia-4,6-diphosphahex-1-yl]amino]-L-phenylalanyl-L-methionyl-L-asparaginyll-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-A



PAGE 2-B



PAGE 2-C



L22 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:37882 HCAPLUS

DOCUMENT NUMBER: 134:218831

TITLE: Mechanism-based design of a protein kinase inhibitor

AUTHOR(S): Parang, Keykavous; Till, Jeffrey H.; Ablooglu, Ararat J.; Kohanski, Ronald A.; Hubbard, Stevan R.; Cole, Philip A.

CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

SOURCE: Nature Structural Biology (2001), 8(1), 37-41

CODEN: NSBIEW; ISSN: 1072-8368

PUBLISHER: Nature America Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein kinase inhibitors have applications as anticancer therapeutic agents and biol. tools in cell signaling. Based on a phosphoryl transfer mechanism involving a dissociative transition state, a potent and selective bisubstrate inhibitor for the insulin receptor tyrosine kinase

was synthesized by linking ATPyS to a peptide substrate analog via a two-carbon spacer. The compound was a high affinity competitive inhibitor against both nucleotide and peptide substrates and showed a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirmed the key design features inspired by a dissociative transition state, and revealed that the linker takes part in the octahedral coordination of an active site  $Mg^{2+}$ . These studies suggest a general strategy for the development of selective protein kinase inhibitors.

IT 329783-44-0D, complexes with insulin receptor kinase

RL: PRP (Properties)


(crystal structure of bisubstrate inhibitor complexes with insulin receptor kinase)

RN 329783-44-0 HCAPLUS


CN L-Aspartic acid, N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-4-[[6-(5'-adenylyloxy)-4,6-dihydroxy-4,6-dioxido-1-oxo-5-oxa-3-thia-4,6-diphosphahex-1-yl]amino]-L-phenylalanyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C







PAGE 2-A



PAGE 2-B




PAGE 2-C



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(mechanism-based design of bisubstrate inhibitor of insulin receptor kinase

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> => d stat que  
L15 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE  
 L17 125972 SEA FILE=REGISTRY SSS FUL L15  
 L18 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 18  
 GGCAT IS PCY AT 19  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE  
 L19 6 SEA FILE=REGISTRY SUB=L17 SSS FUL L18  
 L20 45 SEA FILE=REGISTRY ABB=ON PLU=ON KKKLPATGD|MNMSPVGD/SQSP  
 L21 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("INSULIN RECEPTOR KINASE"/CN  
 OR "INSULIN RECEPTOR KINASE (SYCON RAPHANUS ISOFORM 1)"/CN OR  
 "INSULIN RECEPTOR KINASE (SYCON RAPHANUS ISOFORM 2)"/CN OR  
 "INSULIN RECEPTOR KINASE (SYCON RAPHANUS ISOFORM 3)"/CN)  
 L22 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L19  
 L23 41 SEA FILE=HCAPLUS ABB=ON PLU=ON L20  
 L24 6708 SEA FILE=HCAPLUS ABB=ON PLU=ON L21 OR INSULIN(L) RECEPTOR(L) KI  
 NASE  
 L25 17 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L23  
 L26 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L25 NOT L22

=&gt; d ibib abs hitstr 126 1-14

L26 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:239208 HCAPLUS

DOCUMENT NUMBER: 142:311998

TITLE: Assaying transferase activity by using an artificial, multifunctional substrate comprising a small-molecule component linked to biopolymer-substrate-mimetic component

INVENTOR(S): Gellibolian, Robert; Rouhani, Riaz

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005024380	A2	20050317	WO 2004-US29004	20040903
WO 2005024380	A3	20050526		
WO 2005024380	C2	20050707		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-499863P P 20030903

OTHER SOURCE(S): MARPAT 142:311998

AB Embodiments of the present invention are directed to sensitive, specific, and com. feasible assays for transferase activity. Various embodiments of the present invention include artificial, multifunctional substrates specific for particular transferases that are chemical altered by the transferases to produce easily detectable, modified, multifunctional substrates. In one class of embodiments, the artificial, multifunctional substrate comprises a small-mol.-substrate component, or small-mol.-substrate-analog component, linked by a linking component to a biopolymer-substrate-mimetic or biopolymer-substrate-analog component. At least two, generally well-separated reporter moieties are included in the artificial, multifunctional substrate. The transferase, for which the artificial, multifunctional substrate is designed to serve as an assay reagent, catalyzes a generally covalent modification of the artificial, multifunctional substrate to produce a modified, artificial, multifunctional substrate reaction product in which the two reporter moieties are closely positioned to one another. When closely positioned to one another, the reporter moieties are detectable by one of various instrumental techniques. The artificial, multifunctional substrates for assaying protein kinase A, PCAF histone acetyltransferase, and protein arginine methyltransferase PRMT-1 are prepared

IT 848053-30-5

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (biopolymer-substrate-mimetic component; transferase determination using


artificial, multifunctional substrate comprising small-mol. component  
linked to biopolymer-substrate-mimetic component)

RN 848053-30-5 HCAPLUS


CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-tyrosylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C





IT 88201-45-0, **Insulin receptor kinase**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (transferase determination using artificial, multifunctional substrate  
 comprising small-mol. component linked to biopolymer-substrate-mimetic  
 component)  
 RN 88201-45-0 HCAPLUS  
 CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2005:155467 HCAPLUS  
 DOCUMENT NUMBER: 142:236028  
 TITLE: A method for identification of **insulin receptor** substrate protein **kinase** inhibitors or agonists  
 INVENTOR(S): Tennagels, Norbert; Eckel, Juergen; Metzger, Sabine; Sommerfeld, Mark  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
 SOURCE: Eur. Pat. Appl., 50 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1508806	A1	20050223	EP 2003-18517	20030816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005017196	A2	20050224	WO 2004-EP7900	20040716
WO 2005017196	A3	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005106653	A1	20050519	US 2004-918015	20040813
PRIORITY APPLN. INFO.:			EP 2003-18517	A 20030816
			US 2004-535139P	P 20040108
AB The present invention provides a method for identification of <b>insulin receptor</b> substrate (IRS) protein <b>kinase</b> inhibitor or agonists. The detection kit contains PKC- $\zeta$ with IRS				

peptide comprising PKC- $\zeta$ -Ser-phosphorylation site in the presence of putative inhibitor or agonist. To determine the IRS **kinase** inhibitor or agonist, the phosphorylation of PKC- $\zeta$ -Ser-phosphorylation site will be measured.

IT 845592-97-4

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; method for identification of **insulin receptor** substrate protein **kinase** inhibitors or agonists)

RN 845592-97-4 HCAPLUS

CN Kinase (phosphorylating), insulin receptor (rat 1235-amino acids) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 88201-45-0, **Insulin receptor kinase**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(method for identification of **insulin receptor** substrate protein **kinase** inhibitors or agonists)

RN 88201-45-0 HCAPLUS

CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:121193 HCAPLUS

DOCUMENT NUMBER: 142:214836

TITLE: Biomarkers of cyclin-dependent kinase modulation in cancer therapy

INVENTOR(S): Li, Martha; Rupnow, Brent A.; Webster, Kevin R.; Jackson, Donald G.; Wong, Tai W.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012875	A2	20050210	WO 2004-US24424	20040729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-490890P P 20030729

AB Biomarkers having expression patterns that correlate with a response of cells to treatment with one or more cdk modulating agents, and uses thereof. Transcription profiling was used to identify the biomarkers.

Specifically, transcription profiling of the effect of a certain cdk2 inhibitor (BMS 387032 0.5 L-tartaric acid salt) on peripheral blood mononuclear cells was first performed. Gene chips were used to quantitate the levels of gene expression on a large-scale with Affymetrix human gene chips HG-U95A, B, and C. Next, profiling of a cdk2 inhibitor-treated tumor cell line A28780 at multiple doses and time points was performed to establish a correlation of tumor site response with peripheral blood biomarkers. In order to establish the mol. target-specificity of the potential biomarkers, tumor cell line A2780 treated with anti-cdk2 oligonucleotides was also profiles. Overlapping gene expression changes were selected for further evaluation in human ovarian carcinoma xenograft A2780 that were treated with the cdk2 inhibitor. The selected biomarkers were subjected to real-time PCR anal. in order to verify the observed changes from the gene chip anal. The biomarker comprising GenBank accession number W28729 was discovered to have the most consistent and robust regulation in response to cdk inhibition. Provided are methods for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer that comprises administering an agent that modulates cdk activity.

IT 841346-72-3

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (amino acid sequence; biomarkers of cyclin-dependent kinase modulation in cancer therapy)

RN 841346-72-3 HCAPLUS

CN DNA (human clone WO2005012875-SEQID-2417 cyclin-dependent kinase modulator-regulated protein cDNA) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1037263 HCAPLUS

DOCUMENT NUMBER: 142:19236

TITLE: Use of biotinylated peptides as substrates for the assay of protein kinases and protein phosphatases

INVENTOR(S): Tennagels, Norbert; Kannt, Aimo; Thuering, Harald

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004104220	A2	20041202	WO 2004-EP4428	20040427
WO 2004104220	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10323081	A1	20041216	DE 2003-10323081	20030522



PRIORITY APPLN. INFO.: DE 2003-10323081 A 20030522  
AB A method of using peptides derived from substrate domains of protein kinases and phosphatases is described. The substrate peptide is biotinylated to allow its capture by an immobilized avidin, either before or after incubation with the analyte enzyme. The change in the substrate, phosphorylation or dephosphorylation, can be determined after capture. The method is suitable for high throughput screening. Use of biotinylated peptides derived from insulin receptor substrate 1 as substrates for protein kinase C and insulin receptor kinase is demonstrated. Phosphorylation was quantified using com. ALPHAScreen technol.  
IT 800916-52-3D, biotinylated 800916-53-4D, biotinylated  
RL: ARU (Analytical role, unclassified); PRP (Properties); ANST (Analytical study)  
(amino acid sequence, assay substrate; use of biotinylated peptides as substrates for assay of protein kinases and protein phosphatases)  
RN 800916-52-3 HCAPLUS  
CN 516-777-Protein, IRS-1 (insulin receptor substrate 1) (human) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 800916-53-4 HCAPLUS  
CN Protein, IRS-1 (insulin receptor substrate 1) (human) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 88201-45-0, Insulin receptor kinase  
RL: ANT (Analyte); ANST (Analytical study)  
(assays for; use of biotinylated peptides as substrates for assay of protein kinases and protein phosphatases)  
RN 88201-45-0 HCAPLUS  
CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26. ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:847638 HCAPLUS  
DOCUMENT NUMBER: 141:325696  
TITLE: Genes showing altered levels of expression in response to inhibitors of cyclin-dependent kinases and their use in screening for novel inhibitors  
INVENTOR(S): Green, Simon R.; Frame, Sheelagh; Blake, David  
PATENT ASSIGNEE(S): Cyclacel Limited, UK  
SOURCE: PCT Int. Appl., 175 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087954	A2	20041014	WO 2004-GB1334	20040326
WO 2004087954	A3	20050127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-7643 A 20030402

AB Genes that show changes in levels of expression in response to pharmaceutical inhibitors of cyclin-dependent kinases, especially 2,6,9-tri-substituted purines including roscovitine, are identified for use in the screening for roscovitine-like drugs using either animals or cultured cells. The identity of these markers facilitates the convenient identification of roscovitine-like activity both in vitro and in vivo.

IT 481200-98-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; genes showing altered levels of expression in response to inhibitors of cyclin-dependent kinases and their use in screening for novel inhibitors)

RN 481200-98-0 HCAPLUS

CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1, IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392578 HCAPLUS

DOCUMENT NUMBER: 140:405486

TITLE: Polyclonal and monoclonal antibodies specific to phosphorylated insulin receptor substrate-1 and IRS-2 for diagnosis of type 2 diabetes mellitus

INVENTOR(S): Polakiewicz, Roberto; Wu, Jiong; Li, Yu

PATENT ASSIGNEE(S): Cell Signaling Technology, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039963	A2	20040513	WO 2003-US34861	20031029
WO 2004039963	C1	20040729		
WO 2004039963	A3	20050317		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

US 2004097713 A1 20040520 US 2003-694874 20031028

PRIORITY APPLN. INFO.: US 2002-422409P P 20021030

AB The invention discloses newly-discovered phosphorylation sites in human IRS-1 and IRS-2 at serine-1101 and serine-1149 resp., and provides antibodies, both polyclonal and monoclonal, that selectively bind to IRS-1 and/or IRS-2 when phosphorylated at these resp. sites, but do not bind to IRS-1 and/or IRS-2 when not phosphorylated at these resp. sites. The sites are relevant to insulin-resistance in type 2 diabetes. Also

provided are methods for determining the phosphorylation of IRS-1/2 or activity of PKC theta in a biol. sample, by using a detectable reagent, such as the disclosed antibodies, that binds to IRS-1/2 only when phosphorylated at Ser1101/Ser1149. Kits comprising the phosphoIRS-1/2 (Ser1101/1149) antibodies of the invention are also provided.

IT 688069-60-5D, phosphorylated derivs. 688069-62-7D, phosphorylated derivs.  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)  
 (amino acid sequence; polyclonal and monoclonal antibodies specific to phosphorylated insulin receptor substrate-1 and IRS-2 for diagnosis of type 2 diabetes mellitus)  
 RN 688069-60-5 HCAPLUS  
 CN Protein IRS-1 (insulin receptor substrate 1) (human) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 688069-62-7 HCAPLUS  
 CN Protein IRS-1 (insulin receptor substrate 1) (mouse) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:722331 HCAPLUS  
 DOCUMENT NUMBER: 134:53060  
 TITLE: Probing the catalytic mechanism of the **insulin receptor kinase** with a tetrafluorotyrosine-containing peptide substrate  
 AUTHOR(S): Ablooglu, Ararat J.; Till, Jeffrey H.; Kim, Kyonghee; Parang, Keykavous; Cole, Philip A.; Hubbard, Stevan R.; Kohanski, Ronald A.  
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY, 10029, USA  
 SOURCE: Journal of Biological Chemistry (2000), 275(39), 30394-30398  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The interaction of a synthetic tetrafluorotyrosyl peptide substrate with the activated tyrosine **kinase** domain of the **insulin receptor** was studied by steady-state kinetics and x-ray crystallog. The pH-rate profiles indicate that the neutral phenol, rather than the chemical more reactive phenoxide ion, is required for enzyme-catalyzed phosphorylation. The pKa of the tetrafluorotyrosyl hydroxyl is elevated 2 pH units on the enzyme compared with solution, whereas the phenoxide anion species behaves as a weak competitive inhibitor of the tyrosine **kinase**. A structure of the binary enzyme-substrate complex shows the tetrafluorotyrosyl OH group at hydrogen bonding distances from the side chains of Asp1132 and Arg1136, consistent with elevation of the pKa. These findings strongly support a reaction mechanism favoring a dissociative transition state.  
 IT 88201-45-0D, **Insulin receptor tyrosine kinase**, complexes with tetrafluorotyrosine-containing peptide substrate 143376-54-9D, complexes with **insulin receptor tyrosine kinase**  
 RL: PRP (Properties)

(crystal structure; probing the catalytic mechanism of the  
**insulin receptor kinase** with a  
 tetrafluorotyrosine-containing peptide substrate)

RN 88201-45-0 HCAPLUS

CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 143376-54-9 HCAPLUS


CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-  
 threonylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-  
 methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



IT 143376-54-9

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)


(probing the catalytic mechanism of the **insulin receptor kinase** with a tetrafluorotyrosine-containing peptide substrate)

RN 143376-54-9 HCAPLUS


CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT 88201-45-0, **Insulin receptor tyrosine kinase**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(probing the catalytic mechanism of the **insulin receptor kinase** with a tetrafluorotyrosine-containing peptide substrate)

RN 88201-45-0 HCAPLUS

CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:651550 HCAPLUS

DOCUMENT NUMBER: 127:328319

TITLE: Crystal structure of the activated **insulin receptor tyrosine kinase** in complex with peptide substrate and ATP analog

AUTHOR(S): Hubbard, Stevan R.

CORPORATE SOURCE: Dep. Pharm., Skirball Inst. Biomol. Med., New York Univ. Med. Cent., New York, NY, 10016, USA

SOURCE: EMBO Journal (1997), 16(18), 5572-5581  
CODEN: EMJODG; ISSN: 0261-4189

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The crystal structure of the phosphorylated, activated form of **insulin receptor tyrosine kinase** (I) in complex with an 18-residue peptide substrate (KKKLPATGDYMNMSPVGD), and the nonhydrolyzable ATP analog, AMP-PNP, was determined at 1.9 Å resolution. The activation loop (A-loop) of I undergoes a major conformational change upon autophosphorylation of Tyr-1158, Tyr-1162, and Tyr-1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the I

active site. Phosphorylated Tyr-1163 (pTyr-1163) was the key phospho-Tyr group in stabilizing the conformation of the tris-phosphorylated A-loop, whereas pTyr-1158 was completely solvent-exposed, suggesting an availability for interaction with downstream signaling proteins. The YMXM-containing peptide substrate bound as a short anti-parallel  $\beta$ -strand to the C-terminal end of the A-loop, with the Met side-chains occupying 2 hydrophobic pockets on the C-terminal lobe of I. The structure thus reveals the mol. basis for **insulin receptor** activation via autophosphorylation, and provides insights into I substrate specificity and the mechanism of phosphotransfer.

IT 88201-45-0D, **Insulin receptor kinase**

, complexes with peptide substrate and ATP analog 143376-54-9D, complexes with **insulin receptor kinase** and ATP analog

RL: PRP (Properties)

(crystal structure of activated **insulin receptor**

**kinase** in complex with a peptide substrate and an ATP analog)

RN 88201-45-0 HCAPLUS

CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 143376-54-9 HCAPLUS

CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1995:1001748 HCAPLUS  
 DOCUMENT NUMBER: 124:80394  
 TITLE: Substrate specificities of the **insulin** and

**insulin-like growth factor 1 receptor**  
 tyrosine **kinase** catalytic domains

AUTHOR(S): Xu, Bin; Bird, Vincent G.; Miller, W. Todd  
 CORPORATE SOURCE: Sch. Med., State Univ. New York, Stony Brook, NY,  
 11794, USA

SOURCE: Journal of Biological Chemistry (1995), 270(50),  
 29825-30  
 CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Bio  
 logy

DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB To compare the substrate specificities of the **insulin** and  
**insulin-like growth factor 1 (IGF-1) receptor** tyrosine  
**kinases**, the catalytic domains of the enzymes have been expressed  
 in *Escherichia coli* as fusion proteins. The purified proteins have  
**kinase** activity, demonstrating that the catalytic domain of IGF-1  
**receptor**, like that of **insulin receptor**, is  
 active independent of its ligand-binding and transmembrane domains. The  
 specificities of the two enzymes for the divalent cations Mg<sup>2+</sup> and Mn<sup>2+</sup>  
 are indistinguishable. A series of peptides has been prepared that  
 reproduces the major phosphorylation sites of **insulin**  
**receptor** substrate-1, a common substrate for the two  
**receptor** tyrosine **kinases** in vivo. **Insulin**  
 and IGF-1 **receptors** show distinct preferences for these  
 peptides; whereas **insulin receptor** prefers peptides  
 based on Tyr-987 or Tyr-727 of **insulin receptor**  
 substrate-1, the IGF-1 **receptor** preferentially recognizes the  
 Tyr-895 site. The latter site, when phosphorylated, is a binding site for  
 the SH2 domain-containing adaptor protein Grb2. The ability of the two  
**receptor** tyrosine **kinases** to be phosphorylated and  
 activated by v-Src has also been examined. The catalytic activity of IGF-1  
**receptor** is stimulated ≈3.4-fold by treatment with  
 purified v-Src, while **insulin receptor** shows very  
 little effect of Src phosphorylation under these conditions. This  
 observation is relevant to recent findings of IGF-1 **receptor**  
 activation in Src-transformed cells, and may represent one method by which  
 Src amplifies its mitogenic signal. Collectively the data suggest that  
 the catalytic domains of the two **receptor kinases**  
 possess inherently different substrate specificities and signaling  
 potentials.

IT 143376-54-9  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (differential substrate specificities of the **insulin**  
**receptor** and **insulin-like growth factor 1**  
**receptor** tyrosine **kinase** catalytic domains)


RN 143376-54-9 HCAPLUS  
 CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-  
 threonylglycyl-L-α-aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-  
 methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT 88201-45-0, **Insulin receptor tyrosine kinase**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(recombinant; differential substrate specificities of the **insulin receptor** and **insulin-like growth factor 1 receptor tyrosine kinase** catalytic domains)

RN 88201-45-0 HCAPLUS

CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:97466 HCAPLUS

DOCUMENT NUMBER: 120:97466

TITLE: Human skeletal muscle insulin receptor substrate-1: characterization of the cDNA, gene, and chromosomal localization

AUTHOR(S): Araki, Eiichi; Sun, Xiao Jian; Haag, Burritt L., III; Chuang, Lee Ming; Zhang, Yitao; Yang-Feng, Teresa L.; White, Morris F.; Kahn, C. Ronald

CORPORATE SOURCE: Res. Div., Joslin Diabetes Cent., Boston, MA, 02215, USA

SOURCE: Diabetes (1993), 42(7), 1041-54

CODEN: DIAEAZ; ISSN: 0012-1797

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Insulin receptor** substrate-1 is a major substrate of **insulin receptor Tyr kinase**. We have now cloned the IRS-1 cDNA from human skeletal muscle, one of the most important target tissues of **insulin** action, localized and cloned the human IRS-1 gene, and studied the expression of the protein in Chinese hamster ovary cells. Human IRS-1 cDNA encodes a 1242 amino acid sequence

that is 88% identical to rat liver IRS-1. The 14 potential Tyr phosphorylation sites include 6 Tyr-Met-X-Met motifs and 3 Tyr-X-X-Met motifs that are completely conserved in human IRS-1. Human IRS-1 has >50 possible Ser/Thr phosphorylation sites and one potential ATP-binding site close to the NH<sub>2</sub>-terminal. The human IRS-1 gene contains the entire 5'-untranslated region and protein coding region in a single exon and was localized on chromosome 2 q36-37 by in situ hybridization. By Northern blot anal., IRS-1 mRNA is rare and consists of two species of 6.9 and 6 kilobase. By using quant. polymerase chain reaction after reverse transcription of total RNA from human fetal tissues, IRS-1 mRNA could be identified in all tissues. When human IRS-1 cDNA was expressed in Chinese hamster ovary cells, the protein migrated between 170,000-180,000 Mr in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and was rapidly Tyr phosphorylated upon insulin stimulation. Thus, IRS-1 is widely expressed and highly conserved across species and tissues. Compared with rat protein, human IRS-1 contains more potential Ser/Thr phosphorylation sites and only one nucleotide binding site. The entire protein encoding sequence is contained within a single exon.

IT 151086-85-0, Phosphoprotein (human clone  $\lambda$ E36 insulin receptor substrate 1 protein moiety)  
 RL: PRP (Properties)  
 (amino acid sequence and tyrosine phosphorylation sites of)  
 RN 151086-85-0 HCAPLUS  
 CN Phosphoprotein IRS-1 (human clone  $\lambda$ E36 reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 151086-86-1, Phosphoprotein IRS-1 (human clone  $\gamma$ E1 insulin receptor substrate 1 reduced) 151086-87-2, Phosphoprotein IRS-1 (human clone  $\lambda$ E5 insulin receptor substrate 1 reduced)  
 RL: PRP (Properties)  
 (amino acid sequence of)  
 RN 151086-86-1 HCAPLUS  
 CN Phosphoprotein IRS-1 (human clone  $\gamma$ E1 reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 151086-87-2 HCAPLUS  
 CN Phosphoprotein IRS-1 (human clone  $\lambda$ E5 reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:620273 HCAPLUS

DOCUMENT NUMBER: 119:220273

TITLE: Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro

AUTHOR(S): Garcia, Pilar; Shoelson, Steven E.; George, Shaji T.;

Hinds, Duane A.; Goldberg, Allan R.; Miller, W. Todd

CORPORATE SOURCE: Sch. Med., State Univ. New York, Stony Brook, NY, 11794, USA

SOURCE: Journal of Biological Chemistry (1993), 268(33), 25146-51

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several tyrosine phosphorylation sites in the insulin receptor kinase substrate, protein IRS-1, are predicted

to be within Tyr-Met-X-Met (YMXM) motifs, and synthetic peptides corresponding to these sequences are excellent substrates for the **insulin receptor kinase** in vitro. Here, synthetic YMXM-containing peptides are shown to act as substrates for 2 members of the nonreceptor subfamily of tyrosine **kinases**, v-Src and v-Abl (the transforming gene products of Rous sarcoma virus and Abelson murine leukemia virus, resp.). For v-Src, a baculovirus expression system was used which was capable of producing milligram quantities of pure 60-kDa v-Src in *Spodoptera frugiperda* (Sf9) cells. The source of v-Abl was an *Escherichia coli* expression vector that produces a fusion protein of glutathione S-transferase with the abl catalytic domain. The synthetic YMXM-containing peptides had among the highest apparent affinities described to date for either tyrosine **kinase**, with  $K_m$  values as low as 97  $\mu\text{M}$  for v-Src and v-Abl. Comparisons with the results obtained with the **insulin receptor kinase** revealed differences in substrate specificity among the enzymes. In particular, v-Src was more tolerant of substitutions at the Met+1 and Met+3 positions in the YMXM motif than either v-Abl or the **insulin receptor kinase** but was more dependent on the presence of a preceding acidic amino acid. For v-Abl, the presence of threonine at any position in the YMXM motif caused a reduction in catalytic efficiency. Phosphorylated YMXM motifs were recognition elements for binding to the src homol. 2 (SH2) domains of phosphatidylinositol 3'-**kinase** and addnl. proteins; hence, differences in specificity of tyrosine **kinases** toward YMXM-containing proteins may have relevance to downstream signaling events.

IT 143376-54-9

RL: BIOL (Biological study)


(phosphorylation of, by protein tyrosine kinases, kinetics of)

RN 143376-54-9 HCAPLUS


CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



L26 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1993:402479 HCAPLUS  
DOCUMENT NUMBER: 119:2479  
TITLE: Nucleic acid encoding insulin receptor substrate-1  
(IRS-1), IRS-1 protein, diseases, therapy associated

INVENTOR(S): with the metabolism of IRS-1  
Kahn, C. Ronald; White, Morris F.; Rothenberg, Paul  
Louis  
PATENT ASSIGNEE(S): Joslin Diabetes Center, Inc., USA  
SOURCE: PCT Int. Appl., 134 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9213083	A1	19920806	WO 1992-US437	19920117
W: JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
EP 572508	A1	19931208	EP 1992-906151	19920117
R: CH, DE, DK, LI				
US 5260200	A	19931109	US 1992-962023	19921015
US 5621075	A	19970415	US 1993-94948	19930721
PRIORITY APPLN. INFO.:			US 1991-643982	A 19910118
			WO 1992-US437	W 19920117
			US 1992-962023	A3 19921015

AB Mammalian IRS-1 cDNA is cloned and sequenced. This cDNA may be expressed in cells to prepare IRS-1. **Insulin**-related diseases such as diabetes may be diagnosed by measuring aspects of IRS-1 metabolism, e.g. measurement of IRS-1 levels, level of phosphorylation of IRS-1, or **kinase** activity of IRS-1 (no data). Similar measurements may be used to assay the effects of therapeutic agents (no data). Therapeutic treatment of mammals by altering IRS-1 metabolism is claimed. Rat liver IRS-1 cDNA was cloned and sequenced. Phosphorylation of **insulin receptor** and intracellular proteins was examined Pp185, called IRS-1, was found to be phosphorylated by the **receptor**. Phosphatidyl inositol 3-**kinase** activity was associated with the purified IRS-1.

IT **145559-05-3**, Phosphoprotein IRS 1 (rat clone C18/P2-2)  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence of, complete, cloning of cDNA for)

RN **145559-05-3** HCAPLUS

CN Phosphoprotein IRS 1 (rat clone C18/P2-2) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L26 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:527074 HCAPLUS

DOCUMENT NUMBER: 117:127074

TITLE: YMXM motifs of IRS-1 define substrate specificity of the **insulin receptor kinase**

AUTHOR(S): Shoelson, Steven E.; Chatterjee, Swati; Chaudhuri, Manas; White, Morris F.

CORPORATE SOURCE: Brigham Women's Hosp., Harvard Med. Sch., Boston, MA, 02215, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1992), 89(6), 2027-31  
CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Of 34 tyrosine residues in **insulin receptor** substrate



1 (IRS-1), 14 are adjacent to acidic residues, suggesting that they might be phosphorylation sites. Synthetic peptides corresponding to sequences surrounding these tyrosines were used as substrates of the **insulin receptor kinase**. Surprisingly six of these, each within YMXM motifs, were phosphorylated with greatest efficiency ( $K_m$ , 24-92  $\mu M$ ;  $k_{cat}/K_m$ ,  $0.6-2.1 \times 10^4 M^{-1} sec^{-1}$ ). Substituted YMXM peptides revealed a strong preference of the **insulin receptor kinase** for methionine at Y + 1 and Y + 3 positions. When phosphorylated, related YMXM sequences are recognition motifs for binding to proteins with src-homol. (SH2) domains. The combined hydrophobic and flexible nature of methionine side chains adjacent to the targeted tyrosines provides a versatile contact for recognition by diverse proteins involved in signal transduction.

IT 141349-62-4, Phosphoprotein IRS 1 (rat clone C18/S27 protein moiety reduced)  
 RL: BIOL (Biological study)  
 (YMXM motifs of, **insulin receptor kinase** phosphorylation of)  
 RN 141349-62-4 HCAPLUS  
 CN Phosphoprotein IRS 1 (rat clone C18/S27 protein moiety reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IT 88201-45-0, **Insulin receptor kinase**  
 RL: BIOL (Biological study)  
 (insulin receptor substrate-1 recognition by, YMXM motif in)  
 RN 88201-45-0 HCAPLUS  
 CN Kinase (phosphorylating), insulin receptor (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IT 143376-54-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with **insulin receptor kinase**, kinetics of, enzyme recognition motifs in relation to)  
 RN 143376-54-9 HCAPLUS  
 CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L26 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:228381 HCAPLUS

DOCUMENT NUMBER: 116:228381

TITLE: Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein

AUTHOR(S): Sun, Xiao Jian; Rothenberg, Paul; Kahn, C. Ronald; Backer, Jonathan M.; Araki, Eiichi; Wilden, Peter A.; Cahill, Deborah A.; Goldstein, Barry J.; White, Morris F.

CORPORATE SOURCE: Dep. Med., Harvard Med. Sch., Boston, MA, 02215, USA

SOURCE: Nature (London, United Kingdom) (1991), 352(6330), 73-7

CODEN: NATUAS; ISSN: 0028-0836

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The **insulin receptor** substrate IRS-1, which encodes a component of the pp185 band was cloned. IRS-1 contains over ten potential tyrosine phosphorylation sites, six of which are in Tyr-Met-X-Met motifs. During **insulin** stimulation, the IRS-1 protein undergoes tyrosine phosphorylation and binds phosphatidylinositol 3-**kinase**, suggesting that IRS-1 acts as a multisite docking protein to bind signal-transducing mols. containing Src-homol. 2 and Src-homol.-3 domains. Thus IRS-1 may link the **insulin receptor**

IT 141349-62-4, Phosphoprotein IRS 1 (rat clone C18/S27 protein moiety reduced)

RL: PRP (Properties)

(amino acid sequence of, complete)

RN 141349-62-4 HCAPLUS

CN Phosphoprotein IRS 1 (rat clone C18/S27 protein moiety reduced) (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=&gt; =&gt; d stat que 127

```

L1      161 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("COLE PHIL"/AU OR "COLE
        PHILIP"/AU OR "COLE PHILIP A"/AU OR "COLE PHILIP ARTHUR"/AU)
        OR COLE P/AU OR COLE P A/AU
L2      57  SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("PARANG K"/AU OR "PARANG
        KAYKAVOOS"/AU OR "PARANG KEYKAVOVS"/AU)
L3      8   SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ABLOOGLU ARARAT J"/AU OR
        "ABLOOGLU ARARAT JAN"/AU OR "ABLOOGU ARARAT"/AU) NOT L2
L4      45  SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("KOHANSKI R"/AU OR "KOHANSKI
        R A"/AU OR "KOHANSKI RON"/AU OR "KOHANSKI RON A"/AU OR
        "KOHANSKI RONALD"/AU OR "KOHANSKI RONALD A"/AU) NOT (L2 OR L3)
L5      22  SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("COURTNEY A"/AU OR "COURTNEY
        A D"/AU OR ("COURTNEY ALIYA"/AU OR "COURTNEY ALIYA D"/AU)) NOT
        (L2 OR L3 OR L4)
L6      151 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT (L2 OR L3 OR L4 OR L5)
L7      64  SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6 AND (BISUB? OR INHIBITOR
        OR KINASE)
L15     STR

```



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

```

L17      125972 SEA FILE=REGISTRY SSS FUL L15
L18      STR

```



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 18  
 GGCAT IS PCY AT 19  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 25

## STEREO ATTRIBUTES: NONE

L19 6 SEA FILE=REGISTRY SUB=L17 SSS FUL L18  
L20 45 SEA FILE=REGISTRY ABB=ON PLU=ON KKKLPATGD|MNMSPVGD/SQSP  
L21 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("INSULIN RECEPTOR KINASE"/CN  
OR "INSULIN RECEPTOR KINASE (SYCON RAPHANUS ISOFORM 1)"/CN OR  
"INSULIN RECEPTOR KINASE (SYCON RAPHANUS ISOFORM 2)"/CN OR  
"INSULIN RECEPTOR KINASE (SYCON RAPHANUS ISOFORM 3)"/CN)  
L22 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L19  
L23 41 SEA FILE=HCAPLUS ABB=ON PLU=ON L20  
L24 6708 SEA FILE=HCAPLUS ABB=ON PLU=ON L21 OR INSULIN(L) RECEPTOR(L) KI  
NASE  
L25 17 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L23  
L26 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L25 NOT L22  
L27 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L23 NOT (L2 OR L3 OR L4 OR L5  
OR L7 OR L22 OR L26)

=> d ibib abs hitstr l27 1-24

L27 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:588338 HCAPLUS

DOCUMENT NUMBER: 143:72805

TITLE: Polymorphisms in known genes associated with type II  
diabetes and obesity and methods of detection and uses  
INVENTOR(S): Venter, J. Craig; Zhang, Jinghui N.; Liu, Xiangjun;  
Rowe, William; Cravchik, Anibal; Kalush, Francis;  
Naik, Ashwinikumar; Subramanian, Gangadharan; Woodage,  
Trevor

PATENT ASSIGNEE(S): Applera Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 31 pp., Cont. of U.S. Ser. No.  
948,947, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005147987	A1	20050707	US 2004-893315	20040719
PRIORITY APPLN. INFO.:			US 2000-231397P	P 20000908
			US 2001-948947	B1 20010910

AB The present invention is based on the discovery of 1988 novel  
polymorphisms (SNPs) in 61 genes known in the art to contribute to type II  
diabetes and obesity. Such polymorphisms can lead to a variety of  
disorders that are mediated/modulated by a variant type II diabetes and  
obesity associated protein. The present invention provides reagents used for  
detecting and expressing the variant nucleic acid/protein sequence as well  
as methods of identifying and using these variants.

IT 855029-97-9

RL: ADV (Adverse effect, including toxicity); ANT (Analyte); DGN  
(Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL  
(Biological study); USES (Uses)

(amino acid sequence; polymorphisms in known genes associated with type II  
diabetes and obesity and methods of detection and uses)

RN 855029-97-9 HCAPLUS  
 CN Type II diabetes and obesity-associated protein (human clone  
 US20050147987-SEQID-97)) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:547044 HCAPLUS  
 DOCUMENT NUMBER: 143:76253  
 TITLE: cDNA microarray technology identifies obesity-related  
 gene expression profiles in fat tissue, which may be  
 useful for development of obesity treatments in humans  
 INVENTOR(S): Clerc, Roger G.; Duchateau-Nguyen, Guillemette;  
 Gardes, Christophe; Mizrahi, Jacques; Ostenson,  
 Claes-Goran  
 PATENT ASSIGNEE(S): Switz.  
 SOURCE: U.S. Pat. Appl. Publ., 21 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005136465	A1	20050623	US 2004-19829	20041222
EP 1548445	A2	20050629	EP 2004-29641	20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CA 2487098	AA	20050622	CA 2004-2487098	20041221
JP 2005176846	A2	20050707	JP 2004-370470	20041222
PRIORITY APPLN. INFO.:			EP 2003-104902	A 20031222

AB The present invention relates to novel targets for identifying compds.  
 that may be useful for the prevention and treatment of obesity. CDNA  
 microarray anal., using RNA extracted from human fat tissue, was performed to  
 identify obesity-related changes in gene expression profiles. A total of  
 146 candidate gene or protein sequences were identified. The goal of this  
 work is to develop preventions or treatments for obesity in humans.

IT 855025-84-2  
 RL: BSU (Biological study, unclassified); PRP (Properties); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino acid sequence; cDNA microarray technol. identifies  
 obesity-related gene expression profiles in fat tissue, which may be  
 useful for development of obesity treatments in humans)

RN 855025-84-2 HCAPLUS  
 CN Protein IRS-1 (insulin receptor substrate 1) (human 1242-amino acid) (9CI)  
 (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:497224 HCAPLUS  
 DOCUMENT NUMBER: 143:38377  
 TITLE: Sequences of a human aspartyl (asparaginyl)  
 $\beta$ -hydroxylase (HAAH) and use for diagnosis and  
 treatment of pancreatic cancer  
 INVENTOR(S): Wands, Jack R.; De La Monte, Suzanne M.; Deutch, Alan  
 H.; Ghanbari, Hossein A.  
 PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 436,184.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123545	A1	20050609	US 2004-918685	20040813
US 2003031670	A1	20030213	US 1999-436184	19991108
PRIORITY APPLN. INFO.:			US 1999-436184	A2 19991108
			US 2003-494896P	P 20030813

AB The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymic activity of human aspartyl (asparaginy)  $\beta$ -hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex.

IT 853285-80-0

RL: PRP (Properties)

(unclaimed protein sequence; sequences of a human aspartyl (asparaginy)  $\beta$ -hydroxylase (HAAH) and use for diagnosis and treatment of pancreatic cancer)

RN 853285-80-0 HCAPLUS

CN 5: PN: US20050123545 SEQID: 5 unclaimed protein (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:158511 HCAPLUS

DOCUMENT NUMBER: 142:259951

TITLE: Diagnosis and treatment of pancreatic carcinoma by detecting and inhibiting aspartylpeptide  $\beta$ -di-oxygenase

INVENTOR(S): Wands, Jack R.; De La Monte, Suzanne M.; Deutch, Alan H.; Ghanbari, Hossein A.

PATENT ASSIGNEE(S): Rhode Island Hospital, USA

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016281	A2	20050224	WO 2004-US26336	20040813
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-494896P P 20030813  
AB The invention features a method of inhibiting tumor growth and/or tumor  
invasiveness in a mammal by administering to a mammal a compound (e.g., an  
antagonistic antibody) which inhibits expression or enzymic activity of  
human aspartylpeptide  $\beta$ -di-oxygenase. The invention also features a  
method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic  
cancer) in a mammal by contacting a tissue or bodily fluid from the mammal  
with an antibody which binds to a HAAH polypeptide under conditions  
sufficient to form an antigen-antibody complex and/or detecting the  
antigen-antibody complex.  
IT **845703-57-3**  
RL: PRP (Properties)  
(unclaimed protein sequence; diagnosis and treatment of pancreatic  
carcinoma by detecting and inhibiting aspartylpeptide  
 $\beta$ -di-oxygenase)  
RN 845703-57-3 HCAPLUS  
CN 6: PN: WO2005016281 SEQID: 5 unclaimed protein (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STM  
ACCESSION NUMBER: 2005:9198 HCAPLUS  
DOCUMENT NUMBER: 142:91478  
TITLE: Gene expression profiles in rheumatoid arthritis and  
osteoarthritis and their use in diagnosis and  
monitoring disease progress  
INVENTOR(S): Blaess, Stefan  
PATENT ASSIGNEE(S): Germany  
SOURCE: Ger. Offen., 89 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 10328033	A1	20050105	DE 2003-10328033	20030619

PRIORITY APPLN. INFO.: DE 2003-10328033 20030619  
AB DNA microarrays that can be used to diagnose and monitor rheumatoid  
arthritis (RA) and osteoarthritis (OA) are described. Gene expression is  
analyzed using software that can compare m-dimensional gene expression  
profiles multi-parametrical with n-dimensional reference gene expression  
profiles for diagnostics, sub diagnostics classification and therapy  
decisions.  
IT **481200-98-0**  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
(Biological study)  
(amino acid sequence; gene expression profiles in rheumatoid arthritis  
and osteoarthritis and their use in diagnosis and monitoring disease  
progress)  
RN 481200-98-0 HCAPLUS  
CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1,  
IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*



L27 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:979655 HCAPLUS  
DOCUMENT NUMBER: 142:18205  
TITLE: The status, quality, and expansion of the NIH full-length cDNA project: The mammalian gene collection (MGC)  
AUTHOR(S): Gerhard, Daniela S.; Wagner, Lukas; Feingold, Elise A.; Shenmen, Carolyn M.; Grouse, Lynette H.; Schuler, Greg; Klein, Steven L.; Old, Susan; Rasooly, Rebekah; Good, Peter; Guyer, Mark; Peck, Allicon M.; Derge, Jeffery G.; Lipman, David; Collins, Francis S.  
CORPORATE SOURCE: The MGC Project Team, NIH, USA  
SOURCE: Genome Research (2004), 14(10b), 2121-2127  
CODEN: GEREFS; ISSN: 1088-9051  
PUBLISHER: Cold Spring Harbor Laboratory Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The National Institutes of Health's Mammalian Gene Collection (MGC) project was designed to generate and sequence a publicly accessible cDNA resource containing a complete open reading frame (ORF) for every human and mouse gene. The project initially used a random strategy to select clones from a large number of cDNA libraries from diverse tissues. Candidate clones were chosen based on 5'-EST sequences, and then fully sequenced to high accuracy and analyzed by algorithms developed for this project. Currently, more than 11,000 human and 10,000 mouse genes are represented in MGC by at least one clone with a full ORF. The random selection approach is now reaching a saturation point, and a transition to protocols targeted at the missing transcripts is now required to complete the mouse and human collections. Comparison of the sequence of the MGC clones to reference genome sequences reveals that most cDNA clones are of very high sequence quality, although it is likely that some cDNAs may carry missense variants as a consequence of exptl. artifact, such as PCR, cloning, or reverse transcriptase errors. Recently, a rat cDNA component was added to the project, and ongoing frog (Xenopus) and zebrafish (Danio) cDNA projects were expanded to take advantage of the high-throughput MGC pipeline. The sequence data for the full-length clones from this study have been submitted to GenBank/EMBL/DDBJ under accession nos. BC000001-BC077073. [This abstr record is one of 39 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].  
IT 625303-37-9, GenBank AAH53895  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; status, quality, and expansion of the NIH full-length cDNA project and mammalian gene collection (MGC))  
RN 625303-37-9 HCAPLUS  
CN Insulin receptor substrate 1 (human clone MGC:61462 IMAGE:6144252) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:449883 HCAPLUS  
DOCUMENT NUMBER: 140:402911  
TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications  
INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.  
PATENT ASSIGNEE(S): Duke University, USA  
SOURCE: PCT Int. Appl., 886 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XA33946	20031024
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004038376	A2	20040506	WO 2003-US33946	20031024
WO 2004038376	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

## PRIORITY APPLN. INFO.:

US 2002-420729P	P	20021024
US 2002-421062P	P	20021025
US 2002-421102P	P	20021025
US 2002-424701P	P	20021108
US 2002-424715P	P	20021108
US 2002-424718P	P	20021108
US 2002-425256P	P	20021112
US 2003-448461P	P	20030221
US 2003-448462P	P	20030221
US 2003-457877P	P	20030327
US 2003-458373P	P	20030331
WO 2003-US33946	A	20031024

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple patterns of expression of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal

predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assoc. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

IT 481200-98-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; binary prediction tree modeling with many predictors and its uses in clin. and genomic applications)

RN 481200-98-0 HCAPLUS

CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1, IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:219931 HCAPLUS

DOCUMENT NUMBER: 140:248186

TITLE: Use of patterns of gene expression to identify tissue types and in disease diagnosis and prognosis

INVENTOR(S): Glinskii, Guennadi V.

PATENT ASSIGNEE(S): Sidney Kimmel Cancer Center, USA

SOURCE: U.S. Pat. Appl. Publ., 209 pp., which which which which  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004053317	A1	20040318	US 2003-660434	20030910
CA 2498418	AA	20040325	CA 2003-2498418	20030910
WO 2004025258	A2	20040325	WO 2003-US28707	20030910
WO 2004025258	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1552293	A2	20050713	EP 2003-759240	20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005142573	A1	20050630	US 2004-861003	20040603
PRIORITY APPLN. INFO.:			US 2002-410018P	P 20020910
			US 2002-411155P	P 20020916

US 2002-429168P P 20021125  
US 2003-444348P P 20030131  
US 2003-460826P P 20030403  
US 2003-660434 A1 20030910  
WO 2003-US28707 W 20030910

AB Methods of using quant. anal. of array hybridizations to identify normal and diseased tissue in the diagnosis and prognosis of disease are described. The methods segregate individual samples into distinct classes using quant. measurements of expression values for selected sets of genes in individual samples compared to a reference standard. Samples displaying pos. and neg. correlations of the gene expression values with the reference standard samples

exhibit distinct behaviors and pathohistol. features. Also disclosed are methods for identifying sets of genes whose expression patterns are correlated with a phenotype. Such sets are useful for characterizing cellular differentiation pathways and states and for identifying potential drug discovery targets. Panels for diagnosis and determination of risk of invasive and metastatic forms of lung, prostate and breast cancer are identified. Similarly, panels indicating recurrence of the cancers and poor prognostic outcomes are identified.

IT 481200-98-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)  
(amino acid sequence; use of patterns of gene expression to identify tissue types and in disease diagnosis and prognosis)

RN 481200-98-0 HCAPLUS

CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1, IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:80714 HCAPLUS

DOCUMENT NUMBER: 140:141434

TITLE: Human protein sequences of protein complexes of cellular networks underlying the development of cancer and other diseases

INVENTOR(S): Merino, Alejandro; Bouwmeester, Tewis; Bauer, Andreas; Drewes, Gerard; Marzioch, Martina; Kruse, Ulrich; Superti-Furga, Giulio; Eberhard, Dirk; Ruffner, Heinz; Hobson, Scott; Helftenbein, Gerd; Cruciat, Cristina

PATENT ASSIGNEE(S): Cellzome Ag, Germany; et al.

SOURCE: PCT Int. Appl., 810 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004009622	A2	20040129	WO 2003-EP7835	20030718
WO 2004009622	A3	20040910		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2002-16109 A 20020719  
EP 2002-16111 A 20020719  
EP 2002-16123 A 20020719  
EP 2002-16128 A 20020719  
EP 2002-16427 A 20020722

AB The present invention relates to protein complexes involved in cellular processes which have been shown to be critical for the development of various forms of cancer, component proteins of the said complexes, fragments and derivs. of the component proteins, and antibodies specific to the complexes. The present invention also relates to methods for use of the complexes and their interacting proteins in, inter alia, screening, diagnosis, and therapy, as well as to methods of preparing the complexes.

IT 652210-78-1, Protein (human)

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; human protein sequences of protein complexes of cellular networks underlying the development of cancer and other diseases)

RN 652210-78-1 HCAPLUS

CN Protein (human) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:942767 HCAPLUS

DOCUMENT NUMBER: 140:40262

TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics

INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal

PATENT ASSIGNEE(S): Duke University, USA

SOURCE: PCT Int. Appl., 408 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
<p>W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
<p>W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW</p>				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-374547P P 20020423  
US 2002-420784P P 20021024  
US 2002-421043P P 20021025  
US 2002-424680P P 20021108  
WO 2002-US38221 A 20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 481200-98-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics)

RN 481200-98-0 HCAPLUS

CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1, IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:942764 HCAPLUS

DOCUMENT NUMBER: 140:3792

TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics

INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal

PATENT ASSIGNEE(S): Duke University, USA

SOURCE: PCT Int. Appl., 408 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XA38221	20021112
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP,  
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
 TR, TT, UA, UG, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-374547P P 20020423  
 US 2002-420784P P 20021024  
 US 2002-421043P P 20021025  
 US 2002-424680P P 20021108  
 WO 2002-US38221 A 20021112

AB Genes whose expression is correlated with a determinant of an  
 atherosclerotic phenotype are provided. Also provided are methods of  
 using the subject atherosclerotic determinant genes in diagnosis and  
 treatment methods, as well as drug screening methods. In addition, reagents  
 and kits thereof that find use in practicing the subject methods are  
 provided. Also provided are methods of determining whether a gene is  
 correlated

with a disease phenotype, where correlation is determined using a Bayesian  
 anal.

IT 481200-98-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)

(amino acid sequence; genes expressed in atherosclerotic tissue and  
 their use in diagnosis and pharmacogenetics)

RN 481200-98-0 HCAPLUS

CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1,  
 IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:913280 HCAPLUS

DOCUMENT NUMBER: 139:379453

TITLE: Genes showing altered patterns of expression in  
 multiple sclerosis and their diagnostic and  
 therapeutic uses

INVENTOR(S): Dangond, Fernando; Hwang, Daehee

PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095618	A2	20031120	WO 2003-US14462	20030507
WO 2003095618	A3	20041021		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,			
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,			
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2004018522 A1 20040129 US 2003-430762 20030506  
 PRIORITY APPLN. INFO.: US 2002-379284P P 20020509  
 US 2003-430762 A1 20030506

AB The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression. Genes were identified by determination of expression profiling. A large number of genes showing altered patterns of expression were identified, with the most discriminatory genes being those for: phosphatidylinositol transfer protein, inducible nitric oxide synthase, CIC-1 (CLCN1) muscle chloride channel protein, placental bikunin (AMBP), receptor kinase ligand LERK-3/Ephrin-A3, GATA-4, thymopoietin, transcription factor E2f-2, S-adenosylmethionine synthetase, carcinoembryonic antigen, the ret oncogene, a G protein-linked receptor (clone GPCR W), GTP- binding protein RALB, tyrosine kinase Syk, LERK-2/Ephrin-B1, ELK1 tyrosine kinase oncogene, transcription factor SL1, phospholipase C, gastricsin (progastricsin), and the D13S824E locus.

IT 481200-98-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; genes showing altered patterns of expression in multiple sclerosis and their diagnostic and therapeutic uses)

RN 481200-98-0 HCAPLUS

CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1, IRS-1) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:551621 HCAPLUS

DOCUMENT NUMBER: 139:129924

TITLE: CRISSP method for detecting remote sequence homologs, human protein kinase sequences identified with the method, and diagnostic and drug screening uses

INVENTOR(S): Grigoriev, Igor Vyacheslavovich; Sudarsanam, Sucha

PATENT ASSIGNEE(S): Sugan Inc., USA

SOURCE: PCT Int. Appl., 491 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057841	A2	20030717	WO 2002-US41687	20021231
WO 2003057841	C1	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			



US 2004009549 A1 20040115 US 2002-334143 20021231  
 EP 1576087 A2 20050921 EP 2002-799335 20021231  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

WO 2004069154 A2 20040819 WO 2003-US2234 20030128  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-343169P P 20011231  
 WO 2002-US41687 W 20021231

AB The present invention relates to novel methods for detecting remote polypeptide homologs comprising anal. of conserved secondary structure pattern in a protein family, and conserved active site amino acid residues. The anal. are used to identify conserved residues embedded into the secondary structure pattern (CRISSP), which are used to detect remote homologs of the referent protein family. The present invention also relates to human protein kinases and protein kinase-like enzymes, nucleotide sequences encoding the protein kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various protein kinase-related diseases and conditions. The CRISSP method has been applied to the human genome database and 87 novel kinase sequences have been identified. The partial or complete sequences of these kinases are provided together with their classification, predicted protein structure, and encoding nucleotide sequences. Through the use of a bioinformatics strategy, mammalian protein kinases have been identified and their protein structure predicted.

IT 564491-02-7DP, subfragments are claimed  
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (amino acid sequence; CRISSP method for detecting remote sequence homologs, human protein kinase sequences identified with the method, and diagnostic and drug screening uses)

RN 564491-02-7 HCAPLUS

CN Protein (human gene 36909 protein kinase sequence homolog fragment) (9CI)  
 (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:7680 HCAPLUS

DOCUMENT NUMBER: 138:164521

TITLE: Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs

AUTHOR(S): Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nikaido, I.; Osato, N.; Saito, R.; Suzuki, H.; Yamanaka, I.; Kiyosawa, H.; Yagi, K.; Tomaru, Y.; Hasegawa, Y.; Nogami, A.; Schoenbach, C.; Gojobori, T.; Baldarelli, R.; Hill, D. P.; Bult, C.; Hume, D. A.; Quackenbush, J.; Schriml, L. M.; Kanapin, A.; Matsuda, H.; Batalov, S.; Beisel, K. W.; Blake, J. A.; Bradt, D.; Brusic, V.; Chothia, C.; Corbani, L.

E.; Cousins, S.; Dalla, E.; Dragani, T. A.; Fletcher, C. F.; Forrest, A.; Frazer, K. S.; Gaasterland, T.; Gariboldi, M.; Gissi, C.; Godzik, A.; Gough, J.; Grimmond, S.; Gustincich, S.; Hirokawa, N.; Jackson, I. J.; Jarvis, E. D.; Kanai, A.; Kawaji, H.; Kawasaki, Y.; Kedzierski, R. M.; King, B. L.; Konagaya, A.; Kurochkin, I. V.; Lee, Y.; Lenhard, B.; Lyons, P. A.; Maglott, D. R.; Maltais, L.; Marchionni, L.; McKenzie, L.; Miki, H.; Nagashima, T.; Numata, K.; Okido, T.; Pavan, W. J.; Perte, G.; Pesole, G.; Petrovsky, N.; Pillai, R.; Pontius, J. U.; Qi, D.; Ramachandran, S.; Ravasi, T.; Reed, J. C.; Reed, D. J.; Reid, J.; Ring, B. Z.; Ringwald, M.; Sandelin, A.; Schneider, C.; Semple, C. A. M.; Setou, M.; Shimada, K.; Sultana, R.; Takenaka, Y.; Taylor, M. S.; Teasdale, R. D.; Tomita, M.; Verardo, R.; Wagner, L.; Wahlestedt, C.; Wang, Y.; Watanabe, Y.; Wells, C.; Wilming, L. G.; Wynshaw-Boris, A.; Yanagisawa, M.; Yang, I.; Yang, L.; Yuan, Z.; Zavolan, M.; Zhu, Y.; Zimmer, A.; Carninci, P.; Hayatsu, N.; Hirozane-Kishikawa, T.; Konno, H.; Nakamura, M.; Sakazume, N.; Sato, K.; Shiraki, T.; Waki, K.; Kawai, J.; Aizawa, K.; Arakawa, T.; Fukuda, S.; Hara, A.; Hashizume, W.; Imotani, K.; Ishii, Y.; Itoh, M.; Kagawa, I.; Miyazaki, A.; Sakai, K.; Sasaki, D.; Shibata, K.; Shinagawa, A.; Yasunishi, A.; Yoshino, M.; Waterston, R.; Lander, E. S.; Rogers, J.; Birney, E.; Hayashizaki, Y.

## CORPORATE SOURCE:

Laboratory for Genome Exploration Research Group,  
RIKEN Genomic Sciences Center (GSC), Yokohama  
Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,  
Kanagawa, 230-0045, Japan

## SOURCE:

Nature (London, United Kingdom) (2002), 420(6915),  
563-573

CODEN: NATUAS; ISSN: 0028-0836

## PUBLISHER:

Nature Publishing Group

## DOCUMENT TYPE:

Journal

## LANGUAGE:

English

AB Only a small proportion of the mouse genome is transcribed into mature mRNA transcripts. There is an international collaborative effort to identify all full-length mRNA transcripts from the mouse, and to ensure that each is represented in a phys. collection of clones. The manual annotation of 60,770 full-length mouse cDNA sequences is now reported. These are clustered into 33,409 'transcriptional units', contributing 90.1% of a newly established mouse transcriptome database. Of these transcriptional units, 4258 are new protein-coding and 11,665 are new non-coding messages, indicating that non-coding RNA is a major component of the transcriptome. Forty-one percent of all transcriptional units showed evidence of alternative splicing. In protein-coding transcripts, 79% of splice variations altered the protein product. Whole-transcriptome analyses resulted in the identification of 2431 sense-antisense pairs. The present work, completely supported by phys. clones, provides the most comprehensive survey of a mammalian transcriptome so far, and is a valuable resource for functional genomics. The cDNA sequences are deposited in GenBank/EMBL/DDBJ under accession nos. AK002213-AK021412, AK027261-AK054560, AK075567-AK090394, and AK117103-AK117104. [This abstract record is one of thirty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

## IT 493580-91-9

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(amino acid sequence; anal. of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs)

RN 493580-91-9 HCAPLUS

CN Protein (mouse strain C57BL/6J clone B130064P13 1231-amino acid) (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:977994 HCAPLUS

DOCUMENT NUMBER: 138:49932

TITLE: Antisense oligonucleotides for diagnosis and treatment of angiogenesis-related disorders by inhibition of genes encoding IRS-1 proteins

INVENTOR(S): Al-Mahmood, Salman

PATENT ASSIGNEE(S): Gene Signal, Iraq

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002103014	A2	20021227	WO 2002-FR2067	20020614
WO 2002103014	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2826010	A1	20021220	FR 2001-7805	20010614
FR 2826010	B1	20050225		
CA 2451874	AA	20021227	CA 2002-2451874	20020614
EP 1409672	A2	20040421	EP 2002-751246	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004538272	T2	20041224	JP 2003-505336	20020614
US 2004162257	A1	20040819	US 2003-735512	20031212
PRIORITY APPLN. INFO.:			FR 2001-7805	A 20010614
			WO 2002-FR2067	W 20020614
AB The invention relates to pharmaceutical compns. which inhibit the formation of capillary tubes by endothelial cells, comprising at least one oligonucleotide which can inhibit the expression of the IRS-1 (insulin receptor substrate 1) protein. According to the invention, the oligonucleotides are embodied as anti-angiogenesis agents. Said pharmaceutical compns. are particularly useful in treating angiogenesis-related pathologies.				
IT 479165-81-6				
RL: PRP (Properties)				
(unclaimed protein sequence; antisense oligonucleotides for diagnosis and treatment of angiogenesis-related disorders by inhibition of genes encoding IRS-1 proteins)				

RN 479165-81-6 HCAPLUS  
 CN 29: PN: WO02103014 SEQID: 29 unclaimed protein (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:814183 HCAPLUS  
 DOCUMENT NUMBER: 137:334056  
 TITLE: cDNA and protein sequence of human protein IRSAL and  
 the their uses in screening of drugs for treatment of  
 diabetes  
 INVENTOR(S): Takahashi, Shin-Ichiro; Hakuno, Fumihiko; Kurihara,  
 Shigekazu  
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083730	A1	20021024	WO 2002-JP3579	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2001-111864	A 20010410

AB This invention provides cDNA and protein sequence of human insulin  
 receptor substrate associated LIM domain containing protein, IRSAL. The IRSAL  
 protein exhibits activity of modifying the physiolo. activity of insulin  
 and regulating the intake of carbohydrate into cells. Specifically, the  
 IRSAL regulates the insulin mediated signal transduction by regulation of  
 the tyrosine phosphorylation of insulin receptor and insulin receptor  
 substrate. The IRSAL can be used in screening of drugs for treatment of  
 diabetes.

IT 473863-40-0

RL: PRP (Properties)  
 (unclaimed protein sequence; cDNA and protein sequence of human protein  
 IRSAL and the their uses in screening of drugs for treatment of  
 diabetes)

RN 473863-40-0 HCAPLUS

CN 1: PN: WO02083730 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:616205 HCAPLUS  
 DOCUMENT NUMBER: 137:184452  
 TITLE: Diagnosis and treatment of malignant neoplasms  
 INVENTOR(S): Wands, Jack R.; De La Monte, Suzanne M.; Deutch, Alan

H.; Ghanbari, Hossein A.  
 PATENT ASSIGNEE(S): Rhode Island Hospital, USA  
 SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U. S.  
 Ser. No. 436,184.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002110559	A1	20020815	US 2001-859604	20010517
US 6835370	B2	20041228		
US 2003031670	A1	20030213	US 1999-436184	19991108
US 2002102263	A1	20020801	US 2001-903248	20010711
US 6783758	B2	20040831		
US 2002114810	A1	20020822	US 2001-903063	20010711
US 6815415	B2	20041109		
US 2002114811	A1	20020822	US 2001-903216	20010711
US 6812206	B2	20041102		
US 2002122802	A1	20020905	US 2001-903199	20010711
US 6797696	B2	20040928		
US 2002146421	A1	20021010	US 2001-903023	20010711
CA 2447367	AA	20021121	CA 2002-2447367	20020517
WO 2002092782	A2	20021121	WO 2002-US15814	20020517
WO 2002092782	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1429797	A2	20040623	EP 2002-731861	20020517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005501001	T2	20050113	JP 2002-589650	20020517
US 2005113329	A1	20050526	US 2004-20965	20041223
PRIORITY APPLN. INFO.:				
			US 1999-436184	A2 19991108
			US 2001-859604	A 20010517
			WO 2002-US15814	W 20020517
AB	The authors disclose a method for diagnosing and inhibiting growth of a malignant neoplasm in a mammal by contacting a cell or a bodily fluid of the mammal with an antibody which binds to an human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide. Methods of immunization to generate an HAAH-specific immune response are also within the invention.			
IT	448985-00-0 RL: PRP (Properties) (unclaimed protein sequence; diagnosis and treatment of malignant neoplasms)			
RN	448985-00-0 HCAPLUS			
CN	4: PN: US20020110559 SEQID: 5 unclaimed protein (9CI) (CA INDEX NAME)			

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:360288 HCAPLUS

DOCUMENT NUMBER: 135:2206

TITLE: Diagnosis and treatment of malignant neoplasms by detecting and inhibiting aspartyl (asparaginy)  $\beta$ -hydroxylase

INVENTOR(S): Wands, Jack R.; De la Monte, Suzanne M.; Ince, Nedim; Carlson, Rolf I.

PATENT ASSIGNEE(S): Rhode Island Hospital, a Lifespan Partner, USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035102	A2	20010517	WO 2000-US30738	20001108
WO 2001035102	A3	20020912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003031670	A1	20030213	US 1999-436184	19991108
CA 2390374	AA	20010517	CA 2000-2390374	20001108
EP 1259813	A2	20021127	EP 2000-978436	20001108
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003519365	T2	20030617	JP 2001-536582	20001108
US 2002102263	A1	20020801	US 2001-903248	20010711
US 6783758	B2	20040831		
US 2002114810	A1	20020822	US 2001-903063	20010711
US 6815415	B2	20041109		
US 2002114811	A1	20020822	US 2001-903216	20010711
US 6812206	B2	20041102		
US 2002122802	A1	20020905	US 2001-903199	20010711
US 6797696	B2	20040928		
US 2002146421	A1	20021010	US 2001-903023	20010711
PRIORITY APPLN. INFO.:			US 1999-436184	A2 19991108
			WO 2000-US30738	W 20001108

AB The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginy)  $\beta$ -hydroxylase (HAAH) and methods of treating malignant neoplasms by inhibiting HAAH. Methods of inhibiting tumor growth by contacting a tumor cell with an HAAH antisense nucleic acid are also included.

IT 151086-85-0, Phosphoprotein IRS-1 (human clone  $\lambda$ E36 reduced)

RL: PRP (Properties)

(unclaimed protein sequence; diagnosis and treatment of malignant neoplasms by detecting and inhibiting aspartyl (asparaginy)  $\beta$ -hydroxylase)

RN 151086-85-0 HCAPLUS

CN Phosphoprotein IRS-1 (human clone  $\lambda$ E36 reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:303256 HCAPLUS

DOCUMENT NUMBER: 130:322151

TITLE: Proteins having a PI domain that interacts with the amyloid protein precursor, and their use in the treatment and prevention of Alzheimer's and other neurodegenerative diseases

INVENTOR(S): Sabo, Shasta; Buxbaum, Joseph; Greengard, Paul

PATENT ASSIGNEE(S): The Rockefeller University, USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921995	A1	19990506	WO 1998-US22523	19981023
W: AU, CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9911979	A1	19990517	AU 1999-11979	19981023
PRIORITY APPLN. INFO.:			US 1997-957660	A 19971024
			US 1998-62085	A 19980417
			WO 1998-US22523	W 19981023

AB The invention discloses the first demonstration that a polypeptide containing a phosphotyrosine interaction (PI) domain interacts with the cytoplasmic domain of the Alzheimer amyloid protein precursor (APP) and that this binding regulates production of beta amyloid (A $\beta$ ) by a cell. Thus, by intervening in this interaction, APP processing and trafficking, and hence the progression and/or onset of Alzheimer's disease, can be inhibited or prevented. Hence, the invention provides a cell line for screening agents capable of modulating the interaction of APP with a protein having a PI domain, wherein said cell line over-expresses both APP and the protein. The cell line of the invention is preferably derived from Madin-Darby canine kidney (MDCK) cells but can also be derived from other mammalian cells. In an embodiment of the invention, a MDCK-derived cell line that over-expresses APP and rat Fe65, a brain enriched protein of unknown function which binds to the NPTY sequence in the cytoplasmic tail of APP, is provided. The invention further provides sequences of proteins having PI domains and methods for their use in compns. for the treatment and/or prevention of neurodegenerative diseases, such as Alzheimer's disease and dementia.

IT 151086-87-2, Phosphoprotein IRS-1 (human clone  $\lambda$ E5 reduced)

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(amino acid sequence; proteins having a PI domain that interacts with the amyloid protein precursor, and their use in the treatment and prevention of Alzheimer's and other neurodegenerative diseases)

RN 151086-87-2 HCAPLUS

CN Phosphoprotein IRS-1 (human clone  $\lambda$ E5 reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:916029 HCAPLUS

DOCUMENT NUMBER: 124:47072

TITLE: Cloning of a cDNA encoding a 190-kDa insulin receptor substrate-1-like protein of simian COS cells

AUTHOR(S): Wang, Lihong; Hayashi, Hideki; Mitani, Yasumasa; Ishii, Kazuo; Ohnishi, Tetsuo; Niwa, Yasuharu; Kido, Hiroshi; Ebina, Yousuke

CORPORATE SOURCE: Dep. Enzym. Genet., Univ. Tokushima, Tokushima, 770, Japan

SOURCE: Biochemical and Biophysical Research Communications (1995), 216(1), 321-8

CODEN: BBRCA9; ISSN: 0006-291X

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Major insulin signals as stimulation of glucose uptake and DNA synthesis and modification of hexose metabolism are mediated by the tyrosine-phosphorylated insulin receptor substrate-1 (IRS-1; pp180) in many species of cells. We cloned cDNA encoding a 190-kDa IRS 1-like protein (pp190) in simian COS cells and which is slightly larger than IRS-1 (pp180) of human, rat, and mouse cells. The deduced amino acid sequence of COS pp190 consisted of 1251 amino acids and was 96.4%, 87.9% and 88.7% identical to human, mouse and rat IRS-1. The COS pp190 bound to SH2 (src-homol. 2) domains of p85, Grb2/Ash, and SH-PTP2, as did IRS-1. In IRS-1-knockout mice, insulin signals are thought to be mediated by IRS-2 (pp190), which is an alternative signaling mol. and is slightly larger than IRS-1. However, the COS pp190 may be a simian homolog of IRS-1, but not of IRS-2. The results of Southern blotting suggested the possibility that Chinese hamster ovary (CHO) cells have not only the IRS-1 gene but also a gene related to the COS pp190.

IT 172076-41-4

RL: PRP (Properties)

(amino acid sequence; cloning of a cDNA encoding a 190-kDa insulin receptor substrate-1-like protein of simian COS cells)

RN 172076-41-4 HCAPLUS

CN Protein pp 190 (monkey COS cell insulin receptor substrate-1-like 190-kilodalton) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:444221 HCAPLUS

DOCUMENT NUMBER: 122:262954

TITLE: Mutant cDNA encoding insulin receptor substrate 1

INVENTOR(S): Pedersen, Oluf; Bjoerbaek, Christian; Frederiksen, Kathrine Almind

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------



```

-----
WO 9429345      A1      19941222      WO 1994-DK227      19940610
      W: AU, CA, CN, CZ, FI, HU, JP, KR, NO, PL, RU, US
      RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9469693      A1      19950103      AU 1994-69693      19940610
EP 711309       A1      19960515      EP 1994-918310     19940610
      R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
CN 1129001      A       19960814      CN 1994-192962     19940610
CN 1070917      B       20010912
US 5827730      A       19981027      US 1996-557139     19960212
PRIORITY APPLN. INFO.:      DK 1993-683      A 19930610
                              DK 1993-915      A 19930809
                              WO 1994-DK227      W 19940610

```

AB A cDNA encoding a mutant of insulin receptor substrate 1 (IRS-1) is isolated from a patient with non-insulin-dependent diabetes mellitus (NIDDM) by single stranded conformation polymorphism (SSCP) technique and direct DNA sequencing. The cDNA exhibits a G-3494 → A mutation that caused substitution of glycine972 → arginine and 2 silent mutations, i.e., A-2995 → G and G-3262 → C. A further clin. studies indicate that in young obese subjects, the glycine972 → arginine mutation is associated with whole-body insulin resistance and dyslipidemia.

IT 162456-16-8

RL: PRP (Properties)  
(amino acid sequence; cloning of cDNA encoding insulin receptor substrate 1 mutant)

RN 162456-16-8 HCAPLUS

CN Phosphoprotein IRS 1 [972-glycine] (human) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:474840 HCAPLUS

DOCUMENT NUMBER: 121:74840

TITLE: Cloning of the mouse insulin receptor substrate-1 (IRS-1) gene and complete sequence of mouse IRS-1

AUTHOR(S): Araki, Eiichi; Burritt L. Haag III; Kahn, C. Ronald

CORPORATE SOURCE: Research Division, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Joslin Diabetes Center, Room 620, One Joslin Place, Boston, MA, 02215, USA

SOURCE: Biochimica et Biophysica Acta, Molecular Cell Research (1994), 1221(3), 353-6

CODEN: BBAMCO; ISSN: 0167-4889

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The mouse IRS-1 gene has been cloned and its structure determined. Mouse IRS-1 differs from rat by the absence of the potential C-terminal nucleotide binding site. Otherwise, the predicted IRS-1 protein is highly conserved between mouse, rat and humans, especially in the possible phosphorylation sites.

The highly conserved nature of IRS-1 suggests the importance of these domains in the function of IRS-1 or its association with other proteins.

IT 156532-63-7, Phosphoprotein IRS-1 (mouse clone λMG2 insulin receptor substrate-1)

RL: PRP (Properties)

(amino acid sequence of)

RN 156532-63-7 HCAPLUS

CN Phosphoprotein IRS 1 (mouse clone λMG2 reduced) (9CI) (CA INDEX

NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:420841 HCAPLUS

DOCUMENT NUMBER: 119:20841

TITLE: The insulin-elicited 160 kDa phosphotyrosine protein in mouse adipocytes is an insulin receptor substrate 1: identification by cloning

AUTHOR(S): Keller, Susanne R.; Aebersold, Ruedi; Garner, Charles W.; Lienhard, Gustav E.

CORPORATE SOURCE: Dep. Biochem., Dartmouth Med. Sch., Hannover, NH, USA

SOURCE: Biochimica et Biophysica Acta, Gene Structure and Expression (1993), 1172(3), 323-6

CODEN: BBGSD5; ISSN: 0167-4781

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Insulin elicits the tyrosine phosphorylation of one or more proteins of 160-185 kDa in many cell types. Peptide sequences, obtained from this protein purified from mouse 3T3-L1 adipocytes (pp160), were used as the basis for cloning its cDNA. pp160 is highly homologous to the insulin receptor substrate 1, previously cloned from rat liver. Thus, this component of the insulin signaling pathway is the same in adipocytes and in liver.

IT 148221-13-0, Phosphoprotein IRS-1 (mouse 3T3-L1 adipocyte insulin receptor substrate 1 pp160)

RL: BIOL (Biological study)

(amino acid sequence and insulin-induced phosphorylation of)

RN 148221-13-0 HCAPLUS

CN Phosphoprotein IRS 1 (mouse 3T3-L1 cell reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L27 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:183912 HCAPLUS

DOCUMENT NUMBER: 118:183912

TITLE: Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma

AUTHOR(S): Nishiyama, Masaki; Wands, Jack R.

CORPORATE SOURCE: Cancer Cent., Massachusetts Gen. Hosp., Boston, MA, 02114, USA

SOURCE: Biochemical and Biophysical Research Communications (1992), 183(1), 280-5

CODEN: BBRC9A; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Human insulin receptor substrate-1 (hIRS-1) cDNAs were cloned from a  $\lambda$ GT11 expression library using a monoclonal antibody (MAb) produced against a human hepatocellular carcinoma (HCC) cell line (FOCUS). The predicted amino acid sequence derived from both a genomic DNA fragment and the cDNAs showed a 90.5% identity to the previously reported rat IRS-1 cDNA. Multiple potential phosphorylation sites, that suggest an intrinsic function of this mol. in response to insulin action, were highly conserved between the two species. A approx. 180-kDa hIRS-1 protein was immunopptd. and found to be phosphorylated on tyrosine residue(s) following insulin stimulation of HuH-7 HCC cells. Northern blot anal. demonstrated a single approx. 5-kb transcript in HCC cell lines and tissues. Higher levels of

hIRS-1 gene transcripts were observed in HCC tumors compared to adjacent non-involved normal liver.

IT 146811-19-0

RL: PRP (Properties)

(amino acid sequence of, complete)

RN 146811-19-0 HCAPLUS

CN Phosphoprotein IRS 1 (human reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:16:34 ON 06 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 OCT 2005 HIGHEST RN 864628-18-2

DICTIONARY FILE UPDATES: 5 OCT 2005 HIGHEST RN 864628-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> => fil reg

FILE 'REGISTRY' ENTERED AT 12:16:49 ON 06 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 OCT 2005 HIGHEST RN 864628-18-2

DICTIONARY FILE UPDATES: 5 OCT 2005 HIGHEST RN 864628-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d .seq l20 1-45

```
L20  ANSWER 1 OF 45  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   863099-27-8  REGISTRY
CN   INDEX NAME NOT YET ASSIGNED
NTE  modified (modifications unspecified)
SQL  18
```

```
SEQ      1 KKKLPATGDF MNTSPVGD
=====
```

HITS AT: 1-9

REFERENCE 1: 143:243964

```
L20  ANSWER 2 OF 45  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   863099-26-7  REGISTRY
CN   INDEX NAME NOT YET ASSIGNED
NTE  modified (modifications unspecified)
SQL  14
```

```
SEQ      1 KKKLPATGDF MNMS
=====
```

HITS AT: 1-9

REFERENCE 1: 143:243964

```
L20  ANSWER 3 OF 45  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   863099-25-6  REGISTRY
CN   INDEX NAME NOT YET ASSIGNED
NTE  modified (modifications unspecified)
SQL  15
```

```
SEQ      1 LPATGDFMNM SPVGD
```

HITS AT: 8-15

REFERENCE 1: 143:243964

L20 ANSWER 4 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 863099-23-4 REGISTRY  
 CN INDEX NAME NOT YET ASSIGNED  
 NTE modified (modifications unspecified)  
 SQL 18

SEQ 1 KKKLPATGDF MNMSPVGD

HITS AT: 1-9, 11-18

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:243964

L20 ANSWER 5 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 863099-22-3 REGISTRY  
 CN INDEX NAME NOT YET ASSIGNED  
 NTE modified (modifications unspecified)  
 SQL 18

SEQ 1 KKKLPATGDF MNMSPVGD

HITS AT: 1-9, 11-18

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:243964

L20 ANSWER 6 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 863099-21-2 REGISTRY  
 CN INDEX NAME NOT YET ASSIGNED  
 NTE modified

type	location		description
terminal mod.	Lys-1	-	N-acetyl
modification	Tyr-10	-	undetermined modification

SQL 18

SEQ 1 KKKLPATGDY MNMSPVGD

HITS AT: 1-9, 11-18

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:243964

L20 ANSWER 7 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 855029-97-9 REGISTRY  
 CN Type II diabetes and obesity-associated protein (human clone  
 US20050147987-SEQID-97)) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 97: PN: US20050147987 SEQID: 97 claimed protein  
 SQL 1316

SEQ 801 PCTGDYMNMS PVGDSNTSSP SDCYYGPEDP QHKPVLSYYS LPRSFKHTQR

=====

HITS AT: 807-814

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:72805

L20 ANSWER 8 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 855025-84-2 REGISTRY

CN Protein IRS-1 (insulin receptor substrate 1) (human 1242-amino acid) (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN 14: PN: US20050136465 SEQID: 14 claimed protein

SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:76253

L20 ANSWER 9 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 853285-80-0 REGISTRY

CN 5: PN: US20050123545 SEQID: 5 unclaimed protein (9CI) (CA INDEX NAME)

SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:38377

L20 ANSWER 10 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 848053-30-5 REGISTRY

CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-tyrosylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyl-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

SQL 18

SEQ 1 KKKLPAYGDY MNMSPVGD

=====

HITS AT: 11-18

REFERENCE 1: 142:311998

L20 ANSWER 11 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 845703-57-3 REGISTRY

CN 6: PN: WO2005016281 SEQID: 5 unclaimed protein (9CI) (CA INDEX NAME)

SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 142:259951

L20 ANSWER 12 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 845592-97-4 REGISTRY  
 CN Kinase (phosphorylating), insulin receptor (rat 1235-amino acids) (9CI)  
 (CA INDEX NAME)

OTHER NAMES:

CN 3: PN: EP1508806 SEQID: 16 claimed protein  
 SQL 1235

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYGPEP

=== =====

HITS AT: 728-735

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 142:236028

L20 ANSWER 13 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 841346-72-3 REGISTRY  
 CN DNA (human clone WO2005012875-SEQID-2417 cyclin-dependent kinase  
 modulator-regulated protein cDNA) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2417: PN: WO2005012875 SEQID: 2417 claimed protein  
 SQL 1242

SEQ 701 NGVGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 142:214836

L20 ANSWER 14 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 800916-53-4 REGISTRY  
 CN Protein, IRS-1 (insulin receptor substrate 1) (human) (9CI) (CA INDEX  
 NAME)

OTHER NAMES:

CN 1: PN: WO2004104220 SEQID: 1 claimed sequence  
 SQL 1242

SEQ 701 NGVGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 142:19236

L20 ANSWER 15 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 800916-52-3 REGISTRY  
 CN 516-777-Protein, IRS-1 (insulin receptor substrate 1) (human) (9CI) (CA  
 INDEX NAME)

OTHER NAMES:

CN 9: PN: WO2004104220 FIGURE: 3 claimed sequence  
 SQL 262

SEQ 201 PPVSSGGGKL LPCTGDYMNM SPVGDSNTSS PSDCYYPED PQHKPVLSYY

=== =====

HITS AT: 218-225

REFERENCE 1: 142:19236

L20 ANSWER 16 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 732162-72-0 REGISTRY

CN GenBank AAT99886 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAT99886 (Translated from: GenBank AY690661)

SQL 1229

SEQ 701 LPHPKLPVES SSGKLLSCTG DYMNMSPVGD SNTSSPSDCY YGPEDPQHKP

=====

HITS AT: 723-730

L20 ANSWER 17 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 688069-62-7 REGISTRY

CN Protein IRS-1 (insulin receptor substrate 1) (mouse) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3: PN: WO2004039963 SEQID: 3 claimed protein

SQL 1231

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYGPED

=== =====

HITS AT: 728-735

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 140:405486

L20 ANSWER 18 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 688069-60-5 REGISTRY

CN Protein IRS-1 (insulin receptor substrate 1) (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO2004039963 SEQID: 1 claimed protein

SQL 1242

SEQ 701 NGVGGHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 140:405486

L20 ANSWER 19 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 652210-78-1 REGISTRY

CN Protein (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 189: PN: WO2004009622 SEQID: 189 claimed protein

SQL 1242

SEQ 701 NGVGGHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740



\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 140:141434

L20 ANSWER 20 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 625303-37-9 REGISTRY  
 CN Insulin receptor substrate 1 (human clone MGC:61462 IMAGE:6144252) (9CI)  
 (CA INDEX NAME)  
 OTHER NAMES:  
 CN GenBank AAH53895  
 CN GenBank AAH53895 (TRANSLATED FROM: GenBank BC053895)  
 SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 142:18205

L20 ANSWER 21 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 623998-86-7 REGISTRY  
 CN GenBank CAD79961 (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN GenBank CAD79961 (TRANSLATED FROM: GenBank AX659634)  
 SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L20 ANSWER 22 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 564491-02-7 REGISTRY  
 CN Protein (human gene 36909 protein kinase sequence homolog fragment) (9CI)  
 (CA INDEX NAME)  
 OTHER NAMES:  
 CN 18: PN: WO03057841 FIGURE: 2 claimed sequence  
 SQL 1316

SEQ 801 PCTGDYMNMS PVGDSNTSSP SDCYGPEDP QHKPVLSYYS LPRSFKHTQR

====

HITS AT: 807-814

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 139:129924

L20 ANSWER 23 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 493580-91-9 REGISTRY  
 CN Protein (mouse strain C57BL/6J clone B130064P13 1231-amino acid) (9CI)  
 (CA INDEX NAME)  
 OTHER NAMES:  
 CN GenBank BAC32308  
 CN GenBank BAC32308 (Translated from: GenBank AK045317)  
 SQL 1231

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNMS PVGDSNTSS PSECYGPED

=== =====

HITS AT: 728-735

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

REFERENCE 1: 138:164521

L20 ANSWER 24 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 487716-78-9 REGISTRY  
 CN GenBank CAA41264 (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN GenBank CAA41264 (Translated from: GenBank X58375)  
 SQL 1235

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYGPED

=== =====

HITS AT: 728-735

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

L20 ANSWER 25 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 487639-52-1 REGISTRY  
 CN GenBank CAA49378 (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN GenBank CAA49378 (Translated from: GenBank X69722)  
 SQL 1231

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYGPED

=== =====

HITS AT: 728-735

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

L20 ANSWER 26 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 483161-90-6 REGISTRY  
 CN GenBank AAA39335 (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN GenBank AAA39335 (Translated from: GenBank L24563)  
 SQL 1233

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYGPED

=== =====

HITS AT: 728-735

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

L20 ANSWER 27 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 481200-98-0 REGISTRY  
 CN Insulin receptor substrate-1 (human gene insulin receptor substrate-1, IRS-1) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 1485: PN: WO03095618 TABLE: 1 claimed protein  
 CN 263: PN: WO03091391 FIGURE: 20 unclaimed protein  
 CN 2761: PN: WO03091391 TABLE: 20 unclaimed protein  
 CN 3099: PN: WO2004038376 TABLE: 5 unclaimed protein  
 CN 648: PN: WO2004087954 PAGE: 70/116 unclaimed protein  
 CN GenBank AAB27175  
 CN GenBank AAB27175 (Translated from: GenBank S62539)  
 SQL 1242

SEQ 701 NGVGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 142:91478

REFERENCE 2: 141:325696

REFERENCE 3: 140:402911

REFERENCE 4: 140:248186

REFERENCE 5: 140:40262

REFERENCE 6: 140:3792

REFERENCE 7: 139:379453

L20 ANSWER 28 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 481198-64-5 REGISTRY

CN GenBank AAB21608 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAB21608 (Translated from: GenBank S85963)

SQL 1243

SEQ 701 TNGVGHHSH VLPHPKPPVE SSGGKLLPCT GDYMNMPVG DSNTSSPSDC

=====

HITS AT: 734-741

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L20 ANSWER 29 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 481185-75-5 REGISTRY

CN GenBank BAA11026 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank BAA11026 (Translated from: GenBank D64157)

SQL 1251

SEQ 701 VGAHNSQVLL HPKPPVESSG GKLLPCTGDY MNMPVGD SN TSSPSDCYYG

=====

HITS AT: 731-738

L20 ANSWER 30 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 479165-81-6 REGISTRY

CN 29: PN: WO02103014 SEQID: 29 unclaimed protein (9CI) (CA INDEX NAME)

SQL 1242

SEQ 701 NGVGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMPVGD SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 138:49932

L20 ANSWER 31 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 473863-40-0 REGISTRY

CN 1: PN: WO02083730 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)

SQL 1235

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMMN SPVGDSNTSS PSECYYGPD

=== =====

HITS AT: 728-735

REFERENCE 1: 137:334056

L20 ANSWER 32 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 448985-00-0 REGISTRY

CN 4: PN: US20020110559 SEQID: 5 unclaimed protein (9CI) (CA INDEX NAME)

SQL 1242

SEQ 701 NGVGHHSHV LPHPKPPVES SGGKLLPCTG DYMMNSPVG D SNTSSPSDCY

=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 137:184452

L20 ANSWER 33 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 329783-46-2 REGISTRY

CN L-Aspartic acid, N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-4-[(bromoacetyl)amino]-L-phenylalanyl-L-methionyl-L-asparaginy-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SQL 18

SEQ 1 KKKLPATGDF MNMSPVGD

=====

HITS AT: 1-9, 11-18

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 134:218831

L20 ANSWER 34 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN

RN 329783-44-0 REGISTRY

CN L-Aspartic acid, N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-4-[[6-(5'-adenylyloxy)-4,6-dihydroxy-4,6-dioxido-1-oxo-5-oxa-3-thia-4,6-diphosphahex-1-yl]amino]-L-phenylalanyl-L-methionyl-L-asparaginy-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SQL 18

SEQ 1 KKKLPATGDF MNMSPVGD

=====

HITS AT: 1-9, 11-18

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 143:243964

REFERENCE 2: 135:253738

REFERENCE 3: 134:218831

L20 ANSWER 35 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 172076-41-4 REGISTRY  
 CN Protein pp 190 (monkey COS cell insulin receptor substrate-1-like  
 190-kilodalton) (9CI) (CA INDEX NAME)  
 SQL 1251

SEQ 701 VGAHNSQVLL HPKPPVESSG GKLLPCTGDY MNMSPVGDSN TSSPSDCYYG

=====

HITS AT: 731-738

REFERENCE 1: 124:47072

L20 ANSWER 36 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 162456-16-8 REGISTRY  
 CN Phosphoprotein IRS 1 [972-glycine] (human) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Insulin receptor substrate 1 [972Gly] (human)  
 SQL 1243

SEQ 701 TNGVGGHHSH VLPHPKPPVE SSGGKLLPCT GDYMNMSPPVG DSNTSSPSDC

===== =

HITS AT: 734-741

REFERENCE 1: 122:262954

L20 ANSWER 37 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 156532-63-7 REGISTRY  
 CN Phosphoprotein IRS 1 (mouse clone λMG2 reduced) (9CI) (CA INDEX  
 NAME)  
 OTHER NAMES:  
 CN Phosphoprotein IRS-1 (mouse clone λMG2 insulin receptor  
 substrate-1)  
 SQL 1233

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYGPED

=== =====

HITS AT: 728-735

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 121:74840

L20 ANSWER 38 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 151086-87-2 REGISTRY  
 CN Phosphoprotein IRS-1 (human clone λE5 reduced) (9CI) (CA INDEX  
 NAME)  
 OTHER NAMES:  
 CN Insulin receptor substrate 1 (human clone λE5)  
 SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPPVG DSNTSSPSDCY

=====

HITS AT: 733-740

REFERENCE 1: 130:322151

REFERENCE 2: 120:97466

L20 ANSWER 39 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 151086-86-1 REGISTRY

CN Phosphoprotein IRS-1 (human clone  $\gamma$ E1 reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Insulin receptor substrate 1 (human clone  $\gamma$ E1)  
SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY  
=====

HITS AT: 733-740

REFERENCE 1: 120:97466

L20 ANSWER 40 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 151086-85-0 REGISTRY

CN Phosphoprotein IRS-1 (human clone  $\lambda$ E36 reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 8: PN: WO0135102 PAGE: 52 unclaimed protein  
CN Insulin receptor substrate 1 (human clone  $\lambda$ E36)  
SQL 1242

SEQ 701 NGVGGHHSHV LPHPKPPVES SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY  
=====

HITS AT: 733-740

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 135:2206

REFERENCE 2: 120:97466

L20 ANSWER 41 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 148221-13-0 REGISTRY

CN Phosphoprotein IRS 1 (mouse 3T3-L1 cell reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Phosphoprotein IRS-1 (mouse 3T3-L1 adipocyte insulin receptor substrate 1 pp160)  
SQL 1231

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYGPED  
=== =====

HITS AT: 728-735

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 119:20841

L20 ANSWER 42 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 146811-19-0 REGISTRY

CN Phosphoprotein IRS 1 (human reduced) (9CI) (CA INDEX NAME)  
SQL 1243

SEQ 701 TNGVGGHHSH VLPHKPPVE SSGKLLPCT GDYMNMSPVG DSNTSSPSDC  
===== =

HITS AT: 734-741

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 118:183912

L20 ANSWER 43 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 145559-05-3 REGISTRY  
 CN Phosphoprotein IRS 1 (rat clone C18/P2-2) (9CI) (CA INDEX NAME)  
 SQL 1155

SEQ 651 GKPWTNGVGG HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS  
 === =====

HITS AT: 688-695

REFERENCE 1: 119:2479

L20 ANSWER 44 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 143376-54-9 REGISTRY  
 CN L-Aspartic acid, L-lysyl-L-lysyl-L-lysyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycyl-L- $\alpha$ -aspartyl-L-tyrosyl-L-methionyl-L-asparaginyll-L-methionyl-L-seryl-L-prolyl-L-valylglycyl- (9CI) (CA INDEX NAME)  
 SQL 18

SEQ 1 KKKLPATGDY MNMSPVGD  
 =====

HITS AT: 1-9, 11-18

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

REFERENCE 1: 134:53060

REFERENCE 2: 127:328319

REFERENCE 3: 124:80394

REFERENCE 4: 119:220273

REFERENCE 5: 117:127074

L20 ANSWER 45 OF 45 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 141349-62-4 REGISTRY  
 CN Phosphoprotein IRS 1 (rat clone C18/S27 protein moiety reduced) (9CI) (CA INDEX NAME)  
 SQL 1235

SEQ 701 HHTHALPHAK PPVESGGGKL LPCTGDYMNM SPVGDSNTSS PSECYYPED  
 === =====

HITS AT: 728-735

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

REFERENCE 1: 117:127074

REFERENCE 2: 116:228381

=>

**This Page Blank (uspto)**